var title_f3_2_3104="Nephrology pattern 17 answer";
var content_f3_2_3104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 17 answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anti-GBM antibody disease. Immunofluorescence microscopy showing characteristic linear deposition of IgG in anti-GBM antibody disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3104=[""].join("\n");
var outline_f3_2_3104=null;
var title_f3_2_3105="Abdominal hernias PI";
var content_f3_2_3105=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F87588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F87588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Abdominal wall hernias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 615px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abdominal wall hernias can happen in different parts of the torso:",
"    <ul>",
"     <li>",
"      Incisional hernias happen along incisions from surgery.",
"     </li>",
"     <li>",
"      Umbical hernias happen at the belly button.",
"     </li>",
"     <li>",
"      Epigastric hernias happen in the midline above the belly button.",
"     </li>",
"     <li>",
"      Spigelian hernias happen to the left or right of midline, where 2 layers of muscle meet.",
"     </li>",
"     <li>",
"      Lumbar hernias (not shown) happen at the back.",
"     </li>",
"     <li>",
"      Inguinal hernias happen in the groin region.",
"     </li>",
"     <li>",
"      Femoral hernias happen where the thigh joins the torso.",
"     </li>",
"    </ul>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3105=[""].join("\n");
var outline_f3_2_3105=null;
var title_f3_2_3106="Antiretroviral drugs Potential for interaction with anticancer";
var content_f3_2_3106=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antiretroviral drugs: Potential for interaction with anticancer agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antiretroviral drugs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route of elimination",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect on CYP450/transporters",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect of cancer drugs on ARV as a substrate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alteration to cancer drugs due to enzyme or transporter induction or inhibition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Nucleoside reverse-transcriptase inhibitors (NRTIs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abacavir",
"        <sup>",
"         [1-4]",
"        </sup>",
"       </td>",
"       <td>",
"        Renal excretion, ALDH, UGT*, ABCB1, ABCG2",
"       </td>",
"       <td>",
"        Inhibitor: ABCB1, ABCC1, ABCC2, ABCC3, ABCG2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Didanosine",
"        <sup>",
"         [4-5]",
"        </sup>",
"       </td>",
"       <td>",
"        Renal excretion, purine nucleoside phosphorylase, ABCC4",
"       </td>",
"       <td>",
"        None known",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Emtricitabine",
"        <sup>",
"         [6-8]",
"        </sup>",
"       </td>",
"       <td>",
"        Renal excretion, UGT*, ABCC1",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: ABCC5",
"        </p>",
"        Inhibitor: ABCC1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lamivudine",
"        <sup>",
"         [4,9-11]",
"        </sup>",
"       </td>",
"       <td>",
"        Renal excretion, ABCB1, ABCC1, ABCC2, ABCC3, ABCC4, ABCG2, SLC22A1, SLC22A2, SLC22A3",
"       </td>",
"       <td>",
"        Inhibitor: ABCC1, ABCC2, ABCC3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stavudine",
"        <sup>",
"         [4,12]",
"        </sup>",
"       </td>",
"       <td>",
"        Renal excretion, ABCC4",
"       </td>",
"       <td>",
"        Inducer: ABCB1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Zidovudine",
"        <sup>",
"         [4,10,13-15]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2A6, CYP2C9, CYP2E1, CYP3A4, UGT2B7, ABCB1, ABCC4, ABCC5, ABCG2, SLC22A6, SLC22A7,SLC22A8, SLC22A11, SLC28A1, SLC28A3",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: ABCC4, ABCC5",
"        </p>",
"        Inhibitor: ABCG2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Nucleotide reverse-transcriptase inhibitors (NtRTIs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tenofovir",
"        <sup>",
"         [4,10,16-17]",
"        </sup>",
"       </td>",
"       <td>",
"        Renal excretion, ABCC4, ABCC10, SLC22A6, SLC22A8",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: ABCB1",
"        </p>",
"        Inhibitor: CYP1A2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Non-nucleoside reverse-transcriptase inhibitor (NNRTIs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Delavirdine",
"        <sup>",
"         [4,18-19]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2D6, CYP3A4",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: ABCB1",
"        </p>",
"        Inhibitor: CYP2C9, CYP2C19, CYP2D6, CYP3A4, ABCB1, ABCC1, ABCC2, ABCC3, ABCG2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2 (inhibitor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Efavirenz",
"        <sup>",
"         [4,20-26]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2B6, CYP3A, UGT2B7",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: CYP2B6, CYP3A4, ABCC1, ABCC6",
"        </p>",
"        Inhibitor: CYP2C9, CYP2C19, CYP3A4, UGT1A4, UGT1A9, ABCB1, ABCB11, ABCC1, ABCC2, ABCC3, ABCG2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3 (inducer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Etravirine",
"        <sup>",
"         [4,27-28]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2C9, CYP2C19, CYP3A4, UGT1A3, UGT1A8",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: CYP3A4",
"        </p>",
"        Inhibitor: CYP2C9, CYP2C19, ABCB1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3 (inducer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nevirapine",
"        <sup>",
"         [4,24,29,30]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2B6, CYP2D6, CYP3A4, UGT*",
"       </td>",
"       <td>",
"        <p>",
"         Iinducer: CYP2B6, CYP3A4, ABCB1",
"        </p>",
"        Inhibitor: ABCB1, ABCC1, ABCC3, ABCG2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3 (inducer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rilpivirine",
"        <sup>",
"         [31]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Ritonavir or ritonavir-boosted HIV-1 protease inhibitors (PI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amprenavir",
"        <sup>",
"         [4,32-37]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2C9, CYP2D6, CYP3A4, UGT*, ABCB1",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: CYP3A4, ABCB1",
"        </p>",
"        Inhibitor: CYP3A4, ABCB1, ABCC1, ABCG2, SLCO1B1, SLCO1B3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4 (inhibitor)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Darunavir",
"        <sup>",
"         [4,38-40]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, ABCB1, ABCC2, SLCO1A2, SLCO1B1",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: ABCB1, SLCO2B1",
"        </p>",
"        Inhibitor: CYP2D6, CYP3A4, ABCB1, ABCG2, SLCO1B1, SLCO1B3, SLCO2B1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4 (inhibitor)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fosamprenavir (prodrug)",
"        <sup>",
"         [32-33,41]",
"        </sup>",
"       </td>",
"       <td>",
"        Hydrolyzed to amprenavir",
"       </td>",
"       <td>",
"        See amprenavir",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4 (inhibitor)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Indinavir",
"        <sup>",
"         [4,32,36,40,42-47]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, UGT*, ABCB1, ABCC2",
"       </td>",
"       <td>",
"        Inhibitor: CYP2D6, CYP3A4, UGT1A1, ABCB1, SLCO1A2, SLCO1B1, SLCO1B3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4 (inhibitor)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lopinavir",
"        <sup>",
"         [4,40,47-51]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, ABCB1, ABCC1, ABCC2, SLCO1A2, SLCO1B1",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: CYP1A2, CYP2C9, CYP2C19",
"        </p>",
"        Inhibitor: CYP3A4, UGT1A1, ABCB1, ABCG2, SLCO1B1, SLCO1B3, SLCO2B1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4 (inhibitor)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ritonavir",
"        <sup>",
"         [4,24-25,32,36,40,42,44-45,52-56]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A2, CYP2B6, CYP2D6, CYP3A4, ABCB1, ABCC2",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP3A4, UGT*, ABCB1, ABCC1",
"        </p>",
"        Inhibitor: CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A, ABCB1, ABCB11, ABCG2, SLCO1A2, SLCO1B1, SLCO1B3, SLCO2B1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4 (inhibitor or inducer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Saquinavir",
"        <sup>",
"         [4,25,32,36,39,40,42,44-45,47,50]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2D6, CYP3A4, ABCB1, ABCC2, SLCO1A2, SLCO1B1, SLCO1B3",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: ABCB1, ABCC1, ABCC2, ABCC4, ABCC5, ABCG2",
"        </p>",
"        Inhibitor: CYP2C9, CYP2C19, CYP2D6, CYP3A4, UGT1A1, ABCB1, ABCB11, ABCC2, ABCG2, SLCO1B1, SLCO1B3, SLCO2B1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4 (inhibitor)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tipranavir",
"        <sup>",
"         [4,57-59]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, UGT*, ABCB1",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: CYP3A4, ABCB1",
"        </p>",
"        Inhibitor: CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCG2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4 (inhibitor or inducer)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Non-ritonavir boosted HIV-1 protease inhibitors (PI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atazanavir",
"        <sup>",
"         [4,40,47,50,60-63]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, ABCB1, ABCC1, ABCG2",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: ABCB1, ABCC1",
"        </p>",
"        Inhibitor: CYP2C8, CYP3A4, UGT1A1, ABCB1, ABCC1, ABCC2, ABCG2, SLCO1B1, SLCO1B3, SLCO2B1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2 (inhibitor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nelfinavir",
"        <sup>",
"         [4,32,35,42,44,64-66]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2C9, CYP2C19, CYP2D6, CYP3A4, ABCB1",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: CYP2C9, CYP3A4, UGT*, ABCB1, ABCC2",
"        </p>",
"        Inhibitor: CYP2D6, CYP3A4, ABCB1, ABCG2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2 (inhibitor or inducer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Integrase strand transfer inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Raltegravir",
"        <sup>",
"         [4,67-69]",
"        </sup>",
"       </td>",
"       <td>",
"        UGT1A1, ABCB1, SLC15A1, SLC22A6",
"       </td>",
"       <td>",
"        Inducer: ABCB1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Fusion inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enfuvirtide",
"        <sup>",
"         [4,70]",
"        </sup>",
"       </td>",
"       <td>",
"        Catabolism",
"       </td>",
"       <td>",
"        None known",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Entry inhibitors (chemokine receptor antagonists)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maraviroc",
"        <sup>",
"         [4,68,71-75]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, ABCB1, SLCO1B1",
"       </td>",
"       <td>",
"        ABCB1, ABCC3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    DDI potential code and clinical relevance:",
"    <br/>",
"    <ol>",
"     <li>",
"      Interaction unlikely or known minor interaction not requiring modification to therapy.",
"     </li>",
"     <li>",
"      Possible interaction based on pharmacology of the drug. No modification to therapy but monitor closely for signs of toxicity.",
"     </li>",
"     <li>",
"      Potential for significant interaction based on pharmacology of the drug. No modification to therapy but monitor closely for signs of toxicity. Consider therapy modification if unable to monitor closely.",
"     </li>",
"     <li>",
"      Potential for clinically significant interaction based on pharmacology of the drug or known interaction. Need for dose adjustment or consideration of therapy modification.",
"     </li>",
"     <li>",
"      Major clinically significant interaction or potential critical interaction. Co-administration is contraindicated.",
"     </li>",
"    </ol>",
"    <div class=\"footnotes\">",
"     ARV: antiretroviral; ABC: ATP-binding cassette sub-family/member; ALDH: alcohol dehydrogenase; CYP: cytochrome P450; SLC: sodium-coupled nucleoside transport family/member; SLCO: solute carrier organic anion transporter family/member; UGT: uridine 5'-diphospho-glucuronosyltransferase.",
"     <br/>",
"     * Isozyme not specified.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     When used as a ritonavir-boosted PI.",
"    </div>",
"    <div class=\"reference\">",
"     Original table modified for this publication. Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011; 12:905. Table used with the permission of Elsevier Inc. All rights reserved.",
"     <br/>",
"     References:",
"     <ol>",
"      <li>",
"       Walsh JS, Reese MJ, Thurmond LM. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem Biol Interact 2002; 142:135.",
"      </li>",
"      <li>",
"       Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008; 47:351.",
"      </li>",
"      <li>",
"       McDowell JA, Chittick GE, Ravitch JR, et al. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999; 43:2855.",
"      </li>",
"      <li>",
"       Weiss, J, Haefeli, WE. Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. International review of cell and molecular biology 2010; 280:219.",
"      </li>",
"      <li>",
"       Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004; 48:1089.",
"      </li>",
"      <li>",
"       Zong J, Chittick GE, Wang LH, et al. Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. J Clin Pharmacol 2007; 47:877.",
"      </li>",
"      <li>",
"       Gilead Sciences, I. Emtriva&reg; (emtricitabine) capsules and oral solution prescribing information (file://www.gilead.com/pdf/emtriva_pi.pdf). Foster City, CA November 2011.",
"      </li>",
"      <li>",
"       Bousquet L, Pruvost A, Didier N, et al. Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2008; 35:247.",
"      </li>",
"      <li>",
"       Johnson MA, Moore KH, Yuen GJ, et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999; 36:41.",
"      </li>",
"      <li>",
"       McDonagh EM, Whirl-Carrillo M, Garten Y, et al. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomarkers in medicine 2011; 5:795.",
"      </li>",
"      <li>",
"       Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Lamivudine Pathway, Pharmacokinetics/Pharmacodynamics. Available at: file://curation.pharmgkb.org/pathway/PA165860384. Accessed 06/13/12.",
"      </li>",
"      <li>",
"       Grasela DM, Stoltz RR, Barry M, et al. Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis. Antimicrob Agents Chemother 2000; 44:2149.",
"      </li>",
"      <li>",
"       Court MH, Krishnaswamy S, Hao Q, et al. Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 2003; 31:1125.",
"      </li>",
"      <li>",
"       Blum MR, Liao SH, Good SS, de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988; 85:189.",
"      </li>",
"      <li>",
"       Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics . Available at: file://curation.pharmgkb.org/pathway/PA165859361. Accessed 06/13/12.",
"      </li>",
"      <li>",
"       Gilead Sciences, I. VIREAD&reg; (tenofovir disoproxil fumarate) tablets prescribing information (file://www.gilead.com/pdf/viread_pi.pdf). Foster City, CA October 2010.",
"      </li>",
"      <li>",
"       Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Tenofovir/Adefovir Pathway, Pharmacodynamics. Available at: file://curation.pharmgkb.org/pathway/PA155028030. Accessed 06/13/12.",
"      </li>",
"      <li>",
"       Voorman RL, Payne NA, Wienkers LC, et al. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. Drug Metab Dispos 2001; 29:41.",
"      </li>",
"      <li>",
"       Voorman RL, Maio SM, Hauer MJ, et al. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. Drug Metab Dispos 1998; 26:631.",
"      </li>",
"      <li>",
"       Hariparsad N, Nallani SC, Sane RS, et al. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004; 44:1273.",
"      </li>",
"      <li>",
"       Robertson SM, Maldarelli F, Natarajan V, et al. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 2008; 49:513.",
"      </li>",
"      <li>",
"       Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306:287.",
"      </li>",
"      <li>",
"       Belanger AS, Caron P, Harvey M, et al. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 2009; 37:1793.",
"      </li>",
"      <li>",
"       Faucette SR, Zhang TC, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007; 320:72.",
"      </li>",
"      <li>",
"       McRae MP, Lowe CM, Tian X, et al. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. The Journal of pharmacology and experimental therapeutics 2006; 318:1068.",
"      </li>",
"      <li>",
"       Ji HY, Lee H, Lim SR, et al. Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. Molecules 2012; 17:851.",
"      </li>",
"      <li>",
"       Scholler-Gyure M, Kakuda TN, Raoof, A, et al. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet 2009; 48:561.",
"      </li>",
"      <li>",
"       Yanakakis LJ, Bumpus NN. Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug metabolism and disposition: the biological fate of chemicals 2012; 40:803.",
"      </li>",
"      <li>",
"       Erickson DA, Mather G, Trager WF, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27:1488.",
"      </li>",
"      <li>",
"       Riska P, Lamson M, MacGregor T, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999; 27:895.",
"      </li>",
"      <li>",
"       Tibotec Inc. EDURANT&trade; (rilpivirine) tablets prescribing information. Raritan NJ 2011.",
"      </li>",
"      <li>",
"       Granfors MT, Wang JS, Kajosaari LI, et al. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 2006; 98:79.",
"      </li>",
"      <li>",
"       Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clinical pharmacokinetics 2006; 45:137.",
"      </li>",
"      <li>",
"       Decker CJ, Laitinen LM, Bridson GW, et al. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998; 87:803.",
"      </li>",
"      <li>",
"       Huang L, Wring SA, Woolley JL, et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001; 29:754.",
"      </li>",
"      <li>",
"       Polli JW, Jarrett JL, Studenberg SD, et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 1999; 16:1206.",
"      </li>",
"      <li>",
"       Singh R, Chang SY, Taylor LC. In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9. Rapid Commun Mass Spectrom 1996; 10:1019.",
"      </li>",
"      <li>",
"       Rittweger M, Arasteh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007; 46:739.",
"      </li>",
"      <li>",
"       Konig SK, Herzog M, Theile D, et al. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 2010; 65:2319.",
"      </li>",
"      <li>",
"       Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica; the fate of foreign compounds in biological systems 2010; 40:163.",
"      </li>",
"      <li>",
"       Furfine ES, Baker CT, Hale MR, et al. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother 2004; 48:791.",
"      </li>",
"      <li>",
"       von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38:106.",
"      </li>",
"      <li>",
"       Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 2001; 98:12671.",
"      </li>",
"      <li>",
"       von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci 1998; 87:1184.",
"      </li>",
"      <li>",
"       Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44:190.",
"      </li>",
"      <li>",
"       Balani SK, Woolf EJ, Hoagland VL, et al. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos 1996; 24:1389.",
"      </li>",
"      <li>",
"       Ye ZW, Camus S, Augustijns P, Annaert P. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos 2010; 31:178.",
"      </li>",
"      <li>",
"       Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos 1999; 27:902.",
"      </li>",
"      <li>",
"       Kumar GN, Jayanti VK, Johnson MK, et al. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm Res 2004; 21:1622.",
"      </li>",
"      <li>",
"       Zhang D, Chando TJ, Everett DW, et al. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33:1729.",
"      </li>",
"      <li>",
"       Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. Journal of acquired immune deficiency syndromes 2006; 42:52.",
"      </li>",
"      <li>",
"       Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277:423.",
"      </li>",
"      <li>",
"       Lim ML, Min SS, Eron JJ, et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 2004; 36:1034.",
"      </li>",
"      <li>",
"       Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 2008; 52:1663.",
"      </li>",
"      <li>",
"       Greenblatt DJ, von Moltke LL, Daily JP, et al. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol 1999; 19:293.",
"      </li>",
"      <li>",
"       Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998; 46:111.",
"      </li>",
"      <li>",
"       Vourvahis M, Kashuba AD. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 2007; 27:888.",
"      </li>",
"      <li>",
"       King JR, Acosta EP. Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clin Pharmacokinet 2006; 45:665.",
"      </li>",
"      <li>",
"       Mukwaya G, MacGregor T, Hoelscher D, et al. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother 2005; 49:4903.",
"      </li>",
"      <li>",
"       Lankisch TO, Moebius U, Wehmeier M, et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 2006; 44:1324.",
"      </li>",
"      <li>",
"       Colombo S, Buclin T, Franc C, et al. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. Antivir Ther 2006; 11:53.",
"      </li>",
"      <li>",
"       Bristol-Myers Squibb Company. REYATAZ&reg; (atazanavir sulfate) Capsules Package Insert (file://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021567s023lbl.pdf). Princeton, NJ April 2010.",
"      </li>",
"      <li>",
"       Friedland G, Andrews L, Schreibman T, et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005; 19:1635.",
"      </li>",
"      <li>",
"       Wu E, Sandoval T, Zhang K, et al. Cytochrome P450 isoforms involved in the metabolism of nelfinavir mesylate, an HIV-1 protease inhibitor. ISSX Proc. 1998; 13:110.",
"      </li>",
"      <li>",
"       Lillibridge JH, Liang BH, Kerr BM, et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998; 26:609.",
"      </li>",
"      <li>",
"       Dixit V, Hariparsad N, Li F, et al. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007; 35:1853.",
"      </li>",
"      <li>",
"       Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35:1657.",
"      </li>",
"      <li>",
"       Zembruski NC, Buchel G, Jodicke L, et al. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. The Journal of antimicrobial chemotherapy 2011; 66:802.",
"      </li>",
"      <li>",
"       Moss DM, Kwan WS, Liptrott NJ, et al. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrobial agents and chemotherapy 2011; 55:879.",
"      </li>",
"      <li>",
"       Ruxrungtham K, Boyd M, Bellibas SE, et al. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. J Clin Pharmacol 2004; 44:793.",
"      </li>",
"      <li>",
"       Hyland R, Dickins M, Collins C, et al. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol 2008; 66:498.",
"      </li>",
"      <li>",
"       Walker DK, Abel S, Comby P, et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005; 33:587.",
"      </li>",
"      <li>",
"       Boffito M, Abel S. A review of the clinical pharmacology of maraviroc. Introduction. Br J Clin Pharmacol 2008; 65 Suppl 1:1.",
"      </li>",
"      <li>",
"       Abel S, van der Ryst E, Rosario MC, et al. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008; 65 Suppl 1:5.",
"      </li>",
"      <li>",
"       Siccardi M, D'Avolio A, Nozza S, et al. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T&gt;C polymorphism. Pharmacogenetics and genomics 2010; 20:759.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3106=[""].join("\n");
var outline_f3_2_3106=null;
var title_f3_2_3107="Cellulitis of the forearm";
var content_f3_2_3107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cellulitis of the forearm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 540px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIcAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwg+n6inDOcrjjtSDjr/8Aqp+cjAxzXQYDSclgTjApvTp+FKfu4PXNIdyt1zjvQMlzkcHp7VPbq8rYUZ4+Y9ABTLWIyDc4Ijz1x1PoKlMvGI8pF2B68HvTETbYo8HPmPj7xHy/gO9RtK5OUJzkEMeo+npR9eW9acD8uB2p3FYiQEYyM02VcD2qTHcUDB44OaTGisvOMn8qlQcZOfpTHXaxK4BH6VKBgcHmkMkRRgkD8a6XwDAr600zYJiTge5Nc1nCcDjPNdH4LcrdTsPQVz4p2pSsdWDV60bnsuk3JgIIP4VT8Rot3DIGUEMOar2cxYKG6+tT3gHYk8V4a0Po9LniGr2bWOovbD/Vtlo8+ncfhVYIztgDLHoB6+ldh8QLAyWvnRj99Gd6/UVofDrw+L6wi1FmRXlXcmVzgV6scWo0uaW54lXBt1uWOzOa0/SLfaHvnIc/wDOF+tXX0G1lgMse3YDgsrZx9RXrU3hpvsm4eSxC5JJwfyrgNb0+4s7lnWDCBeWXufSuF4icne51LCqKslc4bUdOe0JIbfH+oqiBjg966e5O6F0PII4rlwrJIY2ycZ2n2r0sLXc1yy3POxNFQd47EgABz6/rSLheDSr1BycinAZPHP1rsOQacZx1GaADnacY7GpSCAR360mAN2P8KYhjjAx0NC89etOYHOcYPQf4UL1OOPrTAFwecimvnOOuB0qSMYJwOvP0okXc2cDOOPSgQzjOO1MwGJIHFPICkkjPqB2oIOM9PoaAGNjByOnSgAggZOOv0pSo249KVhg4596ABiADgfSmvxwB1H1pxH1z1xSjHzccdfpQAwg4OOBj8aYMdB1p7AjBHpSBTkEA4POBQA0/r3owN3P44/lSnHUjOe1OAPcDvmmAwgnuaMZHPX17Cn89iMDpQVO0jOf89KBEYQkEj9aYcE4Ud+9TEfLj8KYFDHPJ7CgCIDg+veipCpzyeKKVhlPr160uMnJoJ6cUqHgg85/SoGIx3KP51Jbxhh5k7MIQeg/iP+HvSxIoUSyg7OyjgtTppGlYFuBjAVeMD0oAe0jS4O0KvQIOgx6UhGR6eh9Kah55HtmpCDgAHPpTAapIbJ6CpvXbwe9REkdOKk7f560CFGMDGPSg9ACpApQB1NDA4HoegNMCGZMqSMk47UQ5O3HT+VS8E4wajX72AD+NJlImPC4PQdK1vDl2LW/BbGxxyDWSduRg5yMZ9as6e6/bbfzFDAOAfcVlVjzQaZrRk4TUj1Sw1CJkX1HetH7WJUPOCePpWBD4fk+WSyuMRHnY/OPoa0bfS9REm1DE59mxXg7n0d2lcyvEUayRsAOAOc96Phvq8K6cbIttltWMRHoM5B/I1s3egTDJu3THdU6H8fSvML4y6L4skkhJAlXBHrjn+VaQh7T3OplVqeztUPe/7TQQbWkU8da5fXbuJoZTnIrAstahngVZn2MRn5v8ap3t295J5FgrTyNxhOfzNYqLvY057q6MGRyJyqqWYthQOpJ6CqGpWEnkkRpm4VshRySe4rvLHRY9EtWv9QdXvSpKKOViB449WpNJ01SPtE0bs7/MPQV0Kryao5Z0ue553LYXUYBkt5VHuvSo1BDZIIxXqr20TP5TREN6EVzviHRoirMq4PYgV1U8fd2kjlqYDlV4s44g5xk9KewIAA+8eajlBhcpJwexxwak+6Ac+1ejGakro86UXF2Y3gAN/OlGOn8WOgoOcZAz29qQ8nOB/jVkgq/KMnGDjp0qRceWcHnvmmkZHP1zTlBDEgAU0SMZGB5x059qZ0J7e2Km24Yrk8frUf3sck/WgCMD0z7Z5ozk5GQBUhwOG6YpAMjHUn0oENAx0HzYwM0h9hg9Of507AI45PXFIexycZ4oGMPBpOfwHUU7aC2Se+c9KcMFjnnkf5+lMQw4GOMn1FSKM9uDQFyC2fal3LgADgd/WgBj4B7YPp/OmsemDkdsd6kYfLyfm9f8KYUwSTg4oAaeRnPP86YcA5BBz3qTHygdajIzjgfQ0AKASDzRTkACcnk9jRQBmnPp1qaJVRRJIOOy+v19qUxiDg4efrjsP8aaRuyxyWPFZlBzI25+p6An7v0pyA+w5oA3YyRtHFKeTwMYzQA5eAfXvTx2zwT1NNQ5wA3J608D+9TAQLge1PTnoPpSKQeOmKeuN3QE+ooAfjB56dqCvyjBoGcH16U9eWwOSBQBXcFWzilIwwcZGf0qZxztGPcUxMsCD+GaGNAfvdc9j7U+HKSp0GGHP41F0O0cEGpY8E+pHSpexS3PZdBnKWyq5GOoNb0N3DGA4AL1xOn3EiQLHcRlWUDp0PvWpDJMxAURruP8T4zXzbWp9LBu1mb17ILpAM9OcCvLPiVZiKRblB8yEOMe3X9K9EjLBQPPjZzxtiBZjXPeMtImOn3FzcqVVUKxof5mrptxkmTVjzxcTL03TZk0m0uLVVuIpow7RP2J9K1bK8ubVDHHpjIe4RKveA0WfwnpyMu4iEDmukj8PyOy7JHUn+63QUSleTuEILlSOQ+y6hqN8iTQeSiFXIk5+mR+tbi2H2dM/K57knk1d0S3WJp452cyrMyvk9MHFbmpafYPpxVXdX6cdhWd2wcNLnD3DRyeXtJBRiSfT2rB8QXQFq+CCzHA+tdHqsVvY2n7o8KuMnqa4iLN9f7pBm3gPmMP7zfwitILqKcbKxmalaK0ojZc9c1n6fp13dM48tikTFS5HDDtj1r0bw/4dXUG+0XKs/J+X0rRvLeCxYRLEwc/KqheCfatoYp07qJyzw0aj1PP4vDbOo+Z1JH8QxmqWpaRcWKeY4DxZ6+n1r0Z7V5giqNqoc8nqfQe1QatbCSxeJ1HIq4YuopXbugng6bjtZnmKk5I9TUhHGffn3ptzA1tdPE/Ufdz3FPCknPGMen+cV7MJqaTR404uDaY11+XpzjoDUI9Djr3qcHBPIGe3aopIsADsemTVkABnLY6DketIFwAApOelBOFwpzk9qONucGgBp5bgcdetHXkg7c55p2BgcZz39aQD5TuBwPemAbAwbpz60w9OMHPGPb1p5IA3bs80gBB689cUABHYdW9f6Ug+Xj+I8UoABGB153dzQeAB0oENJwACRnOBkUh4GF6DpTwmVJP05/nTXxwFPPXmgCNh0JPJ4GO1JjsR0PSnlVBGcA9fajB3DBP1IoAApC88kHt3op4xt4zk+9FAGWR25yPen7dg4PJ6Y7U5VAPvUgXIA6n2rMoiB9D3pzfdyPqacFAA9xzTSckY+7QA5QMe/anEjIPY/rTATnjk5/OncE84A9KYDwBu4zn+dOxgkdqap7UgJPFAycDAXkc9acuQTn8qjBzjHU1JjI6k80gFUd8/WlKbTu/h6Z7U5CDxyT0pxHJ+n40wKkiYfK8BqlixvUcH5h/Ogx7o/cevemxnBz2BzUvYpHvmj2sN1bRKyBjt7iteDw/aSv81vHtXn61m+FT5llbSg8lAfrxXZaewDAsMg8V81rc+l5tNBYtGt7WzaWCCGIgc7FwT+NcD47UHSrhSckAmvSL2YfZXVg2T+FedeNNr6bKqkbsceppt6oUb63MD4YXCN4eth1MeYyPcE16Lb3aRITjJHbPavG/hrOFgv4MgFLlyAfSvQ1S6eNSkRcHnhqKkWpMVOScVcXxVLLFcNqdlCzZAE8a9Wx/EB61gHxjbzwsqSbSvBVuCD7iukee8tQGmtHdeuAQa5bVItPudSjla1EbuxWVWGM0JXV2Xz2djnNX1ibUbhLezjluHc4Cxiuw0T4f6z9kXK21vkb2Zm3sCfYV0OiWFjbov2O3ijc9WA5/Ouqg1YRQhCmRjFVGaRNRN/CcH5E/he4SzuZPNik+ZJemT3B96tz30M6lnAd+zHtVnxei39pIs3zKRlWXqp7EGvKV1bU7fVDp7J56YZhIODgeopcvNqgUrLU79p4evCmsXULlZZwkW52c7VVRlmPsKisLO91Ah5J4YYSOSp3Gus0y107R4BJb/NdsCGuHOXx7en4VastzKV2eYeONJkhiiyuy7jJZsHOD6fl1rmFYPGCuOfevTNfEVyZGkYAHpmvMb+B7TUpbcjaj4lTPYH/64r0cFV15GedjKX2kO284AJokz36AYpUPy7erA/hRIMkZBzXpo84jYYycH8KME5+Xn1FA4B28mm7gxJOeO3vQIeMhT6gfhUZGSMDmpBnGOvHp0pj9cLx7mmIaoO4cc549KCMDPJ9KBkN0p7N8g9B+dAXGnJAIB4/KnEFhtBUkfhSdVI7ketN+Y5/UmgBSckE5IPr296Q43EAjjril6YOOOwPb60hLKfbrQIjbqMnj+dHORn7vYUhJ3cqPXNKBu6Z+p5zQMlGCmCcUUBeOOM0UBczQCCMcipFYc9MngY71FnoM/hTx2wOtZlCE47Y+lL1ANKRngYpwXgelMBgB/WnAfMM8mlwQeAMHoaBye5HegCSKN5pFjiUtIxwoFehaR4Dt/sqPfyNJIRkqpwo9q4TTLr7HeRy4+Xo3sPWvY/Dmprdqqtg8duhB7ivNx1WpBpR0R6OChTldy3OfuPBVjtPlKyH2JrJuvBVxEpaCUMP9oZr1pLZZBjgeuaDZBgVwPxrhjiqsep6UsJSl0PBbzTLrT3xcIQvTcBxVduMYyTXtWpaXDJEwdAwPqK848Q+HntZGmtFPlHqh7fSvQoY1S92e552IwLh70NUcuCAxJ5okXa5I6duKV0464z60oG6LHpXccJ7d4Lcx6JauxDfIvSu0jvI41yW49fSvN/B9y0+iWsUKPvCAE9ga6a10i7uFBuJyqjsnU181UVpM+jp2cEy1rPiaOEFIm8yQjhV5JrkL6LWdZVm+ziFG6FzyPwrsrHRLe3kVkRdxHVvWtZLdV+Ugce1JOw3Gx5LoPgya0nujLcgCR9+1V5HHrXX2ej3FvEEiupiAM43V0cunAFpRxIfyNWdMgVo+V+cCnKTk9RxjCK0OTfSbmUqLi4lbHQFqxde8MzOnmwyMk4OVY8816hdQKrg8emKbPZ+bHyOtKN0J2Z5rp2pTW0aR6lDJEwH31G5T+IrZj1SKVALecSfQ5J9q6CbS127Ag471l3Ph9WlzsCkdCvBp6FW7MzpbtpS8Uu1P95v6VydlCIvGBY7dpiKjPua6688PrIG3eYCe+TXJ3lhe6XrlpcTfvrBAyPJj5lz0J9quPWxGzV0dTJ4dt5yHgkkjLcnZxmro8EosQP2y5ZmxgMcfkKfpl5lUlhdSAOMHIIrpEv2mjUyKeBxilGRc12OLn8PWVgxYo0si87n5FeR+NmJ8UKyjBMBH4bq9w1Zn2uz4OR+leG+MiD4lJAyBCf8A0IV14N3qo4carUjLTgDHGDn/AOvUisecnryc0wDAOOW6mkztIJ/OvbR4bJWPyEDjHrULMc/KPrTyRzu65wOc5qNgQCT70xD04OODu9qa4Gc5yRjpTwdoGRjPpTnIz8oBHX0xTERMvGeefUUhGeg+tPdiWxmjhixHANAEW4qc4x6j0pxUlv8APNKACAW5OPyoOSSKAI8EEgnPuaGA6LkH6dKkGSTg8+47Uo7nG3AxzTERhfm5H4djTm65B47rSkDsOemPSm4wMMeAelIY5xhhkcfyopoYngfkO9FAGWoyeuDSsdx9aQdSDn0peCRjoe9ZlDwRnOckd6kByePyqME+mcfrUgbGR6imAPggc9O1KBgAj+dJ1PSnAgjbwaAE5z71qaFrNzo95HLGxkgBw8ee3fFZgHYkUh4/lUTgprlkaQm4O6Pf9G1aO9hheCQNGwHPeujtwJXGcEY4rxn4Z3ha7ks5GwpG9cnp617Np+4Iij72OtfP1qfspuDPoKFb2kFJDb2zCDLkBT61zGp27PlIot4Pf0ru3sfPQPIcnHfqaz/sgBbEeMHoeprKzN4s8O8TaBNbPJcRxjy+rKOce9cyQQx5zn0r3zUbGOTcGA+bI6V4x4h006TrslsRiF/30JP93PI/A16mDxDkuSXyPMx2FUf3kfmeu+ErRbbSbaGIDO0c+9dVAzKuwN8x5rnvDRSSxiORtIH4V09uCMgYZgO47e1eVJ3bbPShH3USLFkhXPTnHeprSINuDNhc8U9U87BjGHxnI6EVKiqMjpu7mgG9LDJoZAHIG4dxUFmUjncKSQeSa1Y5USMCU444J6Vk3SCG6EkZBB5bHem2kQtdCSVi5U5G7GSKkinzz2Hb0qGMpNC2H+deRj0qRUUqBnIJ6ClfUdlsy48a+WGHfHSolG58Mu44+nU0NIFjCHjntSOxSMFOc9Kq5Cu9CSW0QqxUAnNZt5pQYAsikYwR7VtW8geEA4z7UpKSyAHkjt6UaMq7jocBdeFY0dptPke3cnJC/dP4U5BeWcYFwDKO5TjNd8IImBzjOc+1Zmo2owegPbNOw1K+jOTuWjeNigzxwM5NeJeL8/8ACVTEjhYhgZ/2q9r12LajCPII7ivDdcyfEN+ZGZiAgH05rswOtQ4sc/3ZSUZUgnpz9TTSB1HGelOGMdhjnNJtzwR83YHvXto8UPrnJ79qUgMozyfX09qTrk4zznGakTZ+HvTEMUHGCcU5yHXkZHekYYU9ueBSpyHODjp9aZJHkkEnGevApQv94YJ6g05gVPPc0qgglupPc96AGHcD6jHWjoc4zjn6VIF+U9MHpTSuXzkjPNMCPGDyCDTyQOc5/wBmgDA4zwefamHaB0A/oaAJGxgkHcOnFNUDGcYLcc9voKVPusDgcYprHcPUnqPakFxrZBKrjBPJopx4zg9uuKKAuZGcn+VOUYU5OBTVx34PXNOHy9DzUFCpkL8xyBUgI6Z4FR8n696TOeg6UASqe469D70843ccZ7VFkcjPtzSg9ySB60DJD3yMUAHOcGmk5xjpU0LAAgg+uKQFvTbmSzuop42wQfzFe9aPqomjUhhjKc/UV8/qV25Gcen/ANeux8Ha26SrazN3BU/TtXnY+hzLnXQ9DA1uR8j6n0LpZSRMseM9zTr63XzV8kl1xzkVm+FLlbizQ5wTx171s342oUVuhBHuDXlo9ZbnMXsWJDkd+DXnXxN0SS+gsri0VfPhnAHb5G4YH9D+Feo38bsWIPfsO1cr4lObKRI03O/GPQ+tEZuElJGk6aqRsw8P6bJYW6KJixVMF2+4PwrZkZW2m2lnlcdTGMD865rSr43kQOov5aw4UxZ+8fU11NvDcagmSGt7cfdiXgt9aTWtyE2lYy2vbu0d9pnEfbOG/Or1hrTy5UsHHoDgj8K1k0C3IVXb5sdOwqrf+GEDCSB8N2ZTgipY01csWt8XG1lYYOMZ61aWJGXLEBh+tcxcLqFlIpl2yJ3yME+/FX4dUkjVWurZyuMh0O4fjSKLDsY8sgKgZ+Wrmn3aM4wBuAxye9U4tRt7gsUUEHoB60PaCRsRZjkHIPepFJXWpcuZMpgMC2ckDrSqHKIEyF6Zase5N1Gd0iF9p+9H3+tW7XUo5VEUjfP2BOKLlRjY1YGZBtDD1JFXLUuXODg9eBkVjmdEYZz7HFalvfwEAKQOPmxVJoU0+hoOvGc5yM59Kyb9pC5Dde3pWnFcRquASQeeaztTYMMR/eParuZrTc5PV5sQSZ469RXg/iQFfEd6AeCF/rXtviFiqsPX1rw/XmDa/flTwCq/kK7cB/EOLH/AVlI3DPOBSA8nJOc8Y9KRAMHJwRUuMKMjnGDivaTPHY3YO5+XtilQFQeme9PwD0OW7Cmrz7eq1RLGydARnj1pqBsjHBqWTCoOTzxmmgYHSmIQAbjknI/X6UjAgkYxz1608ZJVvpkelDdMYyevFAhW4LZGSejelNQggZz60ZbABwD/ACprMuARnJ/IUAAG4Ep0Pf1FMI+Ygc9s9qlfr8o46U0jnafxA7mgCFflODnH+eKe6kHJOAefegqTnhT/ACp6qCvzdR096AIgPm3EY7gf1op52hSPTvRQIxhwPU0pIXjHXvUYPPB+ntS9884FZmg7dgAfrSqcjj68VGcHpxx0p6egyM96AJAwHXvxS/5PtTRweBz6GpEGeeelAD4iC2Gx68+lSqFGADz+dQqOQfUVMnTOcc4xQBKCMdfrgVJayPBOkydUbIqJWwefwpy4wQTik1dWZSdtT6C8AXf2nTYmi5c/MMV2t1JuQEAbiORXlvwbeRtKOT8odlU16U0zRLyDkHPSvnJx5JuJ9FSk5QUmRXGXhGHAY9cDH41iTxIsm5sOxOCDWlcXQVNq7TzjPqO1UJLWV08wgrnv6Vk9TqTSWpX/ALBgup0mMe2YchhxitG3jv7ADy2Fwin7rDn86jt7m5tTh7dpE7leTitfTr6wuZseaY37KTtK/getUkZNrdmb/bLO4Wa3ljcHpt6flVyK8luGAEZRR93d1Nad6s4X9x9nuo27EYYVDHdMsaJLCV+i5P50OIr3WiI5bZrmBhJGSxHFYlpBJZzG1l/1TZKNj9K6Vb9AiqADjjBOTWffN5sZKRkDqD3zUuxKb6lW60eKYiS3+R+uV7VVR7uOYrIVO04B9RV7Tb4vBhuCOGxxRfeWyLhwCOTwSajc0V+o/wA5mgI2Kd3rUBsQYyxVT6jFS288ThV28jqasoXAJBxntTSB3WxkPp5bCwF0B5wDxmoRYSJyZHLjnmuiCsGAXr/KpmgVl5GW6U7EqTW5gxzytlX3JjowPAqSW5lixvOcDoeM1oPAId2UO0jPNY2pkj5lOF9PSqsDaZzviKZvJdm64PHXFeITMJby6lUkrJMxHuBx/SvV/F18sWm3OTyillb1HpXlFim2GEHPIyx9c8/1r1MvjvI8zMJbRHKuBkcfWnHkDOfm6+9SvFgA5O7qRiljXr2J7V6p5RCYwmeBnuRTxtAPfA4Ip0nCYHzevHSkZdyjaQegAHeqQmRy55DckH8KUsAFyPY4oIzxhgBwR6UnQgkZycD6UxE0cZLZYqB/Oomxv+YE9vpSiMnG8jr92jaSuDgAdKAI2B5PrSYCgE9e/Hensv3flwDTCPlwQcdqBD8Zzg5wM59faoz6Y4/p709cZORg4GQKZLlgec559M0ANAGMnjnkelJnp39aeynHPLZx700jB/p3/GgBMFn+TJIHXpxRTQWcFScD0A4ooAxmBHTFB5JxS9DjjOfWnBQCTj8TWZYij5cjuOtPXjnBJNKDtBPrxT/XP4+9ACKORngnv61Iik5HcnpTSMgeoPFPRckEDB96YDwowSeD7U9V6c4xzRggZI5NPOBgDPPTtmgA5zz06Zo79aAvyDH0zikXryef1pFI9n+FBEGhR88sxOfxr0YyN5DMBkYzivLfhlcZ0aLHOx2j/WvTXbfCkeeo3EV85W0qSv3PoaGtONuxnW9qzN5kjFtx9Ogq79lkC7kbIBwTn+lXbUCUlc9OnFWmhCqmcg9Cf6Vmbc1yhBB8vzcntjg0k2lR3URDICR2I5Fa8cSpLnIJHoOD+FXgikJIFwnfFNIlyS2OIOn6hZPus7l8KP8AVv8AMKmh11k+TUrcp23r0rt2t45QGGGLfmKoXWjRSkjaMN1Bp2JU4vcz7aa0uApjmD7hkVbCbo2XrnoKwNQ8Py2kpktWaM5yMdD+FV0nvLNszBs/3geKhhy+ZZkiaC5O5Mg9D2qyIi/bjGScdqge/E0QD43Lg+lXYpCYSo5Vu/pUGybK4thHcB2BAatMIyJvIHPSoAuUGW3Ljp0qa3Z5EVsjGMY9PWmiJNskjBclsgHtUshxEcLlz1IqCJCd2QR3x61ZZ8RHJYHHKntVIh7mfcTYBV8+uf7v/wBaue1fCqQDwfXtWtfSlHJbgep5rntSmXLdML6UXG0eZfEZymntCpIMrhOPQmuPXjk5AHT0ro/iJMJb2ziUlR5hY/gM1zkQHUk8c9P0r3MDG1O542MleoSo+CByR060ZG4knqPTp/8AWpFBKnAAA9Kc4C4B/wA+1dyOIT7wBPAzgEUj5AU9Bzxj+VOMZBJx+BNNX5WIYA449etMQ0kk+o4ANR5ySMk7KlbGSVP1z2qEHLsc5HtxQA5fmI78UrZ/+uKTuTxtNOXnrw36UxDS2UCgfLnnNIF+VdvBHr1NKRnA6DPBPGKZnBBPO7rmgBSAQueD2pG68jGT9cUpZgQR6Z+ppobBXGSaBCOxUhcEeoHWggAZfgdMUrEhsdAeOaR1ClTggj+9zQApXg4wc/yoprbsnJz64ooEYeRk1IMD+mKi4JIqRSccAY9qzNCVVOB0HHWkzg4JOOtA6DBHFKeQMjgUwFPqe9Sr1BI4HOKiC88d+amHT1PegCcZO0E+/rTT94dcAZqRFJTPf25psnBw3H86AAYUHuKCo74x1xQo6Y6EZ5p3PAPb86Q0dx8Mb7ypLqyYgZxMme+OCP5V7LYkMq7uoUYPrntXzZpt3JY3kVxF/rIzn6juK9v8P65HfadHPE25SOnoa8TH0nGfOtmezgat48nY7SFiSJBwfu4/nVrzSIyWP3jwMVk2M4e3Awd44zWrCx4jbjB71xJ3O56IDaSMuYZfmxnBoN5PbqFnjdVHYd6tRgZbByOlTtKs0O2WJZBVCv3Kllfsxzu4HOOlaUV8JAGl5xxnNZsmk29wN1rMYZP7pOKqzQXdicTpvXP3l60XaJcYyZ0JkWXCnBXr81UbvT4bk8Dn+7WYl8wkznn06fpWnaXYkcE9F65GCPrSbTE4uGqOY1PT2gkOwfMvIFXrM5hyAenI9DWvqMaXMfDAODuz3qpZkYL/AMQGGX1rNo2UrrUrruyMDGOnvSeXKshyPlPp2rUZUlQhWAA796mijRgo3LnoapITl1M2KKQEMDjB/Sn3BlJJyCAOMCtG8i2oAgBz2zWaZiHHOB3Bp2sKPvaoyL9xKhVlOfU1yGrsLcnJJz69q7HUTli2MZ6Ad64vxF80TlR0zQtWOWiPLPGE/n6/FjAMcbE+2cCs5F554OcYNF9KZtYvJCxITbGP5mjPHTIz27V9Dho8tNI+exEuao2TRNg/MCFPcUNy20A49qaD8pyCR6U5enygnGPmB6V0nONTGSDnB7ilOWztOQaRm2tjGCTx6UDA5GTn3xzTAjyOcdDTTgOeoyOQRUu3ucD1HrUW7AJB5POc8UxDiB8oAyO1IFJCnGB70FtrY5OOQaRmPBOT70CHSD97gd85J/wphAJznr7UqgjIOPcHqfelU4H1H5igQ1ckhRj3xQQFAIHfpTgMsMD2yBjFP2YA5GQ3rzQBXYkhtnQHrigg53Ag44x1qR1AON2Qeo9aYSQeD0PTpmgBCOCFyQDj0opyrlccgZooA5sDBye1TrwOpAPrUPPOAeamhB3Hjrx1qCx449OP0pwJ/wD1Uc84PHel2jjkZPQUCBQB82OTx1qZMEEDr6VETuIzUsLYbGR647UDLcZJGO/p0pHAPrtB60sYDJxwex6ZpGBHGcEep6UADDBOCOtIvIwD09qTJHGD05p6kEYz+PrSGNX5QcfSuk8H6z/Zd08UzEW8vfsrVzseQQPc59KeSCvAGDWVWmqkXFmlKo6clJH0NpGpI0KBMEsR37V0MVxucEfNn868P8FeIDE8VrO2CpwjHuPSvV9LvQcMT8x6GvnqlOVKTiz6ClONWPMjsrFleMlunbHpUiOuDGqEAHIPrWZZTx7f3vyjv71owTIEAjbp3x29KExNWJwu5iGVWzx0qXcFUpJllHY81G0il1AU7v71TqAU/qe9Mh+ZUbTLa6+eP5HweKzZLWW3kKt8wPO6tnO3J/izx71J96PEqjd6HvScUylJrfYwnlZ+vY8Z60+OPJBHB7kVqtbw7h8oxnmkNmNoIXj1qeU09qigkAkl5AxUggcBtu7b9elWfKYSDGPSpkX5Tk8elNRE5mK93sYqTjaeSRxiobiRZE3Y/wD11Zv413k4ypPPvWfIQAQvT61JvG25lanMY0Lckkdq4zxDdhbaTdwuDXY6lKEgYAYI5ry7x/cmHSriSN8FVJ/H/wDXV0o80kjGvLlizgIG88zTHA82VmBHp0H8qnAzx2qO2hEUMcfK7VA/Spjg9epHA9PavpYKySPm5O7uKD0xzk0pIVeSOCCAeM/SmhvoD/KnPgqVPLKMfhVkiMeeRnvx2prEYOcYPOcdvSlCjBJO447GmEg5B49qYhpORt7DocUpUsQSeaXC4HenjHbBx2x1/Gi4hij5iR3/ADFIRvDEDAGDUmAT8wPHPJpDkYIz/jTENZAMADDdCD2FNC44zxnof5VIWyMH5cdCeMD/AOvTQBhiy9BwKAHYBUkY3e/FRv8AMOjHsMmpEYNgA/Me/rRypHHGPXk0CG7fmBY8k9v8KRz8+SOe+Tzj/Gg5B9PXnpT8AAYGMrnkc0AMGcYAxx1oprHjHRehooA51umR/OpI/YYoRS2PX68UoHGScdjUFky9e+B6Uqgc49aamQOnHvUpAB+XjHNOwhpBPHX3qRM5PHHfikHJHuKkTGcdR9OtAEqkAEMR7+1ObBXnBb3qNHGemDnrTgfX60DFxke54yaQgegI/LinBRtOeQOgpoIJOc49B/KkAqlh0HNTIN5IAAzTE+bByRxiplwpHGBSGPhfyJUcA5Xt616j4V1E3EKESbsgfX8RXlbMS3zD8a6Hwc3nStEXKyqdyYbBx3xXn46ipR5+x3YKs4S5e57vpsytFtbLDGBWzZnC7Q3I/OuA0S6nt4lWR2yTxnnNdfZM+1WZiW/rXjbM9hq60OlhQBWJYZfr7CpJRiMKufYDvWWLjYN+44HXNWba/wABTIg3dcelWmZOL3RZitn3lnCkY/KrATahHc0kl6j5xgccimLMHZfSq0M/eerF+zMAvULmrap8jHcCPSoHnMmdo4x61VWdkPB4z3707pBaUtyZ9o45OKrySfgrdvSia7AbG35iOOKq3U2TjIBI6ZqGzWEX1KdzIw+Vu57Cse5fZuwdwzV+abClRyx6E1iXznLegGPrUM61sUdUnXyySQcCvHPiBdG51C1slYbWYySYP8I55/SvQ9bvVht5GzgD17mvHo5TqGo3d+3KyMYoz/sr1P4mu7A0+ad+x5uPqcsbdywvUZOee44pQflGPpSgDtySOBnrQAcAnvzx6969s8Uau0LhucnoKUktgNwOhx3+tKVw28lacCNpQcmqENUbVxgA9cU3YoOcZ7/Q08n5cj7tJuIXndjrg/pTEMIw2SQB9KkVjuyDgc9R+WKRUDdcrx1oJH3VGfTFAh2TkHA3Huf1NRsc5XpnpQ/PzHk9MjpTGVuQcnI4HtTEBZfMLYOByDmlGAp3daRcg56E98cU4AKMZO4nn1FACK/z7iDjrS5zjsKQ53jdwoONvcigEBQCMA80ANC5GRgH1Pagg4O3twSaViQeOffvSjduxkY7jP6GgQxhj5ifm64opXQ7sZ/DHeigNzCHB5/CnIo5GRn3oXqO/wBKk2AMCTgg8kVBQ5OF56+xp4X5RkjPeowduM8g+lSDl+OR2poBRj05xkYpVHf3yPXFCL16j3FSIOT2HfFAABuRcYFTYwpK4Y/WodvPOPUVIeMZBAPegBGJ4PSgYxno3pQQQRwfwoXO/J6ntSGPHQ7ercfjT0ySc8t/nikX5ecZGOtA+VdzHB9elIY5+M7valgnkt5klibbIhyCO9NJUnPXt9Kb/FnaCD6etS1fRlJ21R6P4Z8TpcqqXGFmHXJ4/CvQdO1VZTguAvqK+fIGaN1ZDhhzkd/au30LU5FiSRkk2H+IAnB/CvFxeF9m+aOx6+FxXMuWW57KNRXYijDDPYdqsxTksCOc9O1efWGrCTDCVFx74P61txaspVT5kfGc5YVxao7bo7VJPMCrxuPb0q4cxgAlQcdjXF22uRLKpMyD1+YVdl8Q27KAkpLdBxkmqTFY6b7WkUeNwyffpUP2sbvkGQfXpiuOl1WSWTcsUzr0/wBWaT+2pV2hYZ1/4Af1p3GoI6ue5I5Qb1HU9xUBeOVGfIz1NcjNr8xJXyJsehQgUW2tlQEMco9fkNSzRRsjeuDEFUhh6/KetYeq3DIh2YCH1qtca0FJEccpI6YjPFc1rWr3kkbbLY4/vHiklcG9DlPiPqLpZvDDLl5DsUD1PFcvbxeRBHCp+RF2j0z3p+sedcarbNcHJ3MwHbgU8qBjJx6+le7g6ajC54WLm5TBB1OPmpzcxlSCGPYUKBuyuSBxnoKUgBucgfn/AJFdiONgQSMnAHTH8hTQVUlSAR0PFA+ZQR0Hb2oGTwCTgEA9iKokTJ7n2NKSzFT1A6Unc4zjv609Bjls8enWgBUIXnGRjkg0rEKChHyn9DSA8cDHGR3oJyDxtxxj2piE3bTwef73XA+lJtAJ25JxyBSFyenGf1pTgHHb+VOwEiEbTnn2HNROCMsMLkcU77qkkDOcgCo2zluRz3PSgQ1eW4yM9zzinJz97Ax+OaMZORnjinbhhQFGOpoBht3EgY2g4yO/vQoAckYbHBPb8aCcjKnJ7dsU3ndznHcUABTLEMe+feipZQFyQwLHkkdCP8aKAOdwNuByB3p4YhQeuKjyfvY49KmQYA474qRi7c4w2ee/alCkkEjIxk04AqR0Htmngg+wz1oAXcpIC8e570uQSO+O1Rld3Xhh7U8HbgH+fSiwDgDuxj6U+PnoCcGkGCdy8j1704rjpwT2oGPyOcEE/wBKa7FTwAFPp1oPXjqBihWA6jikA4ZIHzcYoGSOemMAU0DcPmPzUjMQcN6c8YoGPCqcZ6gcU5ec7enTA70wN8rN0x0FAfB4OCeARUjJlBJJX64Fb3hm9eC8ESsdrjIGfSsJCwOBkNjsKt2LmO7hZDh1fg9hWOIgp02ma0pOM0z1bT763ZR5gt2PT5gM1vWf2NmyIoc/7oIritKv2vBZGOxkuLeV2SaeQCPyVX+Iq3zNk9APrWvbxXpigZtJsVmM5WRVuzhYf76nby3+xx9a+daPdjqjsYlt9wKwxH3CirKXNvGTuaFMdRgVxwt9WaC5EMelxSC4H2dnEsimDuXHGJPTHy1ofZtTJv8A7JqNvbiXaLMmxRza46lsn97n3xihLzKtI3p9QgJ2jLHp8qk1Wa6bP/Hu4B67gBVSWPVZZpjHqkUcbQCOJPsany5h1mJz8wP9zgD1ohstTE9s82qxyxx25SZBaKpnm7Sg5+QD+4Mg+tUku47NdCxJcycH7KWA9xURvHKYECgdeWAqitpqyix+0aqk7RFvtZSyVPtY7Yw37rHtnNZh03WFjh3anDPIJy0zyW3l5hP8CqrYDD+8c57iq5I9w1Ne4uJmUhIogB0y/NczqwuirbIojnqS9WLhdVgiuH+xQ3ZWcLDFb3Xlkwnq7lxjeP7o69jVDUdRs7T7Y999otILZ1ja4uI2WOTd90o3O4ds8YPWkodiXK3U898R27W9zFNIV3B+qjIAPFU5M5IBwOnWum8aWjyWc2xCPl3KR3xXLxyeZCjZ6gEcV7OCneFjx8XG07j88EHgn9f/AK9KH5BI7dAOlNAzjefxxQy4APGR19jXacgm7AA4z1IoBPU4BxwPQ0hxk4OM+3Wn4yByMnrxVCFCkjOBz69aVBy2Tx1z0JoyAucZGeKQYI5INAhWJycHaTyQO9MB+TGMAHJ9jTsAAZ6YzSbO+flznI4FMBvPrgdMU4DPOcc8UFRwAMDnOaUnkAdPfvTEOK/KCp6enb3qPJDZADccelSKoGCwO4f09qbJjOM9z0oEHOM4z6E96YSSpAHfHrT/AO6M4BHze9Jt255BB69v1oARTjJP3j09qOSo3YKg9PU/WkxhGwMjPXpmhSByOnv2oEKylDgYJ6EUUpIbjbubPGetFAzD6ZycexNPU8kEcDsKAoK8Kfejox28Y5qQuLkgjI46DPpUqYBycZJ6j0qPA3jjOOlSBuefzoGOOOo5P50v8OTjHqe9MAA+U8EU8HIxzn0AoAUbQ/Ax79hUmee+eoI6U0kYQD3P1p4fYBj6+1ACNnIBz+JpjgEEd+tOJII44+vP0ppYEgDPNIYgbqFGc85NLuPAzx1BJppBPHIBPHPWlZRkDGT65oGOXGzg/L1xSoCFJJwCKEXblgduOKe3JBXsM81IyfaBtye3UVIu0MBgnngf/XqOHDADJ+pqTG6RRjkdD6US2Gtz0jQpjJAig+nNdHBKdu0c+4rkvDr/ALqMew5rq7QBhjo3evlZ6M+kpbGhAnGSTn0zV6NguPkzxwM1UhA4GOenNXIlJJweRUpmxIi7nJ/yKljX5RjaT2JojjBbliPoKspDHvzjLdsitIkNlS4EgySuF6AgYqlOpKAjBI4rXmzjAUs2M+w/OsW8knSYmNU4/h3DkVpa4kykysqkEkY5APFZtwzrkSJndkbs9f8A61Pvpb3zFkPlxjOGGct+XpUM0Mu0JcMpGM5DU+W25EkcprVkMXjWEggubmRZJXcNJG+0YOFJwCR1Ix0rh7aPy3miOR5cjL+GeP0NenahDu+fZnA45wK881WMw6zOnRZVV8fTg16GCn71jy8XCyuQ49Ac4pEX5x1A/wA4pyYwd3bjiggbQMDANeojz2KwAHyjg+/amux3ckjjj6UpIx8uAccZpJPmU4znmqERg856n1qTBC9iSfzpqBeQ3p196d06Drz/AI0CHAZONvbJJ4FKBg49ByOxHtStnA5zj9aj+8QP1Hb6e1NCFyrLyu5h39KXA3A5460q7dpzj6+tM6HnIxgj1FACk4JCnI/nQ6hQcZ2jnPvSFc9cAH9akUg43Nwp6+x7UARYxGxPAyPx+lKcHv15yehx6U8gZyBnaePYVGw5JxwPTtTELKeMgYHTnvTGQDJB/MVIB3JAB/OgFQVxgsODn0oAjOCRwPxPSigqfu5HHPPX6UUCMkEt04xSg7SQOff1qIZ9SPanr8wxnt6dKkomzkkAfMKaG79v5U1P58cmggqM5z1oAep3ZBPBHIFSAYTAP4ehpq/MOAPXOKXooGcZ5xQAu9hkFQR6Gno3cnORgn3qM8tinIv3SCPY+lAx+eOCM9fem9B6DPOKUEZPUH1pw3fxdfShgREjnGDjpmlJyMYPv9aQklunPtT9u5MqfmJwKkYqrzlSQD0zUvVu5zxjpTIhgnn5cdKcAAfl6DpxigZMuFAweD6jFTxYLBWbGTjpkioBkqMnBHHNSR7lYYwD/M0nsNbnoPh/Cxrzkeprq7HlxuGfeuW8OKJbddwxgc+ldbZx7TnPJr5ae7PpaWxfiTecg4x1FXkU4GAQAenrVWPKMoOCBz9TWhAMHPUYrM2Jo0VWyAxHf6VajiGcckE/jTLdCT229s/0q8Fx1UBexYda1iYyZTkVlQqQR2xWddQqdwMYJHT1FbckZOQSd3r7VRlQqnY4PGO9W9CUzk7yBnlccDjjK8iqEtvKg+YE4GA3+NdPexF+MfhjrWXdW5Xo5wP1o5izl7hm2EMDkcYNcD4rQx6jZv1Db0Oe/HA/SvTNShCgkc+/rXnfjVc/ZpOcLMoP45FdWFlaojgxSvBmOuccknIz0pWPAweSf/1UdgB34x0pwwvDH2r3DxyJQCOTk+mKUoMYXB7/AFpfu8np04pwIYHj8cfzqhEYUsSMcd+afEpLKTnr2P50j8Yx2HGOaI2brj6HtQIc+GLE8cf5FNAULlWJXPft+FK2ecjGfQ0qK27A78ZpgKhUEjp9TzmmsMjJ4HTNDYZ8KR6jI60HqMsenOaYiMH5cE4Y8ClXOGO/HGDx1qXYCQcexUHkimMoUfw4/nQAiPsQjk47/wA6VuGxt9yKjxnBOcg4+lSOcse3GMCgQuWZFBXnNNYbuMY3dzSFuTnJJGMj0pvVtueT3zQAqgLkMQM8E4yaKQMdpU5AOKKBGOvcZxj0oUgnJ49RSYGOKRsgYx3zUlEmTnI6Gn4XAPYdhUasOvbv7+1O5IJJ74zQBIp+fkk4NOG7JJJ4OPrTOTwMDHPPelDcjtjqKAHHBI9hx6U9cEDA4PQUwctg8DpjsKeBjDBcnHrQMD94ZBIxipDhif7xH50ihic9D6dakwQuRj34/nQBHggDPIo5U7geexNEnBy3HcAd6ZyzfMfYY7VI0ODF2ULgZGST3qdf7p4IHOagRsZwMAHoRzVrGOeDQMkUZ6Z6d+aeq5bBHJ469PeolB7ZP0qSM7nVTnr0FKWibKWrPRfDeTbpnIwPzrrbU5VBnnNcxoyEW6HPQYrpoHyq4GGI/IV8rPc+lprRGku527jsKvwApt4yfX1qnbNuUdyOxrQiwHAI7Z9KlI1ZoQ5JXO09Pwq8VztL/kPSqEDbVU8Lx0PNWkkVQCe/HWtIo55ImcAqcrgY4OMniqU5jONo46gHirRlP8XyjoB/WqMzhu/OMdKtkxRnXn3WOcMD07VkSgvuyMd/rWzPHvJz06EVl3MJByDj1qDVGHqCb0OMY74rzrx1AV0+V88Kwb8jmvT71CNwAGD3rgfGcPm6bdqc4KH8Dit6DtNM5a6vFnGsVZuCSpxj6e9AU7e5X196bAQ1vE2RygJJ+lPBJxgDHUV9Ejw2MBAGTjrT95KnHC0jx4OccDj60g7469Mdc0xMHIA5OBk0IRtOePYHj8aSRiANwA7Z6g01CuSc444NMRLG2MjpkZHGc0pUHJGRj1600YBI49OT+gqXnBGDk8DHWn1EMJJYkDGfXn8qbI/RSCcf55p5AB4Kn3zSOR2P4g8D/GgQka9U2n09BS8ZLFsg9h0oOCSwOR6VFku3XntxximA4qSRnsO1McMUA4GeRj/GpOTkcnsOaaWJX+EEdxzj6UCIyhb0/pT2xv3Zzn1pzP8ANtCg+nvQFLDA+g7UAyMH5uMgfrRSuvOOcg8+1FAjFyc7Tz/OkJ/HP6UhB3HFOGd3GSO9SUPA7nr7U4nqRg9uKiTgewqQdck8kdKYIVASR69M07GM5Iz705TgDJxnn3pCpwfrSABuU9hnvUo3ZXPKntmmHCjIyT61Ko3M2cUDHspUYXHHJoYhs9Xz6UmSPpjAzTcEnI+Uf1oAVj8wB5HTikz1GMnHpSE5B29B2pyH1zj6fnUsYqkgjcPpmpQSAcZODk0wev8AD1OO1PQ7sdGPTJpDJkPB3E59uKt6ege8iBHVs/SqI9cD0x61raCvmaogXr1/+tWWIdqcma0VeaR6LpEf7pex71sopC+h9az9LG0BQOfStuIDGefT8a+akfSQ0RJDuP3eMDtWpCxyMrwQOaqWw+YcdR1q5CpVguQMHr60I03NCNgY1B6NkDPWr8CLtC8HA6mqNquX+YrwflxV+NG82NhIFUHkbetaRMJ6DpYMxgjjnnPeqEseFOB3zwOtatygUZJ3AdAD1rOumOTgdRwCMCqZnFmbNIcNnp6mqEjJJFlcZ+tWNQj3qCpdfbPesS4hFsS7SsV9D2qLJm3Kmgu3CjJBrjfEqboJMAAMDXWTSxmMncGUjGetcxrnKuF+bAzVU9Gc9VXR5fp3/HlEACGAKnPsTVsemAOe1V4AVNzGw5SdgOexOf61KTnjup4/z619JB3imeDJWbJJODwoHp34qEE5xjBPOBTyoB4TA7A0hCjlsZU8gGrIEzxzg/hR5YIPtyeKSQsTjGRnihO5H05pgLt2txgqegHQfjQ8hBGdxA60Nzkk9eOOlOKhcA5JOPypiGhzj5sY7fSkGN2PvY60rKNwJxuP+elMLEZwTt7Z5piHsMD5gePw/KlHzq2cZ/hJ/wA9aaQcnJHHcnNBAUjB4I79zQA0HAAOWOeuetG4EkHOAaQueG4Jp45Ax68/40CEydvIye4ppkIOdxJP5UjA5BGcng5ppOD0PPr0H40AKTyCCcEYxRTJAdwU8fQ80UAZbKRyACPWmrjdxwP6UoyRjPHWk55OcZ71Ix4XrnGfejPUHjPIpw5IyeT0oJDMRxx3zQA9uOnTp9KCfcYoRiRwPr9aVQSAeu2gBTk42+tSLhMqFye+O1MCnoAD6jPWpVXbnJwenHagY5SAOoIpZB/tcntSMoJ459geKUnjGM7e9AEa4DDPfp7ClH3sknH04o5J2nAHcmhjnkgkEY9aTGiTODgY64NSLtOQuc+/b0quODjv2/xqePcSM45544qRkqfKeWwT3HatrwsjPqGMdBnPesbOM7jznvXReDVJuJJO57+lc+LdqTOjCq9RHoulKo2uPu47961Y23OSoHrWbpSn7OM43L1q7CrGRtvXPevnWfRQ2NOADblsYB5571ZjkAuCCeigkY4rD1FdUEDLpggaXHy+aSB9R7/Wq+zWxNaeYYw7KUlUZKAA5B+vaqjHS5bR28M0ShSzAem0datxSbgCvpnjqPeuKLalb3tvG9ubiFifNMbY2r2I9ee1bEt1fx20T2FpHKzSBZFklY7U7kYGTVpMykjpldcEnIPv3qpcRjOF+6TnrXN6vq02l2xm1FdkABy1tKHwfcHBxVNvFUT2LzRvdG3KbopmgID4wcKe9OzM+WxuXMLYJO3PWse+j3cNnJHPPWnw+JLLUCwtZ0kZMbx0KH0KnkGiSdJ2yvPqDWb0NYpnO6lYIkgkG9c+hrBvEkKyqwyo+6x6muzuQHRlIAUVg6hFtRycYboauMjOeqPI7uMx6xfKGxna4yOuRjP6VJnbjdy1WtciMWtRydA6Mn4jkf1qqxXLKMc49s19Bh5c1NM+frq02hzYI5IABwR1/wD1U0g5wQBxg4pQBtO0E03dng4I69ea3RkIVwwJxk9jTsAglck/ypyxncAMZxS89Ovqvb6UxCHggk4J9B603BGM85HXuKeVJIB+nHbNEg2n5s5HNMRGRlh82M+godegzgEZ/wD109V+U4xknAppyARnGOWzyfxoAYT83J6jHP64prZIHIIHFK7E5AHzYxz3pp6gnv1GKBCFgcYyWGMmkJ4OScnpTkVcs24KQOAe5+tNyWORjB98ZpiDd0DeuPxpccE5wc9PT8aaCCvP6GlHTdkDP50AIW2tz/n3opDhiQQFGemOlFAjJOVIzwafgAcEfWmcYyacoPJ44/SpKHAHqOgoyOcfpTgO2MH+dPRVIAPHPSgBijkLxk9/epVyeCPvdM08BUyQuT600j5eQKAD0A6g8+lPXJwOfQHtUWc8ZIA/SpAeh5J6Y9KBjxtC57+nYUowWJGMHqKZgHoT1IwT0p6/dxjK+lIB2Ay/3e3/AOukJwWXB9hinL2yPoM/zppHXJwRzmgY052knHJGKkiOSAOCfWo3A+XB4Pr2qSMA4yevapGiZckgtgc9+c103hJNruF5DH1rmw3ACqMdRXY+Fk2ovGSOvHeuLHytTsduCjepc7rTwRGMcZ5rYgADdv8AGseyYjYCflxitS2UuAwb7x714LPejsacER9AcDqavoivyf4DwBzWfGdrcD1q9CSFDdM9cVSDUkihUO7ouXfrg4z6VaWFemGjPoDTYdjOMqCQPyFXUxuVMkr0H/1q0SMpyMO80q3mb97EJArchjuz9R3qF9OURlYFABOdhwRx0wO1dNLbA9eCOh7n8qptCyoxH3QD17UOIlWucFq2lXVzKpgWFbiaQK0h4fb3PvgdjWRDY67ot3KkZS9snyxeRtsoYenau+mRg+W2k54/+saqzr5iEg9OVp8zWhd7u5iQSwTw/IjIwPzIw5Un19frVO9hG07v1rTlQNJlc9cVQveFYYBx2qFuTPyPLvGkax+TMV4SdcnHY8f1rGkOM7sHuTj9K6Xx1F/xKrwnJKjePwIP9K5kHOG6AgMB65r28DK8LHiYyNpjoyAhC9z096QDJOeG6gmmqdpB9TwOxqdfLIOR9K7TjGB9vHIHQe9PDgBCQDg5A7UpjIPXOTyabsJXK8gn1pgO83HzgncOpPT8qQSDGM5XGBxzUXy5YEkEe1BJDZxyOQDzVbiH7iCzsSxzjOKaSdw4xjPOM4/GkHLHsM8Up3eXmgBHUKxDcc5phBDd2P8AKl3c4GeBwc0jDgk9ByOeo9qBDcHJDHGO3XJoALYDA7sdP8acCCuTknvkUEfLzyc8DNMRCFI6Kd+e1Jgkdqe2ScHlhTeAw5z9eKAEDFTuxk/nRQF6gEnFFCAzGAOB3FJ90YOOe1G0lhjOR/KnsMdOtSMFHBOPwzTxwMj/APVTVACnsKduzhlI3evYUALu5z/DjrT0Jx6DFRZO7GetKvyk+nTigY/acEg859KcclsLnHYetC9Oy46+4o4+8OtAClcjLAAeo5pVG3g9cdO9DNkc9fagZPXpnp60gHMAQD3BxjFOwTyR9V70zoTtz14PpT1xkc5OO/ekNDmwOSRj6daSH0wcHv6ClIYjJ47H1xRwMdweSKTGTIpYgA8lsYx1r0Hw3DtjVc4wMjNcLpa+bdxADjPOf1r0vSIdqLwMe9eVmMtonqZdHVyNy1QnaA2B2z3rWhVuFBxj86zrdTgEYx1+tacDArgHGRXkHso0I8MuSCV7Zq9AWCngcc9OtUYi20lwMD0q3HlVJXOevWqREixFI+VI5APODyK0IZsNyxOeMgZyP6VRtvkPG47hz7fjWpEoUjgHH8S9D9TWsTCo0KzIS27CoflA6Z9x71WmYkBiDt6H8KtuU+bzCuKzrkGN+Cdp9atmcFcpXXC7WKtj07/4VmzfMCSPlzk+taM3TDLjuB6+1UbjjjGD2NQzZGfNgkkYAPII9KyLoYU7+W9u9bDkgYxgg9DWTfsMttGAefpSsD7HEeLohJp9yp7of5Vwdk4e2iIxzGCSPp0r0bxGgNtJgHkdK8203P2OEZxtBB49CRXq5e9GjycctUy1IRkEAge9O+50J2dcDgmoTkc8hh0z3FSZIZS5OSMZ9q9I4BTK23AYjn7mf1oB2jrtyBj3pPLwu4/dz27+1A4Pp2PHWqESErtXIO4Hlv8A61RuTggdD0B5pxHI5/M5/H/61IQpYgZoEAbOAcgjnOOaeSpYbeTjJJORVdwScgEHNKrheBjJ6Y70wHY3MQfoP/10EA4O0HA55p5IOAcdgP8AGmsCdpPrwR0xQIAvPPPqR6+lCxsH+XDAdu+PWkONzcYYc/L0pS+MdODzjoRQCGkAEDJJJzimMvzjIwpNShsk/wAJbpTVbLAoOo5NMQjHAcDgE96KRkKo5BAA65P8vWigLmIBjPJ5HNPTOwjHfNNUcEd6enyk57HioGIOre9PQYyMcHr6U3GAeD/Sl3HAz9fpQA/pznHakzuII49qaWz1PXv60YJKr3pjJA2GGcDnPSnKxy2ORUOcnAPI7ep+tSjscYB/SkA7A5Jxu/MU/dg8en50gJP3cDnOaaFzjJIPXOKBku0seApz6U5FGD65BwaZGowOcZqRcYGfwpAiQLzk9uOeaRvu9epzg/560dD2xjmm5JZY8Gkyjb8MweZeh25VRzx3r0+zixCiYAx93HpXFeELQ+UjnPPPHp2FdtbD5FVScE4J74rwMbPnqM9zBU7U0aNupK8jHPAq7BhW4OWzjpVaFGQMAQB35zirkMeAXZc54JHWuM9JWRdQbAOeB/FmrkKmRRnkdAT3qna54ABYZ6HtWrbKyA5T5Qcg+lWkZzdiaLMR3HA4xj3q3HMNoJKAew/pVcDLEAoRjqf6U9SCg3Lu7DtitEc0lcfNcKRwuAcD0NZ9zdtgquCoPB9Pakvrd5ImClY1P93gisxFmh+85k7fN3qjWFNFxJxhgG5BzjNVrkr5mW544IrOuC4O9FJAP3RT476Mr+8PlkdjxmszRw6kV1uUkjPA71nXR4DEYB6960WuUeMbSB5p4HtWdeKBu5yKDFo5XXFBgkBOTg15daZQTIGxtmcH8+K9V1hf3T5zyPSvL1xFqF8hHAkDfXI/+tXpYB+80eZjloiUggYU5J44qQ48snI46Y/wpFKN8uDz60rgqAdqsPX+teseaSLtZTuGWzwOlRuH6/j9KYMjJyeeTUh+bGDlQeppoRH7HI55pz5IJJwfc9aDjG0DKkU3BAHUNnOR1piEIJ5JwD654oK4O4AjBwAKft+QkY3Ht1oIxg8nI4GeaAIznksQRjqBTgRgEgnOACe30p2VYY465z/jUY74GD1wTQBKqBzgnOeMf1qIqecHPJB55zQrEKoPXd17UhYAEnqeR2piEAOeB14+lL82Vwep+tA+YEZwOvX+lJlgVHGR19qBCbf4eWx29KKUdj1wfy/xooAxlOCcHI9T2NSKwORnmogTtwOlChjwfWoKHN8xwe/v1pc9e1GMEcc9KRRzg/nQIIx8xJPHWpBgLlug6cc0zuOgJpyckKBj1pjHqDkscDkUpYgkU3IO7b2NLwcKBn9aQE65+6cKfWpMEg4wD/OmAkNj2ANSjK9RhjyT3oAVUIHPQ9qUKfYAjA+tMZjgLwP6mlTHAJz6UiidYQEJY5A9KiQF5FKk8sMe1BYk9fzq7oEQuNXgVl3IPn49qipLli2VFXaR6Lodv5UKqTggYOB0ro7O3UMFzlh3HSs/TIwIgAx4HrWvCoVAfut9ea+Zm7u59JRVkWYYx5m4t7/SrQj3MvXnkYNRqo2ghgdxHQVOuAFB79APSosdK1LMZywXGD+ValsQYvlOccMB2NZa9cngjjB5rRsDtQ7d2Rgc9q0RlNaFolgCozhvukdBTlZgMIcg9BjkUz5Rx1I54NSgZAZF9gX4IrRHOwbbgANng/Ke3tWVfRsxj8mQxKvLqQDvHpntWrJngA5HI44xWfcbWkwX9iD0z6U2aQdjC1OMSW0gRmWQj5WBKkH8O1ctcWeqPb7rjUAJdxEQS3BOO2Sa7S4iLH58AgfXHtVZVUy4ITjBHpURbRpJp7nERR67BcR4+zzQqCxh5Ro+wwx6nmtS1uxe25ZVZTnDK4wwPvXRXkKhwyAYI5HrWHNDGkvmRryeSB3ob5jNWSsYuroQrDrmvLb5fJ126x95kVj+BIr1fViShIwQTwAePpXmXiVNviVdgP7yFh7ZBBruwWk0edjFeBVVx9cZ6etORmGQ3pgE9KYBgkZ6jpSZxgYO0n/Ir2UeUybJCkDg01RzgYz3z0x7UiMzY8vsciguMEMDz6jNMRJt3fM7ZbH5Ux85GMY7Ad/pQpynzH6buv1occnccj19KBAGwW+YqM8gClydpUFeR0/wozuzuGTjg55pjfKQSDjtTARgM9D9B3ozu54z+eaGc4UYzjkYFDHI2kcelAhOG6fr+tRyAZPY5xzx+FO3HJ59s4pM4OccjjmmIYDtHAweuRz/AJFKrng9R/KkO5RjAyOvt/jTc4UkZ3E+lAEjMCuBk98f57UVA5JGAeT7UUIRRxgDOcHrmkHBGCce9HB68UH7p9fWoKF3AggZJpR93jv0PpTcEAnse1Jn5vbsKBkhHcY46+9GDnJoXd6Y9KezHYFXAC85xQAZIU46/wCeKfxnOePTFMXnB6g9alJG0cZ9cUAP2ksCMfWpDPwMqGOMY7VCCGXkHHfnFIW7rkDpzSGTRkNwQuSeSP6U5SByeOcdOtNiA2epx0p2OQQ2d3WgY5gOD15xg10XgyAtczS5O0YXjj3rnDzlc8jvXa+CbYm2Z2JCu2RjvXJjZ8tJ+Z1YSHNUR3lmiqihSSw9B0rQVg23eMMO+M1V06LbKoxt+Xv0rTRUZQoGO31rwD34qxLCwOGIwf4cCre0gIW5XsMVVt4mABwcZ4q7FHgNu9cCkjUfEF8wKB+Y6+1akG5ozsAJbjk81TtEBYfNgjoR1rQjQgqApwOpPetImMxRtGQp4+6f8KkZckhsggDjP3R9KawCooC5GaRY3Zfl++eSCeMe1WjF9xZGBGA27jHTHFUJyCZEJGCQcYz+tW5CwVt2AwHSqtwvyDBB5+bjmguNijIWXJGD24qo6cBsHcO/TAqyTtYDGUzwQP1qKXhDtyT/ADqSmV5G3rxkPg5rGug24n26VryAHliRjrWZdMFDNnLE4oIRg6gQ0BPOSM49a858Tj/ia2En95XXJ+mf6V6NesNp9jxXnvipMSaZIehl2Z+oNdeEdpo48WvcZl7cHAxgc9Ogpp656gkcinMM9wD7nrUYPcHI/WvcPHJGIIBLHeeGz0H40hOcckKOfwph4cjA5Henr8p7kkdfSmIci/Me/XBP9KUbihwS2T3/AK0z7rgj5uKVmyT6HvQIBuQkMDg9QaeSCo2n2qMDAYnGV55o34PGfXP+NMBeB65phII/l7VIxG0lxgjrnpUboVVWwVR/mU4xkUyRu7IJ5Ippb5umFB7GlPTgAg8ZpjZ3dlA6Z7D3oAUNxnv9f5UxmJz6fyoYhSCfXFO3HcQMc9aAGsMjJ6dzRThwQdpx6dqKBGbn5jjrTsZBwaZjuP1pQAHwBx71mWNwQcKT7j1qSMc9OR6ntQSCG6Zp0Y4Ge+aAFHABAzTlOTnj24pCOB6dKXjkk5GKYAV29AWGOADUoHGMVGCVK9gaeSdrYzwKAI3bIAx7GpUO3qB+PeowpJLkfgKm27uu4nFIY9G6gc96evTORx04qA7hj/OBUoIG0gk+ooAU8jcMkjtXpvhS38mygXaflQfjXndpGJb2JEz8zAV6xpCeXGqjOCAOOteVmM9onqZfDVyOgsI/M2jj5emfWtWMBGXK8/XisG11vTLdbjzrkqYrpLGVhE7BJ2AIQkA46jJ6AkAkV0jQvG3zp8yHBVuoryWmtz1VJXHw45bGQeGyKsLGPMT5s4z1HBqGMEgcgHrx3qzGAVChgGJyARTRpclVPkLYJJ7D0q7bdTvz04I5zUSr8wGSR1BzU8A2uwJIQkjJHIq0YyY4AZIZe+OlRtlWAAGffrUxwq8k5Bzn0qGb7gKjBHU1aMyKQljhGZQvK5/zxVRyRLnBVVByM8VZmLHYRkDPFUZmJaRgBjr68UM0iivKwLHBwMVFI6qwDA89+1JIclh/DjjNMkkGBjGOBjvmkNogkwdwDEgisq5AbJBPHoK0ZGXIXJ6nkVTuQAhJyDj0qRHP6hGGDDgelee+N3Ma2o6KsyZH4/8A169EvsshA5DdCa848eAtalj1WRDn/gQrpwz99HJiV7jM9jwVAx29qg4DZXoT0xU0gO5jnv2qIn5yV+mD1xXvnhgcHj+tOyeB949uaRduMhsUu/axzg9j70xCHOGBGCD36ilBPByAf85phfr0wPXt70gZSOp59P8ACmIkLbSu4cCmFxkY+tNwR0XP8qTJUjIJz6D+dAEuMnGM5/SmHjqR64oztU4GR/KmjoODn0NAmG4FSAcfQ0oAPBGM9DSkZLDHOO/GaXaFBJyuBxTAaVPQp8vvQEGcYyo6Yp7Hnae3PWhVJAA5Hc9qAETIDIQN36UUcbmIwCvr2ooEY4bpn8KXcCTyc0wj0PWjJ4P+TWZZNngDGB1znpTgQMY78VEAQvPFSxjn1zTAepGec560EADI5XHemsSAMj2waN3TB/SgB2Q79eO/vTzt29s9vemEkk9yPSl2EckdqAJwP3PHUDnNMGQBjg0xCRjcGOePwqbPpzSGMThiclfrUinB/hPQ5oA34A2ikKkdNpx6Gkxo2/CsXnamjFeEBY16f9pg07TZbq8mWGCNQDIVL7WYhV+Ucn5iOBXDeAbbfJJJjO5gor0Kw3XmuJa290kZ08rLfQmHcXR1PlruPCnI3HHOAOleFjJc1Z+R7WDjy0r9zpdChudNsrWG5ujcXUaBZZioTzWH3mKjgZPao9FtRYx3WmR218tpZFfIuLmTzBOJNzkK3X5CSuDyOKuxrvUHq2cjNVNbiMa22rQWN3fXmn7kjtreXaZFlKq+VPD7R8wHXI4rkjq7HS3bU0YBlVcjgHOcZq5GoBAZQQOMj0qujCN3jUg5PpwcVcjAwpOMEcDt9aDe4+2fIYEHI4FWl4U84747ZqEIABxuZjx7VaQIDydpx1x1q0ZSEIDfdyCOTk8VDOpQ88N/OpnwrnBJA4GfSmTYYgltvByx5NUQUWRmAbOA3Vc1QucAcAbh7VfcP1wDkfdqnOvAI3Hjn2ouaIrFt6kHggEcVUlIEeCCf4Tx6d6vvGN+59owOMd6q3g6nHAPGDUj2M6RwM5655FUNQb9wShwK0JY2WXcy/N+lZeoDegC84PIpCZlXjEQggduP8a878eHOlz8c8EY+tegXQZoxvPXniuD8d7Rpd0Cdvydcdq3ofGjmxHwszB2YY55z/jUcsZxu/i7cf1pIX3RrngYGKl3ZzjvxjNfQnglEbgxC5B9D6U//aPQcU6QruOTnnOfepIypjODwMZpiKzK3rke1KFIII6kYxVgAbsZwc8d6aVDkenp3oQEQyAMDH17UpBbH97+YqfgMT0HTgf5/OmqrAgYA9OKYiEqQSOcfqKFwD3Jz61LjjOWbHU44P4U0kKwIIC0ADZ3BgePbuKkL7twx8vU1GWGc5zz0pmRkkHH40xD920/L1AwfWpBjYTkt2AHHNVxjd0JPtUgJCBhnpzzQA3+Mnv3opVYkH5eh78fjRQIyMYGT9BThyRxzTRkjmndMGsyyVSC3PI6Cn7vl4WolOPmz0pvqSTzQA4ks4I7U7ac7tvXoKRT8x4HTpmjeVPTPrmmBOi7W55Hc0u5mPBCjpj+tQLISBn14pcn5qQFpMEfMQeetKEwSAeR79agPMfXDcc560u7GCTn6UDJiChI7DuKaCGYc4wetLyQeabEvmSKq55I6UnohpXPQvB+ku9iyyXdysc8HlGKMhNmerKw+bcfXPFen6TbJa21tBEgWOKMIF3FuAMDJPJPHeuV8Nw7baJVG3YoFdlbqzRjnDY/IV8xVm5SbPoKUVGKRoIgznG4nqamkhE9vLbM2EnjaNjnHDAg89jg9aSHdsA4IxyfapE6rgg4b5QeefepRXkzK8NNGfD+nbLW7toxbrGkN7/r4wo24f1J2g579a17YttBbkAYH1rC8PeW+nu8d1eXKi5nUvdjEgIlYMv+6Dwp/ugVuwkZJU4j4C46Gqlo2a01eKZcQ7gAScj9fapiSVAxznP0qOPJDdM9sDpTlBwm7Jx39apCY8vuYEYO6o5m+XHOMdCM59qe/wA5AUbef1qJsgBd+COT7UybEDs2GAIBC9DVKVyDt4I6n3q42JR1GWGPTNQyKQSTgDb0oKKZcKpyBz/nmoGA35yDgfKuO1TvjAQcZ9aruoZnAGD2ApNgUrnKnLcmse+wqHghhzmtW5JGTJncKy7nBQn15pAzLn2mM7QSDxXnfxB+XTLrOMmP+tehTnETLgZz27V518RCP7InOMEjGc+9b0PjRy4jSLMSFgFVWGSVGMcVYJyMA+lQxnCKG9P6U8bSuff0r6FHhMZOuAD36nPSiBd3KkH19qdJIcYznHOKZnAB+6e+BwaYiYEkkd/0pSwI+Xj6VCCGAA5BHFCkfxcGmIkDDcckkd+5FJwrZBPqKCVRsnnB49Kax3Pg5BxQA7BLdcjp70x2GRtHAwPpS/wjvj9aYx67RyDmgBOgw3bvSZG0jqe1APyndzkelHzYC+vTn86YgUYwMnk5p4GFC44J9OPrSF1AOPwB6UpJ5blSPX3oAdIqg/3h69waKafudcn160UAZfU4OKBjPP3c0HGPagn0xWZQEc/yzTsZOAee9NOWJyaF7EHnp1pgSL8qn1pMhiMDnvzR/Dxjj86AuRkf/qoAdt+YDH404cAAjp29aN3Q57c0m4cndk5pAPXn/wCtS9wMnPSokZgTtPB4qaMfKPr2oGOU4yCQfQetXtEi8/V7ZOfv5PtVPI2EfxDitzwVEJdcRsglFJIrHES5acn5GtJc00j17TIdkQxjGOa6azUFV6bsY9qw9JTMahvv45HpW/CAYSrYPI5HFfNHvLYuovyhS2Bg49aFTe6gA7eOOxqSBTkA49M+lOZxGyqcuWPOO/sKaEnqY3h+ZbnT3kOof2kRc3CC48vYVCyMPLx/sY2574zWvGpIUnCgVmaE7zWLM1zZ3Di4mCyWgAjwJCApH99Rw3+0DWlAyxrhiOvGaqW7Nqb91FyFgo+bgEetDHoc4JOOTjFQo53SA4GO/bFKc8bxlgeOOtNMdiwG+TjJPXNRzAuV7+oHrQHAQgrgkckU5ztGUXgYzVE7FWQhWwCMgHpVRpGbsP7vPap5vmkdkG319jVWQgfKSetBVtBpbcQCMjB/CqkhONuSvH51O/GSi89yPSq0rbhwedvPsaliKeoFcHB9iD1IrJmyO+4D8607k8ABRuzjNZV6PLbGOVPGKAZnXrYBxwD0rzT4iEf2Y69tyjP416JeyHBGevXHWvM/iAc20aD/AJaTKAfTmunDL30cWJdospIdvIIK+/FTKV2cDnvVVvlbAOQetTI/zZAH4dq99HhsVY23E56Dim7wV5OQO9SfMSwHCnpQ4KqX67RzzTAYqgEsDkevTFDDjAxjHam7+OmO5/woWQnnAA77TQgH7x5YXAJBySD+n0puehPbr7Un8eQw44+lNDEcNkd8UxD88YHB7CkbdgZGSPbimuSCTzmkBLHnnPbNACMOAWYE+meaUElegz9aTouR0z2FLnCAcdevWmIkxtbPH1JoDfNgjB70wH2Ge30oHzHOM46igB5Pyj3BzRUTkKWGe+RRQK5SXC8gdPWkXBUtx1pAeuT19aTjBHANZlgzYHr2pV9AD70mAASR0p28EkD/AAoAkXjI7+tIpwRgdecVEWJ+tAfaNx5pgPYktz60/AAxg8801HVu2AakcZA2nIpAIMj608nHXikTsDjP1pT1yeR7CgY3fxk8dvrXXfDhPN1aYkHd5fGPrXHsef5j0rtvhev/ABMbgqSGCgZrlxmlGR0Yb+Ij1/Soyu0uBnOCB1rcjKgAE8DB4Gax9MQhR0x1zW3GFUKAMKevtXzx7TZaTlw2cL6ev0qCVtn3Tk57dqcJWTaUGMd+tRybckAZLHqPWqQkyjoqvDBewvBZWwS7laJLU5VkLZDuP4ZDklh7571oqBgFmAHUg9qytMgaC71pjp/2SOW683zg+77YxRcy4/h5G3H+zmr8ZJdlyox+tOW5vD4S4CMkt1PSplZjgHt27Yqm25lXGNvcnrUkW4sGUM3PAzSL6FliCrNkj3psjAYCcke/JNJGzfMxGTnvxmms2HwgUAnnPb6VZIyRyrZYDJ6+1VHChgcZqWVgseSMY4zmq0jfKN+COnHelcqwkvK8HrnoaozHYG2kgDOM96mlxgY4U/xDqagmf5Bgcj170E7FOQ7iH5wBis3UGTrkZ71pTAFcjgDsP51j3pDbiOT0BNJIRjXTYDEAFuefWvMvHZ8y80+HPBmB/KvSr5vkYgYA4GK8s8XOX16xTglCzc/Su7CK80efi37rFwCDnrnnA6UK4Ugqfm7ColfOBg4/nTWIGQOmOBXtnjlzORwee+KR2Cpwcn1qFZJPK8vOFJyV9TTn34wwPHemSI3BIBwp4PHrSJxtIOM0NlCu4/KR+QqOR1BwDgex5oAmXOGHUg9qbtDdQfX8aargnaR1HHuKfncDk8d6YCchsZ69AadsHbp603GRubAU/nSLIVPOSOetAD056n8MYpMYyDgY7etKeGDKdo6j1pWIYY2jj9aYhjZOD146CiJQc4I65x/9ejIK8HP8hTUOM57HjtQA7IIz36dKKVjzuBG3HSigRnsOB70h45JphBPRuPSmHJI9KzLJCwHAoJ5HoKaqkDk8VKq/J1wfSgBg5IHc0AZbPSl7mnKOQfXv6UAO6Lxwe1SRtu+UcGoSQOPx+tJ5nIxj8KALIBB5GBmgsO/1x6VCGJ3Hn8KYoy2STn0oGiZnB4rsvhoS1/ckZxsXp9a4oIdw3EYNdr8NsjUrlQCrBV/nXJjP4Mjow38RHs9g26EgnBxwR2PbNa0Jx8xG5uMn0rG0wlFOcbc/jW5bqpwQu09GFeAevzEu8sgRSM8jnr9KhJdS4QEDHfnI9c05lCbTHxlu3XNHzj5ueRgCmgb1M3TEEWq61FHZXaLK8Nw9xI26Kdim3Ef93btAKn1z3q6jFWOWU9qz9ag84Q3kSPJqFh5klqnnGJHdkKlHIzlSMZyOODT9Nv4rrzId0UeoQRxyXFkkiyPbllyA2OCOvzDg4q2rq5tBrY0IZMOQAcDtVmOVk+QAjPGetUYwBEc8EnpVpXBBJYbRyKk0vqWC5C4YkY4Aph5YBVJPX0zTQyFBuUfLzn3pgYDB759e1UhjZVDBnc4Ax93n8KpzDa29OSPwq/LnGGAzndxzVKU/ebBOeSfSkNakEm4q3IDd8VXIG0tgnHOB2qaVyOcgbfbrVWRyVwBgkc0WJbuRyN8uAny4rDvgQCVyAPxrTnkww69fWsvUHU56+vFMl6GJqTfuWPfrzXkmtP53ipu6xxdfQk16jqk3yMOcDjmvJlYza5qUxxwwjB68V6GCj7x5eMlpYubQwIFOCjAKjp6UqAY+X72MZFOL8cKOB+FeujzAGOtOD/uiGB45GTmmYwPmAOR170uOSCOM0yQ2lzlm4AxgVGyGPBHQ88+tTbsdDwOP8+1McbhwPwFMBsbBepJAPy88VYVVK7t2D6DvVYjCjGOvQ8U9GAfjaAR25xSAevJJPPfnpTW+f5cDI6ZPSmS53k7SSD+dJyeF5Unr60wHYK9eakB3dDgdD7UzL9GOcUjK2M46enemIeoGfvYY8f8A66bg9cZNCuVXIXAPODShgoA5APagQw5J5H0ookY8gY46GigGZ5JyO1JgnHtx9KbvwpJ4prSDpnIrMslLfU9qfkAccCq4kyRj0pJJRjgkYoAmdwDxnFKJMLk9KqBsHJ6U0szEe3SgZM8hPSnxMSfUfnUcMYYnOanHyEhOvpSAl3YGO3b3pQQB8oxihIyyktjNTpFxnGD0waAISCzYbpXb/DPCanPnn5FGD9a49vl6cnOc12Xw0UNfXTvztUDH41zYz+DI3w38RHsVqFUgAZ7j3rWi3uEXaBjlsdqwbZm8tRufd64/WtNZkSJi8mY8EqD1J9a+fPWL5kUmTedoAzkdzUURdnZNxx1J7e9UUvHmICqxGNucVehjlbJA2gDpVJ2G9QuhGoVSVB6nHXFUrrTLfUbJ7e4E1uZAF862lMM4AO4ASL8w55xnHWrZjCbSwO49abJcFVbCZ28Dtmi7Noq6sZ981zY3pn3Xl9Z3MkNuLOKBc2hPDTbuGdehYHpnIrXhbgrg/J8rEDge1Z8wadZIZ1Uo6FXUMTwRgjPbg0eGSLTTjZ/ZrmCGzc2sL3MnmNcRKBtk3dwc455G2q3RSbTNjEuxl2AA/rimFcrlicDkYHan5Mqnb8oHTJ7VDu2g7WBbIwck596EU2xVGRna7MRn6VXmyQASdoyTmrIncqxJBI6Y6mql1IowqkknhhnFFhplKcg5ZiPw/rVZ2ZywXA9atSjD7do56c5qtKONoAwDn60dB6FGcjb0O4Vl3sgX5l6jtWjOV3Ec+uc+lYeoPjdg4poymzm9anWOKQschck15jouXinlwcySsSSO1dv4vuDFptw3cqa4nRl8vT4R0Yjdg969XBR3Z4+LetjSGEJIA+tSBBjHBqEHKnGRUijjBYc969E4QU4J46DI9aRH3Ek8+maGI+buRwR6/hSRkL0yM+vpTEOBAA5GD61GTsIIyDn86exwNuce3pUcgIwaYCn5lzuPB5pr8AAdvShTgjG5jjJpZHGNoxnOc9xQA8HcNrYz2NJxkjuaYrZXgDI9aRmIHGQf6UASbgpy2AV7d6d5gDE8fnxUXUg45HajH3TnHoAaBEhkAJ689qYTnP5Ag0wDGQfypQccqQO/pmmIa+SBnp15oo5BPc96KAszJLkjFNb73tUm0e/NPVO5AxWRZAWIX3PSkQMxJccGrSw88jPcU4pu7AUAV1RmIB4FWFiGQMfKOc1IiAc0o5yo4A6570wGKAd23PA61PHGNw9aQKoJApyHJoAkLjIwOe1O3BOR+RqMrxnr9KYSOcjigYM25uOvpXoHwwhzHcu3AMgGfTivPQMnivT/AIbQFdOHbexY56Yrhx7tSsdWEX7w9HgYAKAfkxyR6Ves4RPId33cdu9ULb5l2ZOfUdhW3p6GOJMEKc5yf5V4aPVLEbRJHtjjA6/N/wDXo84hiF5Q8j6UIrBg0icdxRIEURqFO0HP4e9FxpIjEIc7pMlRlhiq17KFDFOHx1FSyzRlmBOUBOBnNZNxcGWMop2gnBJGM00aodbyF3wp56Mc4wKfbxRweJXdbe7kbULb95Puzbp5JwFI/gdg/Xo231FRWqEBdzg54Ht71JrirbWaahIdQcafKl35Vj8zzgZUoU/iXDZI6/LxzVR3sDdtTcdjj5SMLxnNRbQik7165GOfxpzI7SMFUhGOPwx71D5KRycDB7DHFNDuMllVOQ2Rng4zVYuzKWCHJ5PHarMq4A6BfTFQBVGN3AHQmmNMgIz95ueq4qvMwwNrDH+easuY+QxAJ61RuEATcCSOuaRTMu8ZgMYGeoxWDeNuDFj04NbeoNhsAAnvXOXkmC6ngDsauJhUdjgviJPt0541IwzAY9axrdFWKNOgVQMGpvG8pnvrS2HIZ8tUZG0HGMCvZwkbQPFxDvIduz83Y8VICMZ5Pt2pg5T8OuKcpC854PUiutHMPbJOWGMimt90DByBjNR78MCQcA9xT3Vgm9SSvqO1MQp5YHGfXPWkdgykd+9Rhg27g5PoacuQeSMdqYhsn3CD97HrSknauMYxjIpdx546+tDsAp44680BcFHzZc4z1JpGJABU57Z9KIyDnJxjv70hyThR2yRQA4HnA+mTSn5ucEk8dKZjCke2KcBt65pgC88c88ZpNnynJ6ZHIp4Azk4AI+XNDbSuR6cD1oEQjoeaKaz9cc47CigCHywDk8+mad8vAAAqJnPQYpFYDqeOlZlkoIAyTkGmM23hfXB4qN3Gc4zTASTkNz1oAm3Fj6KKnXaMZ7VAi7FBz1pS2MDqKAJuvehfvdP/AK9NHI44p8Y+Y4GT6UAOdumPyHajrj0pp/1nPT+VPkbCjJ4oARtqt15HevXvBEYt9Ktw2FbYP15ryCBTLMin+JgB+Ne26JEIbdE2gAKBg968vMZaKJ34NatnV2TJyQ2Ap64/StOOdnBIT7p/A1h27AttTJ45I9a1QrvjLAADkLx26mvJPQRde4YjBYqRwGNVpbpSSylmVRjGexpoi3RjOcKfvUxRGpwxAwecelBaK8ryBTtZY5Pu+uM+lRCP5s7x8nGM5qzMqZDBicnv6VLGi7AETock/wBKY0xbSAk5UBAeOOprZgiWKFXDZbPYelU4htwzbVJ557CrQfDqYEwNuM//AFqAbMvTbaXT7uTS4Yb97Ta15HezyiVAWc5gB+8NucqDng9eKuykhgGAYjkg03UtNttQFsL1JW+z3CXMRjcqUkQ5U5Hbk8dwSKzrPU5GCWerGyt9caJppbWCQupiDlRImRnaeMjqp61pvqJO2hYunJXCKBnqT2+lVZGKtjb+HpViQt5W5eCeACOvtVTqo8zdnuSc0GkWNkIUZZdzDOf8Ko3DbVA38enb8assSoIJOfTrmsy5ZfKJAGOvHegtvQzdQlyCc8dBXMX8pVHYn8K3dQcCE88np7Vx/iG68iyeWQgYXnHStYK7scdWWhwWoS/bPFDMDlYUP51aZODnn8azNGBkSe4JBMrnDdDitULwNp6+te5SjyxSPGm7yuIcgY7dRTc5PfNOYbeAR7en0psjDGeea1MwJ4Gec05XMZBQ4PPvUG85yOCB2FSDkEADOOnamSPZy6kkAZ60bcgf3s9PWmOeOn4imK+xuvPrRcCT7r8n3OKGOeN3Oc/WgTZwGAHvTWYNnAA4xT3ATGCcnHfI7GpSuVBPB6Y9aiBPIHFPLEgZH0IPWgAA6jptHGe9Jna+T1PpTemOvHTHegDJyaYD1ZsY4yKa2SMenJNABA3NnNDYABH4ZoEMI655+lFGcGigCmTk05V4weM9KbGMnJp+eCO1ZFkbZHGeOmBToVz7cVFKT61aQBVwOlAXB25OBgU0dRxmkkJ8wc08c4J7GgB8blGDDBYdCeaepIHHGeeTTO44HrTpPu570wFyByc4pm8ycEfLSdVU5OScU7aNhPoaVxl3RIvO1a1Q/d8wEj6V7ZpassKFx05zXkXhNAdYiP8AdBI/KvXLZz9lQ+orx8wd5pHo4Re62bennccHAA7+tap4XOCw9qy7VQsa49KsiRjlSchR3rzjtLgcDAbPqfeoJJB84fB54OcVXd2RMr1BwKrOSYwxJyy5NCHsX/MVeAVw38Wf0q3BMzYwVUdBisWI73G7nnrV+FVSQKBx61VgvY21iV03Dnpz6/hT1lJYY42nA45NUkBU/KzDA3DnvVxJG+UcEsQS2OaaQm9SdtwQFsEHtWfqun/brOaJZpLOdlIiurfAlgJxkqSOM4GR0I4NaAH7styWJzmiZQuMd+DTWgjmZNS+yPNFqqJZW6SRww3s8qBLxmXqoH3G3AjafwNK4KkI2UcckMMEVpahFG5aOaOOWPbu2SKGXOfQ/QVx/im3m0iwkuLC/vUlu7uOZy7iUJuOGRA4O1T1wO/TFaJc2iKcrI0rh9wJXjsB6etZFw/O3HQVyfijxbqemf8ACbmAwMujzwR2iyRAhVcgEN3br3NVtX1/UI9S1+3jkRY7TSoryH92pIkcKSTkcjk8HiqVJilVRtXjEoc9+39K8y+ImoN5aWyt87HpXaOkl3pUF7cXEz+bZKkkGQsTFhyxAA+b3B4ryjWAG1+CHGIo9qqvYAdBXRh6fvHJXndF6zj8i0iTGCF6e9TbyMe+TTh84XNRHoPfrXsLQ8zcer5HAB+ppr/Xj27Uw8MSB3pMnfyehpkjsgtgnp/Kjfg9PypikkE96Bzz0oAlVueRz6mkkGOgHTgim9EH4GpV5BGPypgRL785qTOeKizjzPanqflAHFCEISRkAH69qkU4xg5z3POPpUUn3fXPrT4+goGPIAHcjNNLFWyDmkyfMHfJpAfmA4INMRIZQByDTPlPOOeeKH7Uwu2Dz2piHHlT0wBRUJPP1ooEf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cellulitis is characterized by a warm, tender area of erythema that is well demarcated and progresses over time. The skin surrounding the area of erythema may be edematous. The photograph shows forearm cellulitis that developed following repair of lacerations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3107=[""].join("\n");
var outline_f3_2_3107=null;
var title_f3_2_3108="Guanidine: Patient drug information";
var content_f3_2_3108=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Guanidine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/5/31826?source=see_link\">",
"     see \"Guanidine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat myasthenic syndrome of Eaton-Lambert.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702228",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to guanidine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699028",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it, on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12525 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3108=[""].join("\n");
var outline_f3_2_3108=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025356\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025355\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025360\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025361\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025363\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025358\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025359\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025364\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025365\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/5/31826?source=related_link\">",
"      Guanidine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_2_3109="Gross appearance MPM";
var content_f3_2_3109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gross appearance MPM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 293px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAElAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwCW2hu/MCkQ3CnAJ4XPow7fX86yp4pIJnhuEMcqHayN1Br6kuvDll4uvdWS8sVltYpBHFPGoSRcDHyt/Q8V5R4t8HPp17Hps17b3zoMKyqRJFH2WQdA3pg9PwqaeLi1dk/VanOoRV7nmC/MwVNzMeigZNbFp4dv51BbyYAcf61+SPXAzXeaZodtYRKsEeG7kjOfr61s21gQ4LnnuCAc1lPH62gj1qOStq9V/ccjpfgW3eKRr3Ubwtj92LW2Qqx9SXcED8M/Skl8FXCHFpqUbtn7s8ZQ/mCRXdNbRqwMTtKvU8EbfwoIJOMHB6jOMVMcfUTvcueU0rWsecz6Tq2nrm4s2MWceZEwdT+VcfOpjvJI2BRgxwCMcGvai5VS0T+ZE3f/PUVhX+lW92rbraKUg5Mcingf7JHI/Cuv697dKMjzp5XKg3KB5SwHlyqc5BBq3pM3lzlexXH41058JRXUpk0q4xIykG2nPU4/hfv+Iqjp/hR1l3ajdiJFbaywLvdTjoQcYrSL5GpnI4uV6Z2un6hbm0ja5kQRSKM7jjJx+tV9AWTS7y8tFD/wBnM3mQS4woVuSv4Uum6TZ2sRMErys6rtlkUEpg5IA6e1W2uJjOVOWZ+Pl/dqfwHHTtXRXzh3TUdgwvDynFpz3NcXMQVSXjI6g5yT9DWjaz/KerqeCWwcf/AFq5GTY5LRDZgYIPK/iB/Oltp7i2kGx1WQ/8sZW4cY/gbp+B5+ta0Mxp1d9DhxuSVsN5o9Q8N6vLCwtZcSwyDC+bwhx2J7cdDXmPjnVdM1bxQlxoNzLcaetuqYkj2hX3NuVf7w5Bz70uq+Jhb6RcKFYXbqYVV+NrMCM49utYUUPl2vzIVGAcenvXLm2ISiqcep6HDWA5qrry+zt+pZtyCHeEbgpwcdqt28ylCxJDD7rr1BrP8K2st7JcbCcbvmFd3ZadaW1zaeeItgxuA659f8a+dbUXZn3dnON4nP6bfXM7zZYfakG45HEg4A5/pW8l6tzpP2MWe6VGeZ51JJKAYIPOAO3A5xzmtXxBHDsYC3jjCttRQFXr1zj/ABrHhspbea5le5+URYZFX76nrj9KlzUXYcV7SKk9GZmqai0EVukkSpC0Plq6L83QAbj3wFAFRQ2V1HpFtLOWhzJkRSAh8MgYOQexGCD3z1rcvtDvNQSNrKBJIkKqQ7jO7HPbpmsm1slt1a3Zljm8wK6H+Ek4OfTGR/ShO+6KvbSL/UhtL64gt72NJG8tmExUZwWAIDEeuGbn3q/p039mQXLpJA5v7ZomTyw7RgfKx54BOSfXhTx2y7tPs0l3bqgd3WJo9+cgYOR9CTV2OGS/svNEkUH2YOXDjLEY5wO4yCOM9OgHNaQV9jCrJWs+/wB+mgsgWS2srhrqGOV5TC8cgICKNv7xiP4fmPv8pp0EU6G1y2Rn5WiPLAjAx35BqlEhkCwDaUjVn3Zyx6DH0rdsbZxDZqQUlklZ94xkqBgnnpjPX24rJPmdjpceSF29x5tLWxnU6kSDCzRzRRybZHcEgEEgrjOB6cH61WnLNdWsUgJhRwoQYyQCWx055JxmtjVLUTeJlExaW8dlDyH5izN8wcqerc7jnrjmqhht3u5LnzIvs8MwjjjdijSKDtznoCAvcg/MOtWn08zJtaPy/PsMluJJFniidkjyrTSICNgz8uPxI/Sus0/xNdWZktb2EXAiHzSxHJXHY5OG9Mg9vz5y5+z6jO06MYkbCuGThRxjB7kgnsMY70+6l8tkkuA3QN5bcfIANuR2zgmo52tiZYeFWKU1/X9fobeqeP8ATViMaR3TSk4CGIg1ys8t/rE8cl6w3kHyYQfljX/H1JqvPGhdbmSNU6bQv8GTxn361c0k7LeSRmHmzEAKTyg7VonJs5lhKVNOS3Kl5EsRVHZeMfdzgn6etVCkk8hWMHZG2NwHGfStSWIvM0UWGZchnHQH1+voKqSKsaskRZlTsapaia5fULC6a2lLFVLfw5UPg+vNR3rMPnkLnOMknj0/wpmNsq56t0Uf0q1JGWgMbgAYxnPT8KpGTs3djPBuqPp3iKNXf5bmN4mz6qQRXqFlfvtKOSQfTmvBpbsWus6fIxOFnGfxBBr1N7iSaOGOOQokg5C9vrRNXV0edNJVGmegaIhluHdicRDcMfyq3repiOARB9zj5ic9M9KoafcR+HNBh+1yhpCCSzcHnoPwFeU+NvH0FjBNsbdcTHhc5OP6VUIOVkjlrTSu0ZXxT8SJbK9vDJmQkgDP514xI7O7O5LOxyT61Z1K+m1G7e4uGJZugz0FVj9K9ejS9nE8ycuZjeSOOlPUYXg0gpw6VukQ2IKsW0ZkkAxUSKWYADJre0ewcsrEHn2rWEbsyqTUEamlW21V+XrXU2cOAO3fJ71VsbFlI3EZ6Lx1rchi8u2d2A28ArnmvRgrI8arPmZWZQo9hzj0NJDCskYdzjPI+lLcgngkDeeo9K0Le3HlDG0jsTWiMJOx1uv/ABEt7HS5NM8JRublj8186YVfXYp6n3PT3rz/AE+ydlaW6kMkrsXclyWJPqe5q7piW5jzOsvDAFVHOO5Ga070WT3jDSoblLRQMC4dWkPqTtAA57V+de0cvQ/aKWEpYe6ite5lxqkTqyZYe4zVmacKfmOO4wKsSFRK5EcQVR0A4OOM1WmSIoGbkd/TFO7toae7J6igebHvt2G4MFPvWvrfhq50q3R7maJ5ThXjQkkZ9DWZouoyaRqXmw/OhU5GAQRWtrmstqM5lwSZU2sMfdPYfjVRtZ3Oatz865NjmktDBEY7dQAOcdhWBdagbe7eKQeWVb5Gx1FdfcyDyeSFwMHHX3xXLeIrNp1DkHvtJ6n2NWm47ExiptqfUx73MdwJBwSQeP5/WpJ9Ra4BE215MjJAwRjtn0NJCnm2aox+YcdKyLnfuI53KMEf1rqpYh2sediMFFvm6o2kn8i5PWSBsEEdRnvVhrqGZPLL4ue3HJxyD+Vc9Z3l0iqkQjc+kgOK0NPgYv5r/vZC+GwMfy7VNR32NMPHl+I1VYNChCnaeOlIdkq+XKQYyMrxn/Jqza2hEfk7WI5Ksx4HsaWG3RrUxuVRt/XGO/vWUZ8jO2dL2qOTu4xcXUT3ju9vkAgcMoHHH4VvXUUFtatBA7yWx/1TbvmU56E+nv71NNp0EOpwRXYPkHIzj7w9cj39K2LPR0tNagsbV82N/GTGxAIGOhUt2PP6U51HNWkzGnQVFuUFoyLwBIumTXsEyI8dyuNrDBOeuD2PvW5qF15wj0600+zW4FxujuHciRdxUFS/IZduQAw4J3ZHOclbW4s5xHPFt2MCuV+Ujsa6DTD9su5YJ00+wRkJEkjFE4Gdu49z2z16VyRqNyPWdKKg2bOm2FjLpN1Dcxwz3FvK0b73BBwcZDA/XkcdK5WeYpauLcyMruURdwZu/BHXHA5NdT4Rg03UrG5sr5EtZI4gYb1IyyhNwb96B0YAYDAcjAPOKx1cfaF8xnfnACAYBHTPTOB/Oqqq0U0tznp6TnG+q/rT+tDQ0TxWul6BNp9xbwmcXHnRyjHmAkYIIx8w6YyeP5c3q1s0S3M91uN3c3CSh8AYVjntV6/tzdR4htZS+7dvwCuzBxnuDnuOKZJDDNo1+6sWkRVYvJyynps9hn+dJTclZ9BulCLco6OW/wDXQw9RtJb68CxyAlIC2WODxzj9arQh207y7BnmnnXdcxxvn5FYYDfio985rp4bNde/tO6v41F0iRhJIF2gE/TgY+WoNHQQjUBN+8kErJIYowpYhchuBgds/Q1UWkrkNOTsug/w7bAwxAhS13GV2j/lkob8+f6VctLVbnX/ALNBNMqKjZYH7wHb0xnJ/Cs2OWeHyponcyKoRGQkFfy6fWtfSbWR9TZLG7kjLwFXk2DcuegHJ7DOfr9aiM+ZpIurDk1uUYpYbLVLpWEUnzYaSV9pZtxBOQOvzZwMdPTqs9qqaxJLdwssDRMUWDGd4HAwevUVW1OFodegS1/fx3LYZEYZDcDPPQZ/yK1dPs57bULSOd0uG3MgDSLlcZxk9un3j2zV2drMdlbmvv8A18ti5BYyvawecoSVRu2RnJOfX1PXHpmsGaGG5d44oZbmcyogkZjkSEnEYHc4BzXR6/c3YtZorSMw3aSeXJIGwq4IHy46EYY/Tv6ZcNptkZ7qCRZWXYXB2kFgfmYHn5gDz06etUlrYyi7R5mZF06STBZVdURcPJGodgoGSwGR+X69qf4eV5L2NobxNPwhZ5ZULY4wEG35stnqMcZyas6nYwadDLdQ3a3ALOiLGzxPsIAyN3JBLY4HIBOAOaqmS1soCJJMXEeVLeWTvYYO3cOpBJHfp3GDWqjrqRKacXy9fL9DqPFcdqjzDRrJrawKBLcT4EhCqpZsZyGJB+objk4HE3cuGdMgFeozyx69BWpcarPerbqI5tPS3d3iaKbayhicgfxDPHJZjwcEAkVQmMcNuzIFRR0AHH0/Orm1fQ46cJJWluUw5ST5QpHc9Kkui2wBPmbPTp2pj/vZEbysn1YY4p120nlkKBz1xU3bL5UrM4nxU4jeGVDzHICT+Ndr4f8AGOk2MaXWqXm0IvyoAWZz6ACuB8ZEi2wxPJHH41yqgAD6V30aCqRTZ89jqrhVaR3/AI0+JN94gv3e0R4LQEiMSNk49SBxmuElkkmmaSZzJITyzHJpo60jcNXbCnGC91HnSm5bsfSd6QnpilXrWhmOUVctrKWcgKh9q3NA0uOcqWTcT616HomiWq7TLGAMZyRXRTpXOStiVDRHB6V4fdlLshOMV2WjaMNyZX5sZAP8VdALeKKdoowAzKcYGQaepKqQBgHhgO1dkKaiebUxDmU22ReZDGC23GSRjAPcfjVaQ/MQ2S3QEdG+tTXbMkgk38kYDeo96qBgdx2kDHIJ+79K1irGTd9RhG+VduSc4FbSptUDBOB26Vl2ab7jAGdoya20YINqnj61ZlNmnr3wz1XTA1z4du0uowQTa3PytjuQ46/TFc/rdnq1pKzjTZI41wBtcOcYHU/Wvo6aLemB1+lcj4hsVKliMNgjNfAcsXofqEMZXjZt39TwuS9uTgJYXSseCvlk1Xu9QuoNxls7iOMcNlOn1r0pFVbna8XznjcOQa37e8KRhZ4/MQrtKsOCPSrVKL6ilmdRacn4ni+n3KyFWicFDnI3dD7CtJ5tkEkgJwcKMdM5/wAay/HOlNpGoXN3pQCmNjJsxwyHt9RWdp2sJfWaorsXJDeuMGolGyPRo11WszqyiBiAN27gn/69UL8lrcoeQV4JH5UvmtKpZlwF5I6EmqtzMTb5GxiTgjuOKlvQ2jFt3MZtomUIMI47/wCfrVG5iErHy0bexGyQ8AevHcEVtx2sjtHKyHy84XA4P+eK0ptDvLSykvWthc2YbYRG43I2OOOw96SlZlSimrM4tLOW0k8yZVKEcOpztJ4ya3dOjitgWyFdgBg85/LoKdeWrR2rRmJ081A6liOh9cd+KW1lNtaC0dYnhkGPMHLREkc5/wA96v2umu5isPaWj0OoUtBZL9vRWypZJEXLAD37iuY1CW3uNRCRGQ2qyDG/7zdM1aF1PcTS2ocrCFyC5zgd8f4Vp+F7SG1vbgT+W00ijyJGGQO5APYmuecuZ2PRow9lFza17F/UtGt9R0yzv7ScRjy8fMRlgM8Y7HNcu8Vzbw2EkVyQJSwXafuc9Oexxmuus7g6VMCkQMjFw4AyMnPGfxz+FZGoIt3YwwxjfPasXkaMfLtOcnP1NSp9SFBvTp/w5r6VfWOrwGC8eODVbVBvjL/61T0IPQngfrULRhQ6OuZC2Vbk8Dt6YrmNTs7YXjTwFkJdIpFc529OQfQHP4Gu48PW7ahafZlj3zw/f+bk9cNz6jFKaTs0VSk6afNsZ90kq6jA1lDGXlX5V6qwI5BXv3PqD0q9okZnvIoY4hHLEwDI+McdRg1Z1nQdQtrmG7VgkbqCgwC2cAnNZUQlh1WCRQJJcncWH3z2B549OPQVPNy2T2N4ctaDaerX9f13O+8RWUUUMtxHbQec21Xd+SFGcKuPqO3YV5MfMTxBqEDE+W4GAeg9Dx3r0S98RyzRE/ZhEnSNFO8x4425IH+eK5WXTZpJVlRBJNKC+1epC9f51rVnGT9048JCdJNVP6/4YqR6rJp0dzHDvFtKyNL5YBYlQdoB7fSrWg6ittZ3yTRv9ouzvVgmQODxn0HFIywonlR73iKsy5UKTk8Z64x6VPY2KxfZWuSPKeVTKQcgqO30rPmaskzpcIbtf8EfbRToFP2eOTeo2bl5J6/KM8jj34qSWaWwtpb+0mQFtyFTH8oyMDJPtnp2rSuAJo2Uw/Z7YszQqDyhJBxn1wCD9c0/TNNi1Bbl7lhFZwhZ/KV8AEttU85zgtgd/WnBXlaJlUmmuZ/5/wBf5nPW1vEsEjeczeY4LuAC0gwQc9CB06Dvj69Ba6mdPE87eRMrwGJcqA8GD8209shz06lvVcVQt4AjzyRyJFbTSlfPKghBzyPc4NVbs6fHbQktJP5Mh89lcqZ84+QHkZ7+3NOEpJ8yJnSVRcm6/r+v+AWk+03o06znu7aBCSxjijBkUFt2T3Hbkn9KZfQWUN/bJaxho1JM5CE/IfXg4PXt0zwac1pqx0fznSOISqTA2PnVQRkK2eeoyaLS3FgGCTTQvNGAJVfe8hdcMrEZ2jBbJ6kZGPTdasyqJJaPvsZBee4Bd4oo7aItcLcrDkxMVGN2MEheOB0zkAnArlJb37Tc/wCj7mggGyMgYBHc89M1t+KJl1i5g0nThK4WXLRRchpHP3F7nJxn8upNVtRVrOKGwhjWOS3ZllKuCC4PPIznB44q3exEJe8Pt97Kj3TDcAQI88D6+ppI5FnlLBh5KcgN/EfUewqnFskYvcSFwvRQOD/jVwlpjHjhFHHaiPcmqugvm7nMfRRznqac4VE2knPfvTSEUswxuPy/U0+ZMIQxPAJ6e1XzGHKef+NwrRMQ5GCMAdznH+NcoOBiuo8ZEeUOOS4B9q5Y162F/hpnzOY6V2hc5oblMntSUdRXScAA1IvX6VEKeuKcQaO18NysFTHAFegaXdbdpZ8Y5GT1Nea+Hnwqk/8A66662uNisxAIPVa9GlsePiI+8zoTc73dyhI6EDt7irkaySjYjHno57+xrL0vErLLdEpEuCNn3vpWxPfShGWKJbaMZHq5Hc5re5xSVmY2pnY3l9P9jr+JqM5IUZG/sfb3qtcXCicLGdzE4DHr9TTwTGpwpaRvvE+lUga0NOyCxQFi21GO4juO1X4J7Yp875Oey5rJ0+3lvrmOJiSp6Y6KPU16HYDSrG1SBbcNjks3UmnKVkZNa6nrzo6pvI5HOBWL4gg821ZjxkZrrrmdJRu2BDjnHeuQ8SXaLAy7h0wK+ElFJ7n6NCcmtjy6e78q/KFQQD1raW7SSHHQ9K5S8nLahPtGcVPFdMJJBvIRhwMUR0HVhcreI7RLhHYryCR9QRzmvENOmTS/EE9rNvFukzRsUXeyLnqBkZPtkV7bq10rWyIuS5x+deFxaff+IfFt8NHjLhrhiJCcKADjOa1jFNO4qdZ0mmdtpfm3iRmbEat1Y1sx6YWDeVH5ibSS20kVq6P8M76RRJfajKz4BxGAP1Oa3rv4f3wRpdP1SSFiMGEqNjfliuOdGT2Pbo5pRWknY5GfeloIVkWOOPLpx3rR0XUVthKkjbUeMlguCo98GrlnFpemxy6frekGTVEQqkpuGaKTkkPjjAwQpHtmuY1mSTyvIFhBC4UHdACCB6ZJ57+tZOEo2bZ3UpQr3UVo/TXzRLJaJMonYLNY7iiKrEEhuMr+NY0SQW6y2dzAxuSf3TkkBR7+tZN59rtp0vred2hBHmpjAY5yTjJ5+npW4k39ralJdJF8pC7BnkY7/ma1mlGJlTu6jTujTtLBFihuNkfl8AMeM/Wtc2kc4/dqI0Ugk46n0qO3fNmscymMHOUI4NaFvEqxswRRGAAdo6+9cbfc6eaS957lKSNks5pri1kEIY+TKrDaenJB5qrHaKkjPbuAcBnTpx0BFb2rTxyaZBb7oVSMA4jByTnq2aydIC3LSO+3gFFye1OUktjSDk4uT0IZrGKSOdgoLZIweScdiOman0ee40u6sJ7sSRniN8gjKZ6Z+hrTtUkjuk2PFsyVYEZBz3qS3tIJUMc9ztVm45PBPfHcdqakmjJ6PXVHX37QXt01zLcyTaeGYLuchYtwHAHYGuV+zQW17cRNGz25IeJifuj2I64NXtNZJtOudIaWQyRybdyHcsmOdwPUAYPHesvUIxbalE8VwrNCdqrjCtk56fXOMiieqTQqMHFuF/T06E0sjpDgRbUmOwsT6HPP4nrVKWGWAO8czq+cAjGSp6gH3FbDypPlv3isOXEa7m5wMYPHarF2ba2u1SGZlgYZw68qD25HSs7NAqvK7JHMxNEjjCELyDnjGOx+ta8ISVIjI0flKAdjDAAPv3NPksZre7Fw8wDKd0f3SrKAOo7joa0dOWe8eae4LyOJS3lnIEa9mx0A6Y+tNqy8xzqRa5kU9TtZZbGOS3IlSJAzRhfm5U+4zjuKwIo/tsTTgrBAzeZJGnBbAwD7jPYV2LSQQXDxX20WRU8tJgMzA4wfbryMcYrkppF0vy4pJUkjESsrICQwHI6898U1sVQcuVxW/T9fmW45FN1aQXVvItoc/NvwJAOQoGOmMc1sLaC1dLpI4mncGNISo8qItGFzt6ZIyeevNY1jZzQXpvpI3PmRgIsj4YAgFTnuD2rSur6fdJGTLHGSp8rJAdh0ZscHHari+XY5a+9obW1/r+vuMvX5tR0GwhsUNvNuJMNwH+Yr93LKemcehBA4OK5KA3ksDW1oc5YzSOFJ+buce3TNa+r3MlzDNIjhriJgFUA/NycgE+mKyrC9ubSQ3VkrG48sr5ZT76scZ646jHrWybk/Ia51Hla1fX+v+GKLl0vBLIkUhhHlqjIcfiDz1596juZM3DzahKkRcgny067gCCAvGAMfnUtzNdzX0t1t8mac7VI6oPRffHBNV7VFtwZZCWmJIVm64zyfbntWyaRCTdkhIik92wskkNt/AZ12tj3A7/StPaQDj7v8TnqfYVVjlEbquCzkbuBnjp/nNWUdppgojMUS9MEHP40k7l1I8uosMTEr8oPIwPSp5VUQyEOTt4JHqKGVYzgEqfamsMR5IAUnNVfoYWe7POvG5zHGwOcSYJ98VyVdn46iIgjCL/y0yccnoa43Y/8AcavYwl/ZI+VzOyxDE70DqaCrDqpH4UgPPWuk4BT1FPTtTCRt605WXHJqluJnS6HIFjXIyPSuvtWWBFkmUSTNzHH/AHB6muG0adY8MGBYdK63S3URtISXkYjJH+Nd1LY8zErU7fRSIbWa6vAGZjj2aqWqak9wSLdDycKcYC1gahPqdzdafZ6fD5kpBfYT8kSdNzetdBfz2mnLHG0ieax4PJaVvQKOT+FdCmtfI4ZU2mnu2U7GIxPLJMybkHPfJNPtEa9uRFCGx1JxWPeaq/k+TaQNySzSTccn0Uc/nism4ubmYFJ7iQx941O1fyHX8a5546lDSOp0QwdSWstD0b+1dE0Bg17fh5wCDaWx8x/xA4B+pFU5/ifZCTEXh+7kQcBnulQn8Apx+dedkIqYQBR7VGAxHOK45Y2pJ+7obxwNJfHr+H5H3LczlErzvxzqSQREEgE9Oa0dW12SKFjNLCuO5OK8r1jUDrWrSxbLu48nH+riYqc/Qf1r5lu+iPtIJLVkH21S7tv4J7d6eszSHcit0xmmWKSz39zY29gyXkChzDOwjkZT3Ck5x710mh+G9S1gOSkNpHHJtLl95bHXaB/U1rFdCasmlzPqcpe2d/eyLYaXGJdTuFKwxlsbQRy5PYAd/WvQ/hn4TtdA0aO0NuY7xf8Aj4LDnd/hXQ6N4M0W1uheLHcrqZXyzdCZg7L/AHcDjHtiti+tTDcRTRseF2MT1Ye9aqJxSbZWMCRf6oYx3qvLKluhaQ/KTjPpmr074TOMcVxviq8IsrkITlBvGBnpzxRJ8qEk5Oxi/FaBbXRTqMmVe2lT5h1CsQv9RXHW0emXdvPeX98IoraMKFgkBubiRw20gMcbFKrux2PHJrqvi7qEeq/CJtStMHzfKRvr5i9vqK8uNxPIsdxcaeYYXRMeSuFbCgZ6nBPJ/wA4rlxEdpLU+iySp7jpy0d/+HRZ1SdJN7qiKmwhl6Kc9wB0xz+dWtC+yr4ftlaWT7Ucsuxeg5wG9ulZqWV5qtykawyLDld7upGFP/1u+K7GxsI4IRGV8mHbj7p/LPaudytGzPYnFc6kti3oPlStJvfe/QgnqfUA1fVBDE4x8pzxj8qrWpKSBYrZG3AjIIzzVotlZYnV4Nq8xsc8fh1rmbXQmVO7v0KUglPmRSxuMgHBXG3POR+HNTaTYhpfJjQTSBSxJ+XIAJJ+g60lrbCNQXklCk9Qpye+KsWWr3Vjet9kWOVdnlbZo1YOhOSCCOhPWpVr6lTjJxcYf5A0H+jqYVkddyqyou4qx6DI7+n0qM2y/akidBAT8rtKhBUHrnv+lbUWv3R1Lz7WaPT4vONw1vGdkbNjJBAI5OMAdTwM0zV9TXUJJ7stahp5HJEZUksTzkZOB3H6E80cq3M06idmt/P/AIBFprLa+Z9mUvdNjZsTBJx0GevAOT61Fqdjf3Fi4jgtvIIBZlRWkGME/MRkcjsemfWuh8E2lvNcnNyImKFpSUysak9R9eB61LqjQr5wjbCoBKCp28cgg/lXZCneCZyyrctW0Vroc74dR3tzPlAMlCW5yd2Ov5VoayxW3EsipOHAIyMBV6Y/nWfp0QF1dvHuAWT5V6joCRj61q3bQPbKrcxHqAcY59BWbtexlVu6nMjNske4ukbyy0cMYjjMe0ZUc9P61tTssLkNJCHKkqC2cjOCRjrVOztIbe7lltVJQjnPf2H096ra1GZLzzDKylX8t4ywwPTA684rOUb6mkWpySb0saF5FLJCqoNsWCChP3ec8VyUUKXPiXypiIxAGCAkkE/wj+ZrsthMUiE8FQFGckH1zWbBZW8t5cs0MisxGXcDLccnPbkdvShuxdGtywkn2M3VzEsLJJ8iuREGL5GcjAHpisnVrprfzLqRtyBMKo43HNbGpCOWZd0QWVCWjY8lDjGVPY8A1zfiFEaP5TlQOFHQe9UveBNRSTKXiS+js7n7LpCl1mO5WlILJ65x1z1xWda2sitJCsu1kBUsTnJPJ+laFjf2VlpU8Mi7bsDft8vPmD0J9BWHBefZpJvLX7QWbIc5A5AOOf510tNq6HJqOn9MdJPFayqquyvjbvA3EH2qEN9pUqyuuPvMSOaaYppxPOyxZc/e3ElfXA79xUEKsky4mORwoAPHoAO/1ppKKCEud2XQ1o5IUxtwAwGQo59uKtwDcC8g2LnaFHT86y4tiD5AMr9/PXNadqCI/mRmc/MqDqB/QU7jcPvHyqC+2M4CnnntSpGrtuxg4zjqamS1PnMzSEZQEADjPoen50uWAYkYI/i7Gqv3M7XVkzgPiDG39mQsP4ZRk9PWsTRNIhv7cO+owRSFsCKUN+hGf5V0vjwF9ImBAzGVJ/MVq6Zbafc6FYLdxSs7QK58+wQbCoIwjo5cqRjkp2Brd15QpXi7a+X6nh4vDKeIs10OQk8NXDvJ9jy+wZKJIrkcn12nt2qqLee0do7i0HmAciSNkP6j+tdnD4eE17v026kt4nOCVlRvXojkMTgdOpxx6U3VNC1PT5WWeRLyRwoZZHa3nTrjCSAH1+7kVdPH16b3ucNTA05aWOSWaJd3mwSIM7SyqGAP4VaintJVISdCRzg8H6Vfks2cukts4u2xlQnIHTP079Kiv7GGSLbujaTOPLuUBP4MPm/lXbTzmztOKOKplF9YNkXkeYqhGDAjr1p6W7KGxI/0B4zVD7CkBIR7mymB25VvNjz/ADx+OatWEl01y9vd3EEka4+aNT83sehH0969KnmNCav1POqYCvF2T0PSvhh8MNU8dLPdw6n/AGbZxHylnkDO0pH3gihhlVyMnIGTgZwcdF4o+Huq/DwNeWkkV7A6mNrhosyMD2J5Iqh4A8aXGgSxiMgRoNoA/hA/mPavcP8AhLtK8U6M1pdrtE4C4U8q39OvWuWtU9rvt2Lp01BdpL8T5G1OQmdzsKZJOMVnk55r1jx38OnsWW50stNA+W8vqU/z+VeXT27wllZTlTggjGKy5bDUr7lfHbpmm7B7j8akxxnNNI9cUxn2JN4XsEthG1tHKEkEil1BKsOlVdR0/wA26SVY1TjDYHUV1sw+8GrOnOOK8lK2iPom+b3nuc9PoenXk6XF3p9pPcLgCSSFS4A6c9a2YoUgKiJFVfRRgUIyjnPXvUck3XGcVWwnroXHIViVAGRVO8uM4yDgdzVKfUSkbZBLKcAetU3uzIm52AGOlNO+xElbcXULwqh5H41xFzegXEs8zBY1Jzk8ECoNf8Y2kVvJJH5ksKHDTBcIOPU9fwrxrV/E8/ie7SxgmWCxGXO5wpkwCTkn6HA71L97Y1jQa+NWOi1nUBqs82j6YSdMeZZZmzlcrnAH5/oK67TFsrWC1DYe1iYMYphuVgP4T/smuK8Oa1o1vbLDOZoEGPmMJXJ/p+NdlbXtnLaPGRBM38Mhcq5G3AGemAeemT61x1OdS10PfwlKnOFkbGmabBa3DzajcRCNVJRE6TALhCuedpO059Kfr89rJpYZAkdwwEaRJt+c9MkdffNcvczGBfPnj2K8nDs3BYj1xjnFVbtJ72Z7iLzJ0Vc79p2qPr+lZSqpKyR6scI5tTctjstHigjhi+1SKbtAMNGc5/xNW5bVVmj8xizklw+3lT9e39a5DTWiYKI5CJgDuJ6cejVeTUJhciGO5ABXcCV6D61g5W6A8HJttSNG6juGumwrMrDqwK4HtTrWON8FysXzKjSOnQZ54HJxTLc3LQEXExMbfMrY69u30qWN5JIjbXUp27cZiGMDOeT3rNvqDg4q19iZbxLCZfJtwJA7rDJIgL4PIyBj+fGeKyJrl7yZWuHDlRhflCgD0FXZ7WDcrxjIHHOfT+tY9zFbmdt7BT97aT0+lUpNx3FGEL3W5qGe4Fy0mmxQ2aSqu9YySpYAAkA9MkZx2qWMarJcPNJJv3jaTtHzD3HFVdPSYqDs2MRn3zitjTdzwt9tTameVLcfU/4URqyXUwqJQvovzZnW8FzHvlEc2JH3OF24J6YA5q001yXgS4jjCEgAq20sf5e9aVxLAsAZjtGOoHemXEcMieXkh25C+hx1z/npRzanPKrzauJeR1aIo5bZj5mX/Pesy7t4JiwuHyZG2M6nD4HI579KlsWbHlsAhVv3gzySOp+hphCzXxPk77dOOFyuT1/p+ZrZO5zxg4SbTNLw3p063JtIlynk+cJ5ODtHBGT0Oew9aZMW81xgZUc4PBrasQkNpKqRxGGRACRyRyp/DkD86wpzH5sscYGUOZOcYPXr9Kc4pJWMlUc5OTOZ8Q73SXa8bSoucEkbhkArj6Hr9a5hpkuYnJUo8Y27ScgH2rodXC3SNiBWJJPy9COg9KwIrWNftFuVO7Pc53e9Vsjsg1KHK+hjXUKyHdHC+Gzms8hQwKq2zdt3c7Q3oa6S9hWFVAAHVcE/pVC1s7W5vW+2SKkKbd8O4r5vPYjuPXmqjq7CumrJFRkMUCh3LA9o2/LmnQ20FtbTXD3FvFIoXZG37xnDDnhchcHqGIPPfmpFtyz/AGeQo0au22YHJZR2z0H5VS1B7XT1uryKG7M0ezyURVlYsWwSwOAVxnpk5rppx8jKUnFPmf8AX9eRdtLY3RUIHWInIO0At+Hauos7WG2gCnkuc5boexJPtWXYvNdM1zv2yORnCjcxx3HQfTtWrDbuEKvM7R8MVZs7sZx9Bz+tOK12Kqy921/6/r+kRyzfaD9wrOxLM27OR24xgYHHFEsIEBG5Sw5PqPY04MBKuxl6bRhetJKq+UTkueh96dtdTPnsrI4jxdEH0+9LYw0ZP+fyrq/A8tpL4YsIJkuUXyV3hpkuYuDkkRPsKfRGJrmvFsarpt5knHlMP0Na/g29vLfw9YLIsclsY/8AVzoQp/Hj+YrLETdOmrdzlmvaVNex2l3olrewreRnwzc2qFox58MtiznHGGIVcnnqx9Kx7SPTmH2SeS+0yz5484XFuCOn7tlZTk4HX9KINUtojut4LuzkC4knsLgqGHuo46HoWINEqWyAz2V7bXKDB5t5ImbnoxC4+ozXC6rbTSt3/q9xxp8t1L5f1sJdaQ8lnaywarYyRuxKxBjGUbPO6P541z6gKKkS5vrOzjguLRngUllDJFd22PZHV0APU4KnrSwvY+RHIFR51ZvMjkDHI7FZYPmH+64xxnPJFTLNauBLZXUiSqpYoG8wHj+8nzdv4k49aJTqL3l+YnGD0aOK8bXumR6a15b6dZWl5KRGgst0Mch7s8LFl6Y5RgM9ua8+tZGQc5yTyc85rS8YaqdZ12Wbaqwx/u0CqFzjucdzWUg5GOte9hKbjBOW7PDxNRObUdkbNnqTQuN2SPSur0TxIYXTbIw2nOM1wK9RxTkYhgR1rpt2OVpPc+kvC/jRZoEt5pd1uWAkU/Mcc88/h+FHjHwVa+IFk1DSikc+0BsLw5/pXg+k6tJbuuHII7ivTvCPjeS3MYZznr0+9z0rWMk9GcVWi46x1R57rGkz6bdPFMjK68YIxn3rMOM4PUV9PXujaL4105c7ftGzO5DhgevHtXkmu/DHWLTUXitYvtMOMrIGAOPQj1ourkq9rs+pLuVQrE4zXO31yEyS2eaXVtQ8mFmdgK4XVNbaaYCLkDrjtXlXsfQ20sjrIrveSozUd/eRRQklsenqa4i78TR6bZyXE8kUSA4LySBRnGcDJ5P0zXAax8RkuJGTTjNdsR/yzUhR9WNU5KwQoVJvQ9I1zXo7fvkZ7nFcfrnxAtLaJ/PkURldu3PWvNb7VNe1l2+dLOH0Hzsfx6VWTQBETcXDSTSAZZpPmJ/Os3JLVs9ClgnKya/T/gjtb1W/8UgWtvF9k0pcdRgv6fhVvSrK202ExWzMWlAEvGOnfNWLUGSIHbtU5xxV6K0KW/mmMiLOPmGAfpWNSu2rI9fD5fGm+aW5mQWdvcOY1aZVAyA6/IwPpmpJrefTrc3GmiMhfvW8jEge2eqn06iujaJfLRi/7zYFzzgIOij0HtVHxBc2cM4kZf8ARlUKWDkOCe+O5H5c1m5ycrPU6FRp8rcfdfloWPCPirTLmQHUtMlubpMp5M0pZUI6cenP/wBau71J1vtMlubeNYUY5ZIJiVEZ5KgEdiP5V4bbXapq8N7ZtE00bAoJEyJAOzKc5r1rSrrQ/EFgsmn6fNZXP/Lwq3DlHbgYxxt5BPfOe1azikuxxxrS5k3r5/8AAv8AkVPsk0Fys1yNsDAhZEGUP/16mhtlju9oI+2IcGEnGfUVsWekTQzkWM88KAhlfzNzKR/dJ5HvjrTRp/zFrhvlQnaU4P19TXBOEbXR6dPF6Wb/AK/rzNG3QS2gKQfPtzgHbsJ6/X61iPHJFjB2suM4Y9634ftcVuwURgY3KT19wa57U5JvtTSIylHUgxfj2/8Ar1g1dXRVGerRP9ruITtmAlG3Iz6fhUTxI93HIFXHBO4ZI+npUNmst1GyIYF2r0Y8Z9OuRU9jNG6skyqskPA25HHqPUUckiqjUdVua6zHgw8gjLOedp7VI90S+2bJWM5VhwSSOxrPk3YKx4aM8kq2CavWewQSFo1VuAm/kjIpWOKXKlclSeK4lCFlzGMhSeB+fWi4aRUMm4iEsAVHB69qha5RAZ02rGmFyw6570lpe/2jHsRQiq2FVTnd/n2q0iOV/FbREl1MIppZTwzBQnOBk+vsOvvW7Y2kMFvG0TEuByx6vnrmufklj+3Rs6GQRj5cDofxrZSO6lhjeORVJ6KAdoHpWj8jKqnypPQuyzCOAHO2PHJz+Q/OsqV8WRlbZ++xnnAyRWjawlXVZUDgdSG6H2FZt7avHarDFHuTeWUnPAz/AErTpc54xV7GFqXkiUKpZCwwoGQDWVdxq8qYkWLe4DykH5Bnk4HPHXirOpTNb2M8d7GXuFLCNUGT14b2H+e9Zt41xLpaXaFDbbtgbOMn+mKpK9up1+ylBrlM69jdJmUyPIhX75IzkdelZcskkkzR7QN3KnGc46/pWjMWELPE4KjI2kcEetZsxILemOAf73bBHSmrXHqnzItyW0t5rMsFnJFM1ugZZIuE2jhSO/brTUleGZ43WWSJPvuEwwbPIz3xnvjrVGximhLM0csTRPseVSMrgEkY7+/4VM3m73hTMgklBcucblPPPY5I610bkrRo2dHd5URIkViBt3sflGT3PrW5e3U6LHZi4jMQABSGNF3FRjkgZPHXnvVXSnlgvrSUK0SxncGVguMdxw3tjilubiSSQnYqCNBGiAgBVB45+p6nn1JraOi3Oaq7y0Wg+2tRHCJAmyJyUBx/EADjj2IpkpKxoSNofJxn3xmo5CSY96/OF3bQRwe5/wDrU2W5AUqBgY/L3qmkYJt6nKeN8HR7iMKQSoQDdjOSB1rqfD3h28tdNtU3apb7I9oUKJgoP1xn8K47xATfzQWuQnmyqp3HoNw5OM9q7yG8htlhfzmjQDiOOQBCPTkZz/hWFeMKkbSYo0nKem5Y1DQWhKzNqtkz7uBLbvAx+rLx9awpIbm3uX2BJJByZLOcTKfTkY/LNdFdarbTWkaWou7XcpLvE5Uv3B+nHX2rGGqBjv8AKhN5EctKLUeapyACJE2n0HOeveuP6vD7L1N4UalryZnjXRFMI9RjsrjcflF7Gdzf8CQgj8TUHiPX9OfR5Xg0qOCUoyxyxXUjAMT1w27sDxuH3vpRq179qneeBJBMDlhIJGkY++GzXI+KdTS6iht0E26PBkMkzsCx64U8LxiunD4dOVjkxkXSp87f9fgc0vXJHuaekhIDIuVxk9iKYORzTRwvy8fSvaPnS15nAOMZ9e1M8xg4GBg96jznGOKUN3zVEFkPsII6jmrdtfvGw55zyKzc5UdM+lOU9j6daLXBaHonhfxddabcI9vKRg9M8iva9A+INhdacsl9DG85Yhm34zXylFK0bfK1aMOqSxpgAnvkHFS247i9ipu6dj3LxXrGqQq2+3d+uDLKqJj1IBJ/WvNtWm8Q6r/y9i3iJwPKXaOfTua9BvrSR5bpdXtby9uYpvLEsVs4t2IPVMjleoyeuKqWF5YpqRmvbaSN4gxjSZMF26cZwK8OdVxdkfZ4LBQcOaWr8v6ucK/hD7BfstwRfXBwTLIS3Pfr6VqJpfkyHztuxR93g7iegx6V2mmRm9vhNf6eQr/NhDtAGOB39OvvUOqWkaBrqBz5W4/LJgscnhfXI9eKn2rlq2enGhGm1FR/4c5WwS3wyAbJCeVx3JqSS2DkIFKHt7/jXpKeANUuNO0t1tbY300cl2qRSlZXjwuFdW4AyRyDnnGM1jf8K+1241O9s7Wyupbm1YCYGZNg3DK4yQOnYZ/CtPZVbWsY/WcLdyU0vn52+442305FljkWOZ/9hGBZvcCtF50jRvtFkbeU5H7zPzp/eAzjAwen9KZ4isr7RrK0uLlQgumby1SRWbKkqQQDlTnscdDXP79ReNTJKpUMI0jBLErkk44wAOCc469+cYu8XY61H2q5r6eRuyKl0P8ARxCmOUi8w7nyQAAMcnvjr1rB1OIXIcMQw285Xkc1ohZCpCyKHPLbfl/PH8qifMxixJHDuPzZUt09hySaSk2xuCgjjnjhgs1/iuMM52gY4ODmtr4e6zY6ZrdneapayXdlbSbbpI5NrNGRx9cZz79MjrWZfPFBeTB2jZL5Ap+TmIq+7HI4Jx2zwayJESz1eU20m+JckNjAkT0x9K71FSjc8KtJxqOD0W3Y+ndel0y1lin0PUob2wuAWj8okmNewbPIP6+uKhij2p5oy7KMnuW+nuK8m8D6m6iSwU71JEkZJ7V6ho0kq7gy/wCrOd2cgj0rza79660OqFNxha9ybUiqoHiQsWP3QpHP8qxdVt1jjDQhmZhggDNdZIqyxN5ZJHdSvHWs+6UxqwPCEZHHX/6+eKxauro0o1eVpHKjTlPzw5UkhsMMj8uoqIWUq3qTXG0KnBZX6g+35VuWptppIQyzyArwYsLuYdsngD35qpfxPGnkXKbJdpYFs8j2+lCuo3OqVSd7MrWl4liWln3ZZiAgA4Hqat3d9HtZ1hBMv+rVsDt1rKvYRIMMj8henXHWtK0s7WaPymI/4GpbH04pMhKCfPIL6VZRb2SiTcdrSAEgE4+bPsOma0tI0+O0jnXYC+8sAMHIIB/xFQvpa2ZilEc8qzo6qI0LSR7QMNgnGOf/AB01reFLabV9bhjtAUDq28qG49j2wa25HOSsKpU/duSfuop28NzZ6wn2qJUtJoyVZiCSR29xW61vmMeWGAdSOOgra1rTLHRbuFIpDeXLo0c5cdDnjaMccFgfoK5578qnlxqx/gx7+goqQ9nLle5xqt9YtOK/QtR8quw9OR6A/wBav3MEJDQSlgI1BRxnJBGcenrWXZs4mG9NrZBx128c81bv7+2VV+0MxgJxJ24HQfWqhJbGFSLbsjm/EFsLOwk1KSOQjd5Of76jBxjsMc7uhxiuKW3kNoEcsVmXdsY5A5yMDt0ANew3tjFrGmvdWK7RHkeS+3dLjA9c8ZJxXHSWCR25jiPmlR2Az15q6qcUrbG+HxC5HHrc8+mWaNXDsAOcDHQehrEuGeKdUkICucE4yF9/p/Kui8Qb7eXeoLLjGBxt+tYk4MM7RXBROwLNweM0U1c6XdK9tx+k3C2D39lqNwo+YSiQtlc45Gc9enamW0ha3geMOjybWAOAu0Z289j83TpisqSAp50wZGQk5DgkkNwf51q6YI4bwW91IZdqAwgkkbev4da6kuZXRzKajP3up0VvM7WojKzfa8kkZAVRzxkn3FNMTyKyz4UDhUDfzPemy3kaqgCfP13YprXZZScKq9c561Su9yZ2XwivE8IxA6BG5CyDOPxHIqnd3coDK9uWA7wnPH0PNPlnVmKoW+p/lVCZ97SFehHQHpTtroZ891qjCile61uHCFcvhUJ5Aweteh2lvGLWQeeGLqUf5AMp1x3PYGvLjNt8QQRJjfhm5+n/ANet0+IrOLas05mxlUxnDEHn2qKtObeiIo1YLdpO500wvbAsujxCWLZ80O4nA65z2ArEuEnhvFmu7oxXC/MFjbCgf1qkfGUEKAiBtpQghPlyfc85HtTf7f02VWhuTIJgFfd8qq/cYyePQfnWcaNTojqeLpR1k1/XcsXerSrC7GUieR8vKvPHrj156VxesXMVzfO8DSurAbnl+8zd+Ow7D2FbUOrWa3L+bd2i4k3JCEbAHOBvHTn/ADisDVHtXv5HsXDwN8wwhULn+EZ7D1ruw1Nxbujw8zrRqRXK9P66FaRhtIHUVF+8JIyQPWpH+aPrgngGmgsFHc9K7bHjJ2HRjCncQW96ceOBke1R72xkDpQG3YIPQ09iXqTKQQcfjT+MelRI34U7PHtTEPPTIpwY9jx7VEcY55FSAkDGQKAPvwWDp8vllQOxFQz6XBcRmO4hilQ9VkQMPyNWJ9XeaXDKFI44qyLng7XP0rz3y30PS97c5DUfAemyxH7Bvs5OcKrExt7Mvp9CK43VPDd/pCG9l02S7nT5VEQ81EB4PA+Y/iOK9hjuCerJtHqBV0LDKm9Nqt6dj9KylQhU1W52Ucyr4fRu68z5z0LxHcaPcm6sbrcwwptrk7o9mcsq56ZHFaa+PNXOriW3nNhp8quj+TCjuibQASRjzHGBycfzz6L4q8OTDff+HNltfEMs0IVfLuFPUEEYz9eD37GvFPEVlFB9kEstxbO26JkbEgyg9FAZcnPBBxkcmuecqtFWue/hXhce3NwV7W7v7rfc9Sa3s7LUtKiltbG4jmUNHPchg32iVmLIrqfucK2CCScc4rEltGs454ZQIyfvDHK9eB9aktZ2hvI9g3yphgqrg8VZ1B3Aee92rIWyEzlix55NY3UvU9K0oNq+jMN3LxORGBIzZ3g+nAGKqWt1Nsms4pnQEbztON34/Q9Pep71wqYaMPuJYtnBB/pWUjSSXR/dFFQnqMEZ7GpSuxz+G4lxaW4tpIZUZpmI64IA71zN7ILeZYyoBQDBAwCB3/Guon8xnkiiIJJ44/ka57W0Sa2kMmPOAwCOprqpSs7HmYuPPFy6rU2/CUJttaDKpcBW2YYZIA/wr2TQbq1uLK2uS+LaQjcQMMBnHfgHIrxzwDZJfXZJclvK+Rh/e45I79DkV6poAk06whgnt8xozfOVyrAknkA9PbisKsby1IiouknHf9NTf0+ULPco2EKykYDhhkj/AOtTLrE+5VJ4Ocjtx0rBuIo9Oigube4R1lyJreMnMRBAUjPJDfpitfT7uG+I8tdpAyMda5rcrsVUpW/eR2Kt3JDbtBG8fyAc/Nt49sfTtWHrNxPc3v2sxyeQpZYsnPy578D+Q/CumnhL3KAkNjgimajZxT2wjkAw3Kgdc/5FJuyt0NadZRtdamGdn7iRhlMkHPr2/WtyPy4ZY1JOGwAwU8n0+tZjQbZJLWZiJAeCRgDjg1YsfMleK4d8GDooHO4dRSJcVNf18jrrCCScxYMQCncS74VEz39sV0vhL7Fp+rweXc7ovJbLuuMEnpn24FcLbXUmxoSVhLg/KeCR9DUltcSvp4cymIFeY1Py4Bzz+NdFKsoNSS2OKthpTi4t2TOi1jVfs17qUaCCSO5JUtKAxHJ+ZSDwef8AGuaLK0IlUAH7w5/pRIJJRGjCPaxZnbGC2ecsf04qncpKoKREGJzg5/hwOayqVXORdOgo6Lf+kTx3MjPHgLhlPXr2qzHNE5keUqyAY6+nUn+VYgecMisqswOxcNjOQOvpWpFHOIVEnlhcFSmSBgdMj+lKK1NKsLIszTxqEIkhQsMR/Ptbk4AFEctlHbyRGVluuWZto2gAEnnOGPT0/Ose9sPMsiYwkU7MGDBQ3IPHHes6O8njsVt54g5/uqoJc4xkt978Olaxe9wpUI1I+6+pp6posOo2yXERCxsBy4wVz0z6c15X4o0m8spyhUlIn3R5GdvqPpXr0EpiiiXbIJo9gYAAqc9c1s3Wn2WpIyX1skKupzL5TSBOM5/vDOe2R7UUvIUqjp6PVHzrp0qvauG+8oO9X4LHPb86brFqxa3uNNkJMEbeYhbccHnA9OnSvS/E3w7jt5vNhUSwkZLQHccHPQj+XWuHt9NubeaR7a7Ik2+W+6MMrqex9f511RmovXQiX7yF913MTT9bW5QMMbgMEEYxWutwZE+aNeeAwaubfQLqyuZQYzPFI28tC4Vlb1x6daGe6VcW6XqkDpLGK6OWD1gzj9tUi7VInUQNgAblCgZOTyTVa/vVgjYrjcPesiC9udgDx5b3bFE8BuEBkuI488hU5J/E1Wwm+ZHHPcNNrTyzs44KgqcZBHIzn0JHvWijRMwaS8mgCghSEO4ccYBOOfr710SWUJQQ7Y3XGACMmsLVFutIkcwySPZsQZYG+YAeoB6Y5reNRS91aHBOhKlebszPmvJmdgWSb5t+dgwWI5zVUbpJMu8ZkOByevtnpXU6a9rqdu8i6Sk8a4HmhTD9cN0/Srsmj28dv50bbbYjhbq1AZT6ZBwfqPyqpVFF67hToSqK+y/A4lQ88yw26OxkbhF53tzjAH1p8PIB7EcY6V2U3hvTpFDfaLR1YAkQCQYyPdexplt4InlAkM2y2yFAQfTuenUVUa0eplWwNR25bM5cZd9salm7BRkmr9roWp3K5S0ZF6gyMF/+vXbafZafpduXWFRJnYc/M5I+laAtt+15isIfou4lj+FRLEdi4ZYrXk7+hwX/AAjOpA5HkHHYPzVSbRr+FjuiB+jV6lBYrs+fIJJIycnH0pJLK0IY3Fw0Y4C/Lncc0lWkEsBBOyPJJoJbcbponVf7wGR+lMV1dMxsrL2wa9Ant4TMRG4bHvwf84rnNY8PRSFprUiCY/xIMKT7itI109Gc1XBSirxMInA608McdKprLJFMYbpNk6nOD0apz78VutThem59v/b47u2jnt5FKOgdHzkMDzn6VahYS7Xd3Cqc4VuD9a+a4NRvYIkhsdVvLGIDAjRvkA9lOcfhRe614lDxldbuZBHyrELxkdRXiyrwZ9VDKq66n1FNeWcNuVupI0Q/3zjNRReIHu5dtkg8r/no3AI9q+YbDVNWknE1zqE07DkrIBz+PWuwsdVubqGNP7QvIsD58SbR068Vm8Skzb+xqtr7nvFxq0cFq0lzIiKByScCvFPiPrTavexN4YsBf3UbYkuCdkezuA38R/QUWumxzmRrpnunUkjdKWDD8Sf0rc1Ce2aOK2hlSBJMLjZhV9vzqZYjmVnsaYfLXQqKalr5HnNqP9bOx8qcKSY35MbD3HUfTNUmNzJKj3UJZPU/dz6j1rrPE+k/Zo1aN0UQqRuUYLk+tYB1jytNW0kt7ZZAuC77lb29jiufm6HvxTnHmWpV1e7DhPNCKIlI92rHtHLSFym5XbLHripL5mZl3JlccMrhvpUE7jy2FoGJcbSSentWsW3qYzjFLlitB9/KsMBihCg55cjk/wCFctctIwKcFnOP/r1qX04EI8x8yAd+BWj4H0KTXJJroxD+z7OSMTzdgW3bV9fmKnntt966IXS5jzqzXw3Ot+H+iWtjYrqlpHL5Y/dNE8qmWNsZZsAD5Sc7T7EZPf0NB9qsFlto1lCZw0SnLj0cddw9x6e1ZsOlg2yvFEYwilVfofw/zio4Zri1mJD+RMTjcOFf/eHrXHOfM7SFCimvd3Qy8hi8/EkWAp6NwVPQ1ds1XdG0O3GOwwQaqTSvcTtJPkys25gT1PqPSqqboS+8s0ef0PpUNGji2rXNdS6X+ZNhiIA/w/rUkLjzt0i4QDA49+MVSScTQFWQsuME5wceuRUk98ka+VN1YE7yMbh6/nUWvoyGntYdqWySNZgMmMZOT29qraZIfOlVZFAK71bIGQfSq9zceXbSeXlkC9zyBnt/nvUFqyJKsqBcHn5Rxj6UtTSFO0WvuNW2eWfWJZJGBihCqy4HOR1/CrKSRrJ9nTbtIJPHYHpRAYvsPmgfPIGUkcE/3f6VHEyNdyOx+VABn0zigbfN020+7/gk80ogEbEOy7vm47dufrTJibh4o1fYrMzM2MgAY4/pS3xH2EBhtIZQNxx3zmqNoEllMuyQxAEGRTjyx2wAc/U0lvcIRvHmNSBQLhdmC6rhI1H86sFo49jOQXZcDbj69e1UEa4jhW4jb/WMUIRgW7Ljr0Oev/16q6v50VwbWGdHlQ7CiYZGx6Gt1BvUxdPmdk/66lsTlZRarhpHGTsxvwW54P5DpUEVtFHc7ngc5OWdgMj2PNUtHG+4muZLaMzlhufaF4C42hR06Zz6mtK41GC4kaJWKSNx93Ixgc+tKWxPs3CXLH5l1ktwuCqgvzuzng+3502xu5rUK0Lx4U8AqMjB45PasOKGaKRyzo+T1RRz+I4q9Z7/AC2CMzA8sQoyfrUqXK9CpQSjZu6O3s/HKafbSNr1obm0lJdHhsyrSkYHHG18evBqr4m8N+GJybzRRAjzEGWNCV2/L97aenv7++a5mOGBLhGJaRsbUVzkdOw7Yq4twplaPCgDtu+8f8K7frDnHlkr/mefOjCnLmotrv2fyOX8SeGBp0CXSpJFE3RZEK7s9Mev4VzkOiyxhpjBmNSSSrEH8K73XfEd5cT2elG+cKAwUdPKJBUkn02MwGPWuru4dCvoIY7ezS28uIAeZ91toPy/Lg5OPvHnrUqEZX5X950SryoU4+0jfm/L8Dw06VFIyM4K9+FBz+dRXukm7jt7S4AmhXOxQOmefTnr716B4i0e6U266fbGSG4Xahi+dUO8DIbt/wAC6Z5qjLpU0MUSuGWNGGWwSVGcc1K5oGrlCcU779Dh28JRwj91uVe+GAAqXT/DttL56SxSzl12oqlRlj2ye3T/AArp7q3V5CiTxDzSQN7bN3GTgn27dSSKbeaeI7JJIJHW4aWRAkcgbIUjBYDkZzgDvg1pCUt7mapq2vU5s+Glt7uC33yrKuz5FkUbv7uBg4xW1qMd7Gnl3kSzxzuWRWZXfK89x+vvV3SNO1a+sZrm3kj8qNsZaIsxY8ZZu3I4qhDc30d/cxsbCK4TCmaR+UHJJHqPfp0z2rdSej7mbgtUraGPOl9YRq1rbQQ28o3BHKuQe3GMg89KtfZNThlkM9zZ2Mk0CFUkdmFwhGdu5cgZ4+Ukfhg1cu768QKXvLSZ1Jc+aeSe2R90imzanfW+mJNcwRrp84D7AqOshGRklenPY1pFoxafb+v6/pHMasgWaSbAMxfCwRfLHCOeBkknAxjn86dZxzO7BbiZO+Fxk/U9aXUbwzqpdbRYlbb8jAMoxwAOmK0dNj8sKyRk7hkEA/n+hqZWubwbUbL+vmNntmiiV2nuJduCyGVuR0JGOlD2sYBKxjaw4ZxvP5nmtWzVjPHFLPbwJIxy8mdqe7FQT29DUtrY2dzbW5N832ouVkQw4RRjI2tnLdQDkDB6ZHNWo9TnlO2hzE8DEbFVABzwOMeoqCaAso3gZ7H+ldPdWNt5ZwRnOCV4GazZ7SVGb5WZffiqvYy5eY4LxLopuoCyYMsfKt3+lcfHeGJfLnQ+Yh2mvX7i2EiNgdAcgDpiuH1fQI7m9aUcZHbvW9KrbRnnYvDXfNE9A/sspp1tNOhUSMSH3fe/CmQwSK2H5XoAB1/Gr+oaJrlrJ5Os21xFdx4Z4iQoBPOQBwB9Kq22tyWNyxKSbcY3kDMZ5H5EHFfPTi7tH6JTnFxU1rcllsY9y5SSJjg5YVOsDxqHRtyjuas2F7FPFmQ5+bGT0x7e/apLZQ90RCjShlPyD9a5nJ7M61FJXQ3S9RaG9QMrbM5AU9/x4zXX6TqMTyw3N47+Q/MRlj+ZgOMk/XPPUVx1zAspI8og9wataO3l3iwzRkxE4KCTbuGe2e9VCdjKvQjUi2zt/EVxGdBubm1tZREHMQnZc5Y4yG7Zwc1w2maadRtEEVxD9pQv9oSUlEhhG3E5fuuWIIAJG3OK67Wrvy9It45oopWdJREjqWRiQE3FMgBgPm3DuASK5bStNudYv4bDSIjLOY2IG4AyYGWAPA6Z4NdE7OS6+RyYRezott2Sb1e1vP8APp+DMiWCDUJZ7N7e3kaFtnmxsDyDjIYdRwcHvxVXUfCiqqrDPMoYc/N2rTjjitriKVInR3LCQlsqQMABRjg53HOfbHHPWfZ4pLUqGUx4znvio9q76MuvSULXW549e+EJo5AA8kkfTIOau6Vot1puJIJJImBzvTt9RXqM0VrPHCI03nGJV6EehAqibPJ2KitkBgyHOOcY/TpWvt5SVmzhjRjTfNFWZS0bxPeWcxjnAkt+BIQvQ9evf+ddwwsdUskltyrxOuVIPKn0Pv8AWuA1TTplS2g0+xHkICXbzW+d85yck7Tg849K1/DCppl1jVd4s5TuZo1J8s4POMjIHWptfS5VaEXH2kdJdl1/4JoahZS2c720zfOrbUbPIPoT71mJcSpvDbXH5lSPUVt37SMrkFJo2JON2SV9Q3eseS3Jm3bieMMPUev1pJGKlp7wsTxMSj5xj1x+VQXJeWaKCUBhn7x9MetRFhFuRwSAThvUelWHnikWOXIKtgE/3W7H2zQ0EZWZkPcT21y8Vvkxr8uXQNtHsT0rRgZo2jhc7gRnceuD6j61jSTLvZpZPmydy9CPSrjSOkkTE4G3tzwRj+ZFSrtanRWtsjatrkOiQs7bY0G/gnDemPU9aIixLMUIV5Mknqw9D+lUdJLQ3M8EjHc43H3PT/CtckPb/Mx2jn6kf/rqXpoZt8rsQ6s8b2Z3bpPMcBnwfTgbug7cVraePs1gsUhHlhSC2eoFZwVm0IlppAjMZHiHKjBIB+oHf60kF1mzSUqzBSCV7E7gB+HXpmm48tgnHmjyroyxrA+wx2875eQyAsoJ+UZz0+uM1DcyRyAXCFVKDlscn61GN18l55DpJIoIIIOSMDJ6Y5BOOf4T7ZwJ5mDJFHcBIFwu8jkDvyK0jJwWuzHCnzKz3Ru6fdOYZpMgorMUAPBOPmP6dfak0qFElefzAN4AKBsAd+vWqlvArWoRXKx7egPB5qxbosM0flbXODnGMDj0rNu5hK3vJdTZUxMpAUg+hXAPuKqzSQRMSmBJ0yTgD6CqlzPuhAizj/aY81z0ztFcs5fcPQ5x7EVdNJvU45Rkr6mk6TPI2Zi8ZznPGSff/PSrMYmEcTqx+XAYsT+hrnG1BZHjUsQxOSen/wCutGG4eMebE7Y4yB3/AAraUWiVUcrJ7nQRLG1wJJY1d8gMWALe2PatgbcBSAQG3bWHGfWuQ+2MrrJFtOCFNXbHUsXBV2cjGQCelZXcWW6XOvQ63TpRaPIsFw0IdG4RuS3BGc+4HPX0qc3dpdWcqzxst+sOGc5O5zjBGD0xnk9SeawUmi+0o6MySKdyEdcg9qkllCKZNxkwOTyAvX09jW0a7Ssczw93fqQXCx6aYryeUx3AYtA0b54zgkdSOSQOB+IqlbXWllmaBAYvLYOWiB2+4zyD6HsafaR+VOXiS1ErMH8ybMiPjoCh4Pt26VkvbSWscu2QlpgVPYEeooclZWOpU4tWk9f6/L1JoL+ViYNJeaOzvMq0WQm5/wCHk8dT0PYnpnNZl/p92jXK3cUQuLZjBcrvIZumRznpx06Zp0ypbbmjv41BVG4jYHcVBZcY7E7c5wTz0zjKvE8uaKcTSXPltuZGUqPTgEVtFPlsy1ZS93b01/roXdO0qPUlmWC2hijj6kY2qBzyc5qS0+xRtcQybxcl/N8mQK1uwCsARlwSwL5A5z781avr3TL6xgQzCyuLiPy1RFdHXb/Ex6cnngn8OKoxzv8AYbdo5Ed49wYIgQBzxnj73UfoK1j7ruZSakmiqLOCS1ka1QJ5kJDRu8Y3FV3McEDb6qBk5GOTUN7c3Ntdypcrc2BjiyiRxZDAgDB5yA2SMjIOfTJrb1KWVr68vLZ5rgyrmczwIdz5VgWXcwK/KDjI/LiursvAFlc2cBvpLmWby0BKyECLAHCDsPX1+nFbRXNp2OWviI0UnLqef6c4ktJZ0nS3aAbiJm25PUgcYJ4JxnoKibX4Ej/dW85O4HMKNgN7Ee1ep2XgjRdOyLaCRySCTJIetammaVp1sfMt7G2Sb/npsy35nmt40ZNbnmVcygpPljc8el1S71BY0hsZI1Vjs83bEqHOfunnGc9BXSwaTq2p2YU3NvG20MWWLIB59etd1qFlFd/LcQwvg9WQGpbG1jtYNiAAdsDA/KqVFN+9qclTMKnL7mh5cvhK+LMLy4hxkjKZ6emP/r1uWPg2yW3UG3dyO6ogH8q6m5jVFMnQLzisj+0r5MrCilQeSDjmplaL1M1KdVXuefapqU1xqEckl6xtyzAuAu8lmLfMQBuOSeTXN+I75Y53UKHWRcE5z+Jqv4j8H61oUUs0E9xJag5ZW2kKevBXjH5Vz0VzJIw+1AlvUjH/ANavN9kpPmvc+8p4q0eS1vyOt0S7Jto1UnaoO73ratL5YJ8qQdwIOe1cxo1wImYYPl8EMvOPXPpXRW6RSEmNhg8kHqfpXBXilJux7eGkpwSZuPO0sO8bSrjjgg/SibyhbW8qI5uEm6f7I5yPemWlyqKiltwT7qv90H2H4DNWbW5tPPkN8J4g0beUYQMCQ9Cc/wAIPXFYRtcqS5ehOfEsl7psemMxMQl89MkKIieCPXnHTtVSSafTbmOaxlMU9vL5sM0agMrEjPPcDHTpyfWq8EYDhHAZhz5gxkDnp+lV7hvIRgS0irjhjgrWvO3rciNGMNEtPzua1/MbqMXcqRTS3MhZpSMENu3FlwQASc5yMYPFWrBHjVJIyr7iQV64xzXPWl8XtQqhTnrvzwwJwVrR0y7ulkmMEVvuc52SggBfbHbNRe71CdN8llsbemyQt5ruNk4fJUDkf5FaGoWqx3AuRtXB3EZxx/nmuV+3uZWE/l+bIOXJ71ux3KSQwmJRM8I3jJ6L3FJPocVelKElI0LeINE2CrA8hs557/596ziDanYylkZDKOM9zkAVObwWszO8WxJGJAU5zmmzzSStEVfadxBHsRxg1oro4rNPXZlaG6W1QAqv2R/ujH+pY+nopP5VTvZwS4jbDjlHB4+lPuiXmn8zDRE7Gx6HnP4VjOC9uY3ViwXAI4P1NWimov3mTXgeaJnQkSJ+8UDuD1B/UVQSQtIFZSFJ5P0qWO6aCKXzMsMDjqc/4dKgvmkXd5IUEgPirS1FqkV9Qu7eOya3aEKS7FpCBuJPTB+tRaZevNbRrnJUdcdqdeqb2LZjbuXkMOQaytNjeGWRAWx7cHHrTa0NeZSj5nUw3EzNHdyFcAbW46VpfaybWV+QFJJzx15H865+yuNtsbZAXfBHI68/pWto1u5d5bmNZLRfl2SEqXPTg5BwD6VPI5MT5bXfQt2V1ObOez+0RIiKcBxlvm56Z6etC3iiGFITudEI3DkL23Hp2HH1qrZ2/wBtxP8AYw8MUphiEzDMuCQSx4J5wOPQ1oWwS0sVtmKGdpACo569Tk9ccColF8qubycU9Fr/AFcjtZJrKOQRiRxIchnjBH1A9/8ACst5Nks8jId7Nll42jgdP61uvG0dvciGTKIAF3HIXPYe2c1g3UqyT8Dce/OAT/hSUm1ymPPdt2JrWQLbxhs7wACAe+KUXapLlFOW56459celZ0bMpcM5LZJLdufSpZNirlRyADuqkjGdr6li5u3bbyAR1JOAKxL6/CZKvk98nHFQ3rv8wY7Qc9TWGtxDcXxh+zT3MUalmZGwFPYn2renTuzCbSVjodF1Y2KNNNHHPE2QI2IBAJ7E9RnHA71Np91K0rJGjNJK5KRr1GecA+1Nv1sL65H2WNLF7e3CFGjx5pGePl4ZvfvUKQyIY2Rv3mA25D7etdE5JK3Q5lRc5XN+1PlfaPtMbiRGyVbrgjIP5Gnw3Nv5pRSc7iN/QZ/Gs+S5mLyTzASCTapbOc8Yz7VuWWqwxpHHqVpDMUjYL8gYSnjk98jj+lYckZ3szRxa3W/+RILgpMuJSy4+c9OP/wBYq3HdXIuZ/LMbqIy5Vifm6YxgHtn/ABqgkfkrJHcIqTITlM5G09MHuKoXszQSeYs8cRiIIXbncOnAPUVMYK9mRHmbtY2RdGWVvJZD5eNy4Iwe4yKXUEFvFI0VwUaQYwT98ZzjPX8q57TbryIj82XXAYnOH7g81q2Uc+oMssAgmlgHmLG7ld69Co9+g/GlCm+ZJGk52l5Iqi2j/s/7Y8Ms0HmDII2Yx+PT3rVuY476GJiYBEUPlxwvujcgZIZjwHwRxwf0zblv7GfT5lgDBpCoMCoCVIPPynJyPXPasW/tgVeCOSdLVGMwTOFGcZYgf7oxj9K7ErEcynvoyvqVifsPkx3JlIUPtmjMZXvs3EcnHfn61jSBVvBbPv068DofNc7QmemSOB1B3AjGDVmfVJriB1+1zbQQhDoM/L0x36N1NYN5N58gt0aeV87i7ZIP5VcKiM54dpFi31efTbqYRXUjSqTmS3csrnBHXPIwTwexPrXpOmfFLT2soIpNN1BrpYl8zYEKlgOSPm6da8+sLFQgVo9xPOcdDWpDYwxDCRgLnJG05raDt8JwYml7S3Or2PQIfiRo05iVlntW6MZ48KPxBNdJplxBdRGW0niniPO6Nw4/MV461ktyj7VTnrntUC20tjcCfT3ktX9Ym25Naqty7nBPL1P4HY922A/ewBVG8zG21QT9K8tsvGXiC2yss0U4X/nrH/hitP8A4T26dB5+lqZF7xzbf5g1TrROd4Csntc7KSJ3hCuBg9eOTVNtOiBOCqj0yRWG/jfT47dJXjvvOb70Kwg7Tn+9nB9aqy+PtNDf6m9H+9Bg/wA6zlKL3LWHqx+yzqfDdzaahq9wlolz9mMZMtneIG8vGMfPxz9a82+Ifh2ws9amewtfsgkbd5IUYHXPHIx0ODzzVLQdL1231G3uob8iQD59ykkg9ueGHsaS5XUx9ok1Lf5x+YFssJDn1A615M6t1pufZ4bCOnVu5aWMSS1sFRJJYFRvusUzjPqD2/lSrZXNnMslrKJIweYpPlb8CK3hp0ckDSLcqZCOem1v8+9ViTbSpHMpSNflJxyB6Vk5SselBqL0Y+LVbe3aJZTIftCiOWJVIYHcCArEdc46e4rUtLiG71AWkEpRN37t7jCe/OeBWXdWCXkhjgj3DGGUkHn2Fc/qmlXunqJ7DzAExuXJOMdyKUYwnps/wKlXlBXev5/cdjJvgVzExfzB8wK4dPQiiKRkV4JGWZZiHL468Ed/r+lczpOvy3KKLtSzIOq/eH+NbyajbyNDNbt5lupAO452k84rOVOUGdcKkKiVtRYRb2zGJ90o+YnbwQexz7Gr1jcm7aRmuPMngXBJ4JU+vrWZLKHvLx4VTyypwM/dJxjGferemGKOa5eV/tMbMV3ldjP69OnPSko9Qm9CxIIXBJOcDG5h0+gqXS7sxxOmRHC5KKwzhTn1qCZlnVsuVdBjG37wxUP2uKO3K4wvAIUc+xFQ1bUymuZcljeeQzR+Y8y7omwrA/e6Zpi3ISa3CsACeSB3P1rn/L8r5YrohVB3bhgZxVMwXdvIcySLtbbsZucjqMetaK5yzwy2udXO482RQVIbAJz+VZl1MqndwGQ8r37cVSj1ASR+UkghlONxI6c1n6tc4vCY2DAKAcfzq1dHNCi2+VlnUpCIkZTggc8fpUK3sdwY8Fht45HXPv8AhVNpjd20u5icr8ozgH2ppkSNPLL7ojwQoPygds/jWq2JdNr3epoXSglJE++OT7iqJwJlfdkMuAO/TpTbZpBsYklc7SG68/8A66mgsHu5Y9gBBYEAYHQ/5/KqSvoS1yr3mWbbUoLURyTQq0kXOQcGVc9fcjPT2rX1DURK6G0K4kIGzPQk8MPeuQ1qFpDcox2TKGbywBw2TwPbFT2TTXEll/pCrAYzvDAghwOi4461fLpYTlFe8dlZ6ktgoEojZDGyfMPu5JwQex78elV/7QjmmgkdFZl3R7j1cev4VBdxTT6bcgogij+Z/m5XPYD8M02zmYCC5SMrHBHtGSQN56N9P8TWcrtcppBxd5dS3rl/sSbzp8ZATy4uWIHUnn/61YSXIa3EiA735GeOf8irlxpk/wBiaYuhnZAcEbcDOetY10ywMIWZGJQEkNkH1qeS3Qnmja0XexKsrSSAgknGealvLlo4yVJLKKq2/wC9ZmPA46dT7VDqV35MYjiBeRj90Dk89KqMbs56lRIrTQ3V/dw21ikk1xKwBPUgd2I6ADNdP4c0QRG5he+RIijTXCiRQxYAnDD8/QVxHh3U7+w1a41a3IVCjwj0Bzk8HoAQB+FWtI0w3uqILST94x3yzMCc568d67ZQULJnNRbrc009FodZeW8du8TQbGzGs2Y26DOMH047VoR2KJYwy72yctsjAyEH/wBbmqNzo9xb6u1lNdW8siqHJBCqwJAwPx471qag8pmVWgMW0bGBbOT0461ztpXudbW3K99R+iWEGo27G2cCSI75o5mCh1HOFPYkUmr6dp9xqTWekzLJIEYw72IfgZ5YcdM49x6UlpCq3qiJc5AGR8rDn0JqoZTpOtC6toyFRwYzG2CAOMA5/wA4oi0orQxtKTck/Rf5lOK5v3ljikbO0lfMPHHPB/H1qyGCs6XIV8MHR8bgpHUEehqDULo3Wsz3dv8ANDNlpFHA3E/oc/yqtBeLkmQOu3I3bcgkdjjpzU2d7ik5J6BdzpP5r2e4QuxI7hfUH2z0q1DqlyrwOI1jkiVtskCjLHggMvQ1TaQRkNCqjedxUAZDdDioZmdXcXIysmQHJ2NH6N6YGefrVxbZDUW9FY1rbUs20lxI0hk3/MBIFYMcn7vXsecHpVe81KWDeRChc7X3Op3Y9+cEe2OazdTtruza3TUrXKSxiWJjtLNHkjcCMgjKnj2rMhuWk2xTuWjUkoSOfp9OBxWutghGLle9/Qi1C6kmxnMe7kDPqe9bOlR2qrHmaFSBkksOapK0ckgeQgvggFquwMrtGkaLtX724YBpJWLlLm02OjiAdCyMpHbvTjIydGYF+DzWStvb7l4UZJJxx9AalMMKMXVEzjG09D9a1uzm5YvS5qouMlChJBJO/wDpTQ4chXyfepIijWkccTbsLvZWBUBu/wCmOataZpNxqJEVnG087NsCr/GdpY8k44ANDu2SlGKbZmywxscbTzypBx+lV3txGjEBGGerZz+FakumwW0gjmtmhu7V2ilZ3+6ckYx2xg1nXt4pkMUUTEqfvkVDlbc1hDmfuFC4baDt27sdMViXVziYhX4q/qd4ixOAQBjBz2NcfPO9zKzwHcg+XPTmrhHm2Ma9SNL4tDttLlu7i5DwzIyD7sWxmwfTIrp/D0Wp62zw3VrJCi7lVjuBBx/CvH6+tcN4U1+5026ijhl2OMqj4Hyqc8E4r07WdYmGmxMLh4pZIG8yRiXUnjO09jxXnSiou1j25TqTSt1OU8QW+hWOW0vVryS/YHzPNiCLGQDx75PHeudTUJbu32SqnmAfeA+Y/wBKpXOom8nLXGwKD8pHU/WmLhxtDZwcg4p8tlqbKOl07mtbTPayQXBLSQAgHacMhHY11Dvb3dk0kZy2SXZiBx7+9cTFcPNcNCdmWHX+96n61oXNtLE5VTsk284OAw+neolGzErTs5Mk2x2t+l7YSS2l0pP7yIlDn2I6H6VQMpiu4J7e0REiADpGThlHHP8AjVeK7eOUxyjKMcMM4we3NajSLGqPuxIvBIHKn1/+t3rS8krPYlJQlzxEFzax30ssDkW8v3UJ5XjvWlpTF5SyDORuwOgrmNSRBKfuq5GRtPDe4qfSLyWBA0Z3hf73p6VEqenMj0Y1eZW7nZ3CxzW2ZSrSRAMhzgrzkn3qLU7JrZUkSeJ7VjtUnGSCOv0rN08tdwfaWKkBsfL/AHff86tW8Rub4QTRskRQshH938KhK+jRlJ8uvNot/wDgGXcXBt5ZEQEAg53c59wadqF8J1iW1tlhi3AkgZZz05P19zTrq3K3bFhIiqSULN19s/Ws+GG4/tG4WeRmsrgBtnH7t++PrWsKZz1MQrIt3ixC4MSODJgAqw6kDoaoIxl8yRlj24OVJwB9KXUFKXT7DxwCT82F/qahgUSpcbTujTbyeeec1XIZqs2lqEMoGcFWz0yK0laB7WIRKJJ2yCMdOaoSQRAbgQhzsyT2qK01JbKWRQsshyUBUAZ49+lOMSak7rTcuMZLbESxb42O7eDwOM4p8F/GI5FDKvHPGcDsarG4haNZBBIWmYoo3gZPHX2rNaDLmWMkzRjDnHBGOhqrE3unc0b+Yv8Aa7qBR8kK7e5bnnHesy31PfbbThrgSNsUfw5OQfpRqztDpv2pBkKwj5OASw7fn+lVNNi2JHOrqxV0jRe754PFbwjeN2cFWpapypnY26XVxZxieZ/LlX94E+XzCCTip7W7eOzFpK8bKpAQs/3fbHSqD37tAkcceSuVQ8gdemO9U8TSzLKxBbfu2HOwfWsXudEdFY6ORvuqJpQvXLA9hz/SsiaOCTUGluFjS1RFdgCSWHPTHToP0q3eXKSsNm1EbC+QGI2ufU/rWBf2M2m3t5G90k4faHEZJC56Lz37mqSRF2kaemWlzfJ5sEYBB2k5ARc9Kx9TiuEvVSyuijowSWccEMTgqp7AdzXoOjWzSaPFaW8n7lEMnnNhYycZOG6seox+tctqSxT39jbr5uIkzKSuC3Py445J61aajsc/LKo2Y9lbrLYfY7dfJQSsXdjnAGcnPcnj866vwrAukwG7USATpg4Xdlh2/wA+tVNK08zXU0rAmAk7o8ckAYyfQdB710+mXM2l3kMhWQwPuWREXccHGCB+FTUneW5tQglB2RCdQF3dSkxJJOxD5378JjoPpV+zT7dbBszsilwBtyRjuwHTHrWFJcWv/CQ3L6LJi0gj+RiuGJPVueepPNdFZX81vA89vOxkZwJnDYdi2fTt6muaSu2upvUXJFci7b/1oR3Gm/ZrZJlnIkB+85HXHAz/AErIuIoEusPbTLLtDMzDgsfUehBrq9YltJ4bW4Cpb252wPDGnmtkk5bc4C7uegPGcjpUENjbywyq7GctHyc8bu7Hvu/TvitYUtLXOVVvcvI427KRXMdvEAitj7xwvrg+nTrUTN5dzLNa/up1OQTyHx6+v1ra1/SYbYQzRSkrJ8u2TqP5ViJA/nS2+GZlByj8EED3qnFxCFpLchnxHp9vcpLGxdisqA/OD9OgHapYre41KS3htUknSY7IYwuWZvTGf05qAW0jvPOkQfyiA6Dtkd/8aSznhiSSbSbjzGV/31rJjcnuPp0988GtIpPVkT5ov3SlcQrGEEckzQgEiMDIRvYHt0rPu+2+MfMpICnI/P8Aoa17i5t57vfFK0Qk5kQrynqRjv6iqU6pcwsQRtPRx0OD69uauDtuTKCeqKcRMR5JYHrtO4n/AArVsZYRgK+0dt5wR7E1gWr+VPIjAByTyeQwrUjlVAPm5bqBVaIzalI1zK3nIpHUetaNtsYBW4Pv1zWPbs0gXdjIFaUGSd8ZwxoXkFmtGbEMaiUtgHgjPvXQ+FtY/sTUWuvIW4jMbRspcKRu4JBwcflXKC42qD36cjFJNeDcF4Kn3o5nF3QOCqK0tjf1jWJ9c1SW7vlh8ybbuEabVyFAzj8Kp2egXmq3kwsh5UWcvdP92P2H95vYfjimeHrF/EGo/Z7d2jtYcG4mA+6P7o/2j+nWvT1W3srSGyso1jtowQqjn8fc0Knzvmkc9fGLDr2dLf8AI8r1LwKl3KtvFB9tdvvS3MpjUepwvb2AzXofgzwJpWhaGlm48xt5cjsmcfKO/bvVqFzDcb7aFWkIKuW4wO2Kt22rRvHiSLbKp2uFO4A/Wuqk1A8TEynX1l0PnuTyLPUEtFRoJR8zRMqsHVeQTjuSTj26102kJpw0q+vJ5jYyQ4CxO5G/PZBzntnpXY+HvDOi6tIdJuNPurvxB5Ujx3jkRC32f6uPaW+Ydc7hn07YyNa0q1WGWG4J81ANoj5UkHk/59K8idJ2Uk7n21LFQTdGV073+X+XqeU3dtKJGBWVs5ZF2heD0OfSm2MRFsTcO6jHIHp3rrdWaO4nlvFkgbzl8sKjA4K8fMo6dK4nVpZPtMa5IXq7/wBKcby906JThCPP+BYVj5tpLCoQeg5JKnrz3rrLi5S7uBGWCgqNj+/+FcdG7NNZgHGG4/4FVmS4mW8SzjYv9mk2tIo6+uDTnC+xlTkk7SHa6OWB/dzLwwHf3rMS9kkSeKeQqIk8tF3fNhlzn3GR1rW12At5kkeSRwxPauT1VmNkJEbE9uQAf70ZPI/A1tQSlozmxVR01zLodN9rjvNLKSOpnRQQyH5c46fWobGYw6c8/mgjcFbHUf55/I1FCkEljam3YRrKxAZuoAxlmA9Sf0NZ9lHG4a3a5Xa2WUgnqM8Eds4/XNCpLVFrFOKUutjp4br7DKk3mMIZgd5XnHHBxSWmpXJkNwjmTBI3E8EUzw7BPqlzHZ2Ns91dxkgWwBLuMHgAckjk49BWTBqL2MEkaJixeRgqtjsRnaevGRWapXXmb1MZGDtLZnVXk32ySIJKMsdx3PkgVbvLV4bIPAyOwAXavOTn04rlF1OCOdGgYESDcqgjKD39PpXQWGswGMQyMqbvmZycAntSUXHcmUoytyPYgvZ7pHt0+zRlVGSW9z0x24qsk90+nzW8EMCrNIDvC4Zeyru7An2+taUut2ECyx+aJHC7W2jIJ9vxrEnmWINGJAnmrtyBksM9QfUVepmkt2Kl1F5AI8xLgYXfu/dhR+HX361WivGa+V2jSQOSCpPGe3fpVj7BeXCieGaPyApWQZ5x6EDrWXb2dxIk0oWNlQEhCcFsHtTSTG5Pqi5rNvJp17E0kweNj8pXoDjOMew4os5zGjtjcytleR1PbFZcV5CsTDzZfMJ+45JH4elNutQa3hjkIDBOF56+1X7NvRIydeMU5SZW1q6aK9ETxqFkxKD25GP51WN024yj5HWXKgdV5zVvVLAXGljU7chCMAxMenPasiRonkLuWUsAemc59a64JNaHjVpTUm2zpLfVrgxNbed+7Yk4UAnPXgnpVmxvnVBgs3UYc/KP9r6/41lWU10SvzpIhUL88QYKo/z1roIzFJbKXWCG4zlRvA49fcf1rnqRO7Dyb1bsTRTSSxsgXJJOGP8AFn9K2fC9s1uXuri2aRJcpHvAKs3fOe3HX2PpVRNXg0nS5s2KzRsc5cYY54wAfxxXR+JIjexWJSX7N+6y8QOCinnLn+lY25Y8yN+dynyPqQXXiRnV7aO3QrwFVWJEZzk/XtVi+02WPRbq5ZkM5XLvIfnZmBwQe46j6iqeg2MZvJPs8ZeKAB3wuTs/vEdMcjn3rY1fUftFn9ngQpiI+WXH3kBzuz1qKad9TbESpxhy0/mZmkXttYiF7qTdFuCuB1df7tTXM8+oO88MBW2Us7BQcYHTp0UZHPv74rB0O4mN/BcRIr/YnWVQ6gqWBzgg8EcYxWzqkxubjJj/ANZuleKDjC4yWyfXB4qlaOrJlFyajEz7WyAtp5blt9yz/MY32oBxwPXvWtpYJjQlzOqZUlOgOBx79cU9beGYRxKsaMYvOVCxBwMYHXHU81pasyafNbRLbtaLEhmZIsrnfzzx7cdqxkrq5q58ya3f5GRqlw1veoIyy7SDlgSuenI6GtzTRHeu0pu3gvpI9gRCoQgNyQpx83T1zntWQXXUXmt3QmXqM9QMZ6VlxQysvlthm+6S3Qdef6U4Nx9CJQc1bZr+vuOgvzLJvF8s0UpQGFXxIGz8pyRjAPJzyRjHvWVp0NuUkE8rrdKpeB0dSpAB3D3b05z9arFpERkeOAFEJJDEcDAABYk8elY11DFJbJcTzFSSDhkxtbPQdz9a3UlfUydKXLZOxrW7ylpPs15HiUjMbyiMvz64C8e/qK5C609NP1YSxT+XvJfYOWUE85PcfUcVfgiJhRlzvUZYg4+bOev5VCliZrmS5KMu/BUZOR6mri1FWMZQcpKVtize5t5lKtDIV/5aI3mJKOnBH9KpwM/mGDzMo4D9f8+1V7u0kjfcpIXPyjpu7n8q0EtwrjOMYyGp7IbeqYfYIZWDSFy2cjDYAqRbS3Ri6bskdC2aMAZBkyp44bpTnJjhykZcjGFXjjP+TUXZem6J7fcADuLN0wcYrTtmxGSuA3esxMcnoOOSKSe+VAd33QOoPerijKpM07i52rzj2BNcvrniSGyj8vzR50h2jHRR3JrE8Q+IxHujgkLyn9K4maV5ZC8jEsa66VDm1lseTisdye7Dc+rvAniXSho1vaWDLsRcl1YHe3ck+tdONSgkZW3jcp9elfF9nd3FnIJbSaWCTP3o2K133hzxxr8caLO0V3H/AHpRtYDtyP8ACtqkUlc8ilGc5Wjqz6YiaIO8sexZWwCc1YaKOUhwFJPUjHWvGLT4hJZtuvdPmVwoEjRyBwR2OK2bb4oaI0IP70ezAAis42exc41IP3kz1jwPZaHYw2eoalHdrflXnQyJKNzq2N2/o5OR7D8RXP8AxSezkhVLdEj3NJIrRZ8xtxzmQn72DnjHQ9TWfqGvaxqlzHdXr2d35RY2iYJSJW4wenPGAT7ZrE1fxJYwrcNr1tOwhiJisRkCeToqs4IKrnkkemK87nTj7NKyPq40Jqt7eTba6XvbyX3nnc8sMMFynmETjBVhnk/SsW7bdDAoUmVhycnkZ6mlllZ5DLKclugFS6dbGe6w8ojJGA7cgVMVyrU9CrPmbSJLCIy6jartcBZACVXdkjngd6cVe01GRSxxnr6/5NdJZCy0ex8jYf7aEvy3KOCBGw5Axkevr6Vjayot9XEkm50yrEk/f5pbuwqcrNNouQOJ0gMq5ZwUY+uK4jWV8q5mQcqrMpHt6V20wlW0iunRfvMxx2Y9q5LX1VlVgMk8t61WHdpmeOjzUm0aPhnzH0tlDZeM4Bx0Geo/OtaHRJote0m3KNG0IM21kG9Dv+bdxyN3rzWN4LuVE90j3KRQkBsucDpV3WPEzyak91orzWcMYK/bCctPtwDjOerdfrWzUnJpHHCUIU4ylv0+RZ11pJby6e1jWyacmWcRgbgyfdVecjnsPzrib0i2mlthMtw3m8zAHByAeM9OevuDXXQ+I457zT7q6sLR47aGeOffGpWbcjkn5iMyAMdoBzkLgE4Fcffl18QTPq8b27Sfvljkzxu+b69+/NdFCm40lfc83G1lUxTcXp/n1J7tHg01VZwCimRAAO5H+ear6cWe9VZnLYIw+cDJ7HPpir63SQab56TQPPcMYIUbBaMcZcg9ODgZpl7ZTWonto8KrInmEc4IPUUJ2VpdTTl55qcNUuhq+VFNGy7yT34FV2tTHOjI3nInCueMZrHivXjvBaqxeDduLkYYjv1zg1tqty8bvEu2AjavmDpyDn68d/U+2MnT5Fqzshi3Vl7kb23LlvexwxyxyRhX4HzLuH4GrJO6BGiUoh/ukgGuc+1XcE6s58xjwDjBxWlbai2Mx7tp/hz36GsZUrK6O2li1OVpbkkttAwaOWMMP72MMKyUhmhLrA6OAchW6itRpiSA5DMemayL25EO9QRlm656VdJSehz4ycI2kVLy9L5t4pCInGWVuNrVSkKBcKxJ64Yc9f8ACrEgFyY3Vf3vKtj+JcVWNpIZQsa5LHHzYGD75rsjZKx49Scpvmepc0+6aI4zweo6A1cvb1Lj7PFk4Q+v3eecH8KpxWRDKrEFh2FS2NjLc3qxQBfKwGcjnjPT/wCtUPlvzG0faqKizrNDs5Z3jzKtxIFLKGHKepPY9sGuy/suQCGGCOaZc5nbsSADjP0pvhm0t7KzivJZT5AIZ2VQec4woPvwB356DmmX93eS30kXnTxIWMrhGztPH5+nNefNc78j2aDdP1/r8izDbwC7vJJZ3tbLOwyKCy5A4Q4Iz0/lWVcXNzqOoSQWzFbRlSAzH7zYGSB2A4xUkc41GZrFI9sTqMp1UA9TnruJ5z9RwMVrJpgj2gRgLH0UdP8A69Ul1RnO3wy/r/g9znraWPT7q4Ai3kO0cY3Yxz94/lW5p1ytoJ5DG32xlyCfuquDx7nkfhn2rK8QW5hvzNGf3cwG49QrgcjP0xVaWR0s1ZTuJO3I4zn/AOtQ1rZDhJShdmsmqot2LhLV4hLst2TcGBUDDEnrznOM+2e9bd/fbtOtop5C8MZdXlEamRsAbdzdcfj/ADrA8NakyXRgtlUq6lSxGPm7DdjjnvWzrE76aL7TbhXaWVVCxeYYzHMChZtgzuwPMXnjDZFKEXJO5WIkoyiox/rv8irp2oQRvFLbwiSeMP5jMuwYIODnJLY4JGAeoHrWLBLdpEzHy3JdiynIGOucHnn8KsS6dJ9njij2ruw+MYyGI7+36Vdj09gDvXCudodjhST2J/p1pyh2FCtFK73ZlwBZo0aViykhQWbqKWXTEmklfAVFTCZOOR1PNbfh3T/tN7b6RcNBBehxEgkfKuxxgBhle/qO/wBK0PEFpBYaxd6Y1wzwQSupliX72AQCFJx1xnnpmqjB2uzOrXSlyr1+Ryv2RAoRMNkeueaspGRnCDJHAxTizLboBJsYYdSr9D9fUZNMS52qGkcNjjJHJrNp3uaqStYytQs/3kTLy6gvt6cf402O3mit9saNJFjowHH0Na5li+1KWQtI6Y4OcYPUj3pDAkUbNFtEefmQDp9KakDgna5ibQh2hUT0Tqc1YjUmMF8bh+lW5I4U+cAEkc8c1l3d3EmVWRQ3QDPP1rSEXN6HPXq06CvJ2I764SFGbcVPXrXFa/rrE+VA3z45PpWprMN1dROttdQuR94c5A9fX9KwI/D0ki+Y9/abDzuUlv6V3UqNtZHg4nHqfu03+n5mC7M7FmOWPJNW9Lt47q9iinZ1jJySi7mIAJwB3NbUWh2Mf+tvJZf+uahR+uauQW2lQHMdmzsP4nkbP6EV1a9jy3KK3ZXuNPTH2WH7PMQDukjyVC8EcnHP/wBetS00mSG1ha2hL7OJFBP7wevPANOtb4WqbbS1jiU8kKvU1I2o3cp+Zzj0xWU6MpvfQ6qePhS1jH3u5C+l6jKjjEUaE8NJICcfQZpo8POQN14qtjkLGSKtefOxBdzwOwp2S3L8n1yaFSUdjKrmFSq7yPp5dM0GCNZlDW91ICFj8zEVpk9MtksT9e9eMfFLTb0XEOpzRgWt5NJHEUOc7DjOPfqK6XV9buLq0ubNokbZlVZRlmGPyzWJcW3jHxdbWdnZaFcNbWsXlLJIcRqSeXLHgHgflXjNNyTWx9hQbhFuctX37HCwWMr4mdQq4yCTgYH+elWA5W0EioAnJPH3h6V13jDwFrXh7SLS71K6t7mAAREW+SIT6HoOveuR1G3uLe0U3O98qCF6FRnjjtmhu7sddHlceZO6KqXOy4DSDLyEYAPAIpLppXlj8zcTuAUe2azFWR7jzZTsQdEHf61uW8El2xccKiZOevTP5Yq5RUWhc/NdvQki1IfZri33Ft5DY7cf/rrE1TBgkfp/DipIAGwwIDHvUF86uvyjkkcfhThGz0MsRV5oNPdnPKjm6kCyMHCjaF+lbVro1/PZrHcTZtUXfBEJMgFiM8evHP09qp6Q8Z1mTcpZAcEKfT3rop7dsyQqGiwxCrvBIweea66tWUdEeXhcNRqpyl0bMLUo5LZlCjbDsZF3cqx6Zx/Ws64EjSRorCYRxlFcZ5XJOeee9dbNYte2PmTPOqRERWwWAMkzZHmAuSNu1WB4BySM461o22kWQBkP+jHywHiXJ8w5IyDjp6jnkdeeF9YUEk9w/s2deTktrnJ6SltfL9hk8jcZC/nMDvBA+7npg9ee47ZNbFnCXuZImu2cjhZZF/Q1proUEsZmnicFuVcDAwO2e9WZNJtikb4CEEFVJJJ54z/WueriIy0R6OEy+VL4jlrmyjtddjMoIQgllHYgZz78dK7PVTZW9s1uBGTD8u8Orlm7gFSQceo65rnPE8SJfqU2lTgqBwBk5wPQdau3NhdWck4eP/U7kdiwIbHHB79DSk+eKbLpx9lUlBephyI87MGGVTJHHHsKxo7qSzvTHLwxOCD2Yda7CznjtUeKdXRCuXYcgA9CRWf4s02KaMTxoDHtVzIpGWB4yPXGK0pVVzcklozDF4d+z9rTfvIzJruW4hMpUBVbYfmGQfp/Ws+V5LhlSAb5idqjH3R/LNQvB5VzEkkgMUnAlOT+YrShDOTaaQGkYA+ZOQAx7ZHp+HSutRjFXR4znOtJxluV9Okt4stPMC/XPzf0q6ZbSQoB5iMwyCwBGKf/AGP5UIw3luvU7Tx+lVrq2mtplF5GSODuHBx61nzRm7pnX7KrRhaUdCeVJIIlkQllIzla3vCSWxXzJJCiO2+Vtvt0x+dco0mzCyEOo5RgSNp/wro/CpkW2aJW+bcpJK+9RUVqbNMPLnrJbI7tpV1C4s7OECLyAEUdd0uchj2/Dt+dRTStqV1cyvmCziQ/LGu3eRzt+mc80+3tfNmYsSAQqj5sBTxzknHr1xiuourfT5Fmjt7OOAQxlY4UYv5jZwMNyWwTnOTkDrXNDVO53V2oSXL/AMN/X+Zg+GIFea4u/Ljt1lc7V3/cxwB+A/Wt+72LG6GcSRggFx/CMZHBweD3ptsIjeyQwiZi7P5TxxAGTPzBW546GmzqyQ21w0QPnPIrKZRvAQ4JdTgqCeBnrtb2os7Gd1KV9v68/Qz5dLju7V1aYRBBuAyASM9FB6nnoO1cncx7HZAW+RsKW6kZ4rtpIri1eD7VayLGPmCyqRvGAeMkZGCPzFczr8YE8UkbP5YUqC7ZKjPHfAHJ4HeqVrCm3zXvoyvpt2I7a3WIbZEZgXzwAc849Rmt61eJcyeWgcAhcLkgHryeew4rlLcm2uACQY3Ppwprat5NoAH3eoXPQe1SlZ6Gs5Ka1NITRxAM6OdmC4BK8dzkd676413w7KlzJd6S/wBljglVbWHCqJXKlGjGcqQVYF+Tg4wAcV5s86NEwVgAw27TRBdCceTnY3AYHgcc1vCo1ocNWip69jptHtdOOiStqNhJfbZUZZIpyiwgZyrYzy/IHHbr1FJHp5s/DdzqSfZb+xikWGSycss8bsG2OjDkDknb9045BxWJ9tit4/3AdPMbLhsYLD0qc30kKxyRMVlJBDocFW6hgRyPwpOSWgKMnq3u/wCvT1Q2fQ4dZ1Dy9GRS5VAltG0jMx8vL7d3XBVickdeM1Qi0lHlSaSSeSCM7niSQKSuBgBmDYx9DVme5zHwFKooG8n5s1Gl9HGP3i8nktSur3NEpWtfT8S7deG9Nv3STw9etpt0FjWWx1N2eRpXJ2rCVQFwQV+8qgZHODxxV7qN1Z3M1tc27pNGSsiplhkEg9Pp1rrJ/EMhu1up5DPdFxLul+dmYf3gev41xXiTXrqaSdv7QuJ2kclpGlLFic5Ge/3mz9feqUVUkklqZ1Kzw1NznLRbX3v2RQ1bV5nAigIV2GSR/D/9es2AlFYHk92PJJqJFJJc9T0qUcV3unCEOVHy88RVr1faS3JA5DBkyrg8MOoPtVqW0XU1WWzRIdTJIeMDCXXuB0V/boaqgEjinoSAMHp3rKElTegVE6m+5VVfmZWQxyodrIwwVPuKcFGa03MOpsgupfs98AFW5xlXx0Eg/wDZqpsjJO8EyeVOnDIT+o9RXZGakro45RcXZjFHFTxrjj9argjODViMrgAZptki5wfmIH41IroB1FQPtHVSeOuevtTlwB93I7ECs7l2PTL67aaVoo7PypHIaQS9Bz1NdMniO2s9Hjg0rVZtPdSXM0Ue5GOOVZT2rmILJ7uF38stc7QznjJ+g+lZwsJsKIwGbccKQAG96+fdRM/Q3hNk3/XzLWp6hrevQlrjUTfQJIGaGJQu70bA9qseP/DLQaRFqlteNc9PMWQ/MoPCrgcZHeuV0uwaz1eaSUsLV5t0LK5Ug9xx3BNX/Glyth4Vv5UkljdymxUfA3FupBpJXmorqbNunT52rKN7/wBfIw4rCNrZcr5svDfJ0H1+lUr27iS2aOOT98+V2qc4HqawrbXZhYvEGBd/kMhPIX0HpWpoOhapq7Iuk2U1yT/EAFU+uGOBXV7Jw1mcf1uNX4NiCSYLGqIB8nGRyWrK1G7MDON24quP+BGptVWbTL6S1vopLW6iPzRuMEehrHjjbUbuKKMhWkkCZkYBRkgZJ7D1JrqpU1u9jysXinstx+nPMRI6Lng7mzir9rdSziJDKNu8JtHBx61au5THpsenxxQsLUugkiTMkoLE/NgnOO2OxrQ8LeE9Zv8AW7MjTJba2nOEluVaOPJ4HzEE9aqUotNszpKcJQj9/wB53HhpbC002YNYyz3hdRborDZjvuHX8jWhew+aiSKsECNIc24YBY8nO0Z5Pb1/Ci28Papp5mWSLYg3L5gG5HypHBPGOetXX0S+bSkjebyIoiZDEGLjceCwB4BICg+u0V4k6kdU2fVqvSg1JMrQXCNZrFdFjHDkJGBjJ57+2azL6QyRO0ZG3068DtT207UILlYoYmCmMybZG2NjrwT6gg8+tQX+m6jFYRzm2VYZW2oVfzGHcnavP6VKXS5t9boJ7nLao0RcbgoVSGbIJyBye4/mPrXWatNb6u9xqel6cbHSy4SOFrhphEMDBJY5JOCc9O3Fczq/h65Mc0tmZJyflZm+RAfQ55A6100ui+IdVEUEEMWlaIvmT2lrJOJmQHBwSoG4EgDJ7DOO59FRj7K1zx6ld/Wefl0/r8TA1SwjuLZntGIlBVPKOSWBB3MOMYyMYPqK5GXFtLNBc+ZmMfuw3b2/CvaLgzm4jSC00+QrZpZH7PEyEsp5mbJ5kbJB6cdq47xJ4T1HUjPcxmKMxLkiUlC3YgD1/nSpVIxfK3oTiacqseeKs+x53qLf6OqOQ2cFQOxPf9K3/DFpC9nE63RjuiWOwrgADpznnPPHt3qnf+GddsocmBpI3xkRHcT3FaenWt79gXdp1z8hwcw8n8Ov4101Zx5LRZx4SnNVuaomtB/225hugrOo52gu3Gfr2pbaGbVdQ8lLYM44dGbaqH09jVRr0bpLS6Rk5zsccj357V0fg26t38RWsDFfscqRMfmVyuBtOffIzg9MjNYOLjFyS1PQ9tGU1FvQ5bWtGv7NTLJZuIwN7OpD7R6nHIqho2rizu87wFcBS3419JXun6Vf2r/ZRCSpO4hs7SOCNw9euD615v4s+GFtby3N2sY2SZkJVim0MeCFHA/l+lFPERknGojmr4WopKdB2fZ6FnTtSjFuqxOjCQhWA5PQj+ta9vqTo/kT7d/8Tltu4D098dq8qRr7wpfi31KBzayf6qdlwGHb8fau0tLq3vLAlZA6noQc59/rWc4ShrF6HRSrU6nuVFaS37/1+Z2MF0sTeascNzGOADnBHYEjB/8A1VagltJ7csPNS535IOPKCFfz37gORxgCuTsbhlhComxVJIweD7gVONQEaOFkyqjAAbH40o1HbUqVBX91nS63fTX2oSXV35Tzyku8qRgbjgeg6cdPf61y2sTwgSPLKiqqlmdgQB6DA/zzVOTUZbsnzJcRR9cHGav6X4T1LxLNFJvistJibc88pBdmPcJnOBng+/0rWEm/eMKsI00oN2/Q42G6u4o4t4Ezv/yyVDnJ7AdzWhqE2saTZJc32k3dpbZ5d0yBnpnH3c5r1S/Hh7wb4fnv49KuGsrIoJb0Qq1xIXbGVyRtyT0J6V8++L/EuoeJtRluryaX7OrFbW2Vv3cCZ+VQo4zjqe/WunD4Z1nd7f1sedi8wjQVorXt+r/yNSTxIqOJEDncOh70R+K7hw6PBuj9BgY/z61x4AwrZTIPr/nFKSGB3Egj0rs+pQ7nmf2pVO3PicwhBPEzqQGBDBtvGeo6Ulv4kW8n8m2JVyMjewVTgZxXEoDtPzY56jtTWG0lZFG09MdR9af1KNri/tSrc9M1W41DTbhra5MPmhct5TBthx0bnA7H8azru4v4Xkjmnhj2IrnOCVyBjIz7iuDmMyxlY2bZ3VSf5VF9snZwxlZpM5DMST+P5D8qxlh1F2aOmOOcknc6eR5rmV2lmfyYzhzym4+464qJAZCp2bVHCJ/dH+NLpUMk9mkk7HySxOOpkI/pWpGiqCSPxPasfaxpXS3M8TfEyT+yvxKPllTyMUbMHkdO5q5LhhtQZYnGFG41Zt9G1CYZjsbqT0Jj2j8zXPUxK3kx08N2RnAYQ8c01SGQ569q6KLwlqjhnuBa2irz+9l3H8l709fCcYQtPqE7gfwwxCFT/wACc/0rmeMpL7R1QwU5bROVMojUiQgZ65q3aGbUk8o2sskSA7LoLjyT9T1Ht+VdXB4ctE2CxtEnmJwXJM5HuWPyj8K1LfSykn+klAyjgf60j/2UflU/2nGnrDf+uhs8pVRWqP7jzst5cnlXO3dnCuOj/T/CpChXGDxXpNoi2dyXexh1CCf5bmzukEiXEfoePkYc7XX5lPqMg2fEHw9sdYhk1D4bzNNsRnuPD9zJ/pcGMZ8oknzV59SewJJ2j1cLj6WJVlo+3+R4WLy6rhXfePf/ADPMAafmmNuhuZoJkkhuIXMcsMqlHjYcFWU8gg9jT8gfxAexNdjOE9hso4zqMKlFLTbiW9AEJwKhe2jQxrg7C2AAcbTjORRRXyqP1fq/QxdStVTZCzb8yBgzDkZrI1oLdNaxTokivcRghhkHnuKKKHo9DKq70Z37HYf2Fo6xbH0mwckZz5I9avaUWsooItOnurMW7GSFYZcRxkc8IQRRRXkqrNPST+88yEU46ox/Evg3Tte1GaXWTLczx/8ALUNsY55PT3NZcPwl8O+ZlZNRB6qPPGB/47n9aKKtY3EQ0jN/eROhSl7zir+h1dppOneGLW2+z2UTqzFPkzGx4HJbkk/N19q2rU2V9dXERsI0CkIx3lixz1yec0UVria03CzfYcVenzPf/ghpfiPVLKzkRJoprY3AhaG4hWQOgzhWz1xjrjPvUkt9aXqTTWtgun3dsdzm2lIik56CM529exx7UUVl7WbcYt6f1t2+RpOnFSk0rf117/MxLGUXNmLe5QOfJnVJR99NqkjBOe6j8Mjvw24R4dMZY2RWsLeK+ikCDfvUoSM+h3nI9hRRWtBtyV/P8jKas7f1uO8QQ2v/ABKLq3t/Ls9QkE7WhcuAwJUgseo644yAcV1tzpulreLfRaZaxtpWjeesYT5JXMs8RLDockB+QTkDmiiu2i7OVu1/wv8Amc9Rvljr1a/G35Hnl7dKotojArFQ2ZN7bnzzzz74/Cs6CZrS5keDP75FiZZD5gAGPu56Hgcjn8zRRXGq1RdT0VFcpnsv2cSiCSZd7biN+Rn1xjirVpPPco0EsoKhTk7Fyce+KKK3hUk92OcU1cr6jpmj39v/AKVpodo8Ju805JOefrWXo3gazW5kuLe9vI1RWITKnqPXFFFDxNWHuxloRLD02udrU6fR4b3RtPkexv2Uv13Rg9P55rpE8XRyaZYLd6XHOrRNEy+bgEfdz0P1oorejJtXZhKpKfxPqef+NYotX8KXCOrIVQSozNu2sp7cDqCR+NcV4Wsbi1BkW7DRngoY/wCuaKK7aMmqbitrmGL9+vGb3sdfDK3ljP04OKjkRTGWUbW6k+tFFS9zohOXc6j4aaNY69qN2dUh86CzjVkgzhXZmIy3qBjpXuGnwWyS/Z47WFIljLkBQAxzgZx7UUVvDY8vESfO1c8v/aBjjg+FFwiRrg6xCinuoUSAfoMV81lQhXAGSMZ7jBoor3sCl7M+fxTbqO4skiyKxaJM5yW7nj1qrEWlfYDgMcc89KKKnFVJXRphaUZXuje1fQjo11HA9yLhZIVlP7vZ1JGOp9KzMeZHzj06UUV24bWGvmcVbSWnkIh+6vcqCTWr4X8JL4iupR9s+zBSB/qt/X8RRRXl5pUlSwrqQeqsdmXwU66jLY9Y0zwDZraw/aLy5eONQoSPbGMdPQmtdPC2iWqM/wDZ6SspIBlYueOO+aKK+Clias370mfVqlCFkkWLa4iTEFtaW8KsVU4Xj8hisjV9Rn0+co7vKD6EIBx7DP60UU6UVKpZnfhqUJVOVrQi0xbi9ha4M6xLnG1I8t0/vMT/ACqc2UBt5Z9pknyArznzNvTnmiiipJqTSHLST9SzK7Q2rvMfMVVyET92vTNZ0TPLam5kYCEtkQINq/iepoooj8NyIJcl/MmVCbdHkO5G4EYGAPr3NLJbxusc8oLMrK0e0lfLIPBUjkEeo5oooTad0ctV9DL8Xaq2q2UX/CRxLqjhhbWt458u8thnj98P9YvX5ZFbqcEHmsX4k+CH8G+Kp9JXU/tqoiyLK1vsOD2IDHn34+lFFfXZXVnWo3qO9mfLZpShRrWpqx//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical gross appearance of MPM at operation; note the diffuse nodules on the peritoneal surfaces.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. H Richard Alexander, Jr., as published for the National Institutes of Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3109=[""].join("\n");
var outline_f3_2_3109=null;
var title_f3_2_3110="Romidepsin: Drug information";
var content_f3_2_3110=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Romidepsin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/53/15189?source=see_link\">",
"    see \"Romidepsin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9601187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Istodax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9601133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Histone Deacetylase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9661315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cutaneous T-cell lymphoma:",
"     </b>",
"     I.V.: 14 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 8, and 15 of a 28-day treatment cycle; repeat cycle as long as benefit continues and treatment is tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Peripheral T-cell lymphoma:",
"     </b>",
"     I.V.: 14 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 8, and 15 of a 28-day treatment cycle; repeat cycle as long as benefit continues and treatment is tolerated.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9661316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9661317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The pharmacokinetics of romidepsin are unaffected by mild, moderate, or severe renal impairment (based on pharmacokinetic analysis). Use with caution in patients with end-stage renal disease (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9661318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mild hepatic impairment does not significantly influence the pharmacokinetics of romidepsin. The effect of moderate or severe impairment is unknown; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F9661319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Nonhematologic toxicity (excluding alopecia):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 2 or 3: Delay treatment until toxicity returns to &le;grade 1 or baseline, may restart at 14 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 4 or recurrent grade 3 toxicity: Delay treatment until toxicity returns to &le;grade 1 or baseline, permanently reduce dose to 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Recurrent grade 3 or 4 toxicity despite dosage reduction: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Hematologic toxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 3 or 4 neutropenia or thrombocytopenia: Delay treatment until ANC &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or platelets &ge;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or baseline, may restart at 14 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 4 febrile neutropenia or thrombocytopenia requiring platelet transfusion: Delay treatment until toxicity returns to &le;grade 1 or baseline, permanently reduce dose to 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9661325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Istodax&reg;: 10 mg [contains dehydrated ethanol (in diluent), propylene glycol (in diluent); supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9661051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9661320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse over 4 hours. Antiemetics to prevent nausea and vomiting were used in clinical trials (Piekarz, 2009; Piekarz, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9661230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9601135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory cutaneous T-cell lymphoma (CTCL) and refractory peripheral T-cell lymphoma (PTCL)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9601131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       RomiDEPsin may be confused with romiPLOStim",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9661110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: ST-T wave changes (2% to 63%), hypotension (7% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (53% to 77%), fever (20% to 47%), headache (15% to 34%), chills (11% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (7% to 31%), dermatitis/exfoliative dermatitis (4% to 27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypocalcemia (4% to 52%), hyperglycemia (2% to 51%), hypoalbuminemia (3% to 48%), hyperuricemia (&le;33%), hypomagnesemia (22% to 28%), hypermagnesemia (&le;27%), hypophosphatemia (&le;27%), hypokalemia (6% to 20%), hyponatremia (&le;20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (56% to 86%; grades 3/4: 2% to 6%), anorexia (23% to 54%), vomiting (34% to 52%; grades 3/4: &le;10%), taste alteration (15% to 40%), constipation (12% to 40%), diarrhea (20% to 36%), weight loss (10% to 15%), abdominal pain (13% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (19% to 72%; grades 3/4: 3% to 28%), thrombocytopenia (17% to 72%; grades 3/4: &le;36%), neutropenia (11% to 66%; grades 3/4: 4% to 47%), lymphopenia (4% to 57%; grades 3/4: &le;37%), leukopenia (4% to 55%; grades 3/4: &le;45%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: AST increased (3% to 28%), ALT increased (3% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (53% to 77%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (18% to 21%), dyspnea (13% to 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (46% to 54%; grades 3/4: 11% to 33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (6% to 10%), tachycardia (&le;10%), chest pain, DVT, edema, QT prolongation, supraventricular arrhythmia, syncope, ventricular arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Cellulitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Dehydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Stomatitis (6% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenic fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Hyperbilirubinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Hypoxia, pneumonia, pneumonitis, pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Central line infection, hypersensitivity, sepsis, tumor lysis syndrome (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, acute respiratory distress syndrome, atrial fibrillation, bacteremia, candida infection, cardiopulmonary failure, cardiogenic shock, Epstein-Barr virus reactivation, multiorgan failure, septic shock",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9661057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9661058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bone marrow suppression: Anemia, leukopenia, neutropenia, lymphopenia and thrombocytopenia may occur.  May require dosage modification. Monitor blood counts during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infection: Serious infections (occasionally fatal), including pneumonia and sepsis have occurred during or within 30 days of treatment. The risk of life-threatening infection is increased in patients who have received prior intensive or extensive chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation/ECG changes: QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation has been observed; use caution in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, congenital long QT syndrome, with medications known to prolong the QT interval, or with pre-existing cardiac disease. Obtain baseline and periodic ECG (12-lead); monitor and correct electrolyte (potassium, magnesium, and calcium) abnormalities prior to and during treatment. T-wave and ST-segment changes have also been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Tumor lysis syndrome: Tumor lysis syndrome (TLS) has been observed; closely monitor patients with advanced disease and/or with a high tumor burden. If TLS occurs, initiate appropriate treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Mild hepatic impairment does not significantly influence the pharmacokinetics of romidepsin (based on pharmacokinetic analysis). The effect of moderate or severe impairment is unknown; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: The pharmacokinetics of romidepsin are unaffected by mild, moderate or severe renal impairment (based on pharmacokinetic analysis). Use with caution in patients with end-stage renal disease (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Avoid use with strong CYP3A4 inhibitors or inducers. Use with caution with moderate CYP3A4 inhibitors and P-glycoprotein inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging agents: Concurrent use with other drugs which may prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval may increase the risk of potentially-fatal arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9770253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: RomiDEPsin may enhance the therapeutic effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9661184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Avoid grapefruit juice (may increase the levels/effects of romidepsin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may increase metabolism and decrease romidepsin concentrations).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9661052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9661053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Based on the mechanism of action, romidepsin may cause fetal harm if administered during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9661055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9661056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9661188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Istodax Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $2878.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9661322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes (baseline and periodic; especially potassium and magnesium); CBC with differential and platelets, ECG (baseline and periodic; in patients with significant cardiovascular disease, congenital long QT syndrome, and in patients taking QT-prolonging medications); signs/symptoms of infection or tumor lysis syndrome",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9661313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Histone deacetylase inhibitor; catalyzes acetyl group removal from protein lysine residues (including histone and transcription factors). Inhibition of histone deacetylase results in accumulation of acetyl groups, leading to alterations in chromatin structure and transcription factor activation causing termination of cell growth (induces arrest in cell cycle at G",
"     <sub>",
"      1",
"     </sub>",
"     and G",
"     <sub>",
"      2",
"     </sub>",
"     /M phases) leading to cell death.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9661231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 92% to 94%; primarily to &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic, primarily via CYP3A4, minor metabolism from CYP3A5, 1A1, 2B6, and 2C19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~3 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Coiffier B, Pro B, Prince HM, et al, &ldquo;Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin in Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(21):114 [abstract 114 from 2010 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kim Y, Whittaker S, Demierre MF, et al, &ldquo;Clinically Significant Responses Achieved With Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results From a Phase 2B, International, Multicenter, Registration Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(11):263 [abstract 263 from 2008 ASH Annual Meeting]",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lane AA and Chabner BA, &ldquo;Histone Deacetylase Inhibitors in Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5459-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/2/3110/abstract-text/19826124/pubmed\" id=\"19826124\" target=\"_blank\">",
"        19826124",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piekarz RL, Frye AR, Wright JJ, et al, &ldquo;Cardiac Studies in Patients Treated With Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2006, 12(12):3762-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/2/3110/abstract-text/16778104/pubmed\" id=\"16778104\" target=\"_blank\">",
"        16778104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piekarz RL, Frye R, Prince HM, et al, &ldquo;Phase 2 Trial of Romidepsin in Patients With Peripheral T-Cell Lymphoma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 117(22):5827-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/2/3110/abstract-text/21355097/pubmed\" id=\"21355097\" target=\"_blank\">",
"        21355097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piekarz RL, Frye R, Turner M, et al, &ldquo;Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin as Monotherapy for Patients With Cutaneous T-Cell Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5410-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/2/3110/abstract-text/19826128/pubmed\" id=\"19826128\" target=\"_blank\">",
"        19826128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piekarz R, Wright J, Frye R, et al, &ldquo;Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients With Relapsed Peripheral T-Cell Lymphoma (PTCL),&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(11):1567 [abstract 1567 from 2008 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piekarz RL, Robey R, Sandor V, et al, &ldquo;Inhibitor of Histone Deacetylation, Depsipeptide (FR901228), in the Treatment of Peripheral and Cutaneous T-Cell Lymphoma: A Case Report,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2001, 98(9):2865-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/2/3110/abstract-text/11675364/pubmed\" id=\"11675364\" target=\"_blank\">",
"        11675364",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Woo S, Gardner ER, Chen X, et al, &ldquo;Population Pharmacokinetics of Romidepsin in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2009, 15(4):1496-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/2/3110/abstract-text/19228751/pubmed\" id=\"19228751\" target=\"_blank\">",
"        19228751",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9536 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3110=[""].join("\n");
var outline_f3_2_3110=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9601187\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9601133\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661315\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661316\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661317\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661318\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661319\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661325\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661051\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661320\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661230\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9601135\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9601131\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661110\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661057\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661058\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300014\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770253\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661184\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661052\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661053\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661055\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661056\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661188\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322768\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661322\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661313\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9661231\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9536\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9536|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/53/15189?source=related_link\">",
"      Romidepsin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_2_3111="Aphasia: Prognosis and treatment";
var content_f3_2_3111=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Aphasia: Prognosis and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/2/3111/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/2/3111/contributors\">",
"     David Glenn Clark, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/2/3111/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/2/3111/contributors\">",
"     Mario F Mendez, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/2/3111/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/2/3111/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/2/3111/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aphasia is a loss of ability to produce or understand language. The most common cause of aphasia is cerebrovascular disease, particularly cerebral infarction. Aphasia complicates 15 to 38 percent of ischemic strokes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Other structural pathologies (infection, trauma, neoplasm) and certain neurodegenerative diseases (primary progressive aphasia) can also cause aphasia.",
"   </p>",
"   <p>",
"    Aphasia can be a devastating condition and is one of the most feared consequences of cerebral infarction and other brain injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/5\">",
"     5",
"    </a>",
"    ]. Although quality of life in patients with aphasia is difficult to measure directly, the disruption in communication with its likely effects on employment status and social networks suggests that its impact can be profound [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Caregivers of stroke survivors are likely to experience more stress when caring for a family member with, rather than without, aphasia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Comprehension deficits can also limit rehabilitation efforts targeting other post-stroke deficits such as hemiparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Patients with post-stroke aphasia have greater morbidity and mortality than stroke patients without aphasia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/13\">",
"     13",
"    </a>",
"    ]. While most, if not all, patients with post-stroke aphasia have some functional recovery, residual deficits are common. Unfortunately, there is limited evidence that therapeutic interventions are effective.",
"   </p>",
"   <p>",
"    This topic reviews the prognosis and management of aphasia, focusing on post-stroke aphasia, which is the most common etiology. The evaluation of aphasia, the management of primary progressive aphasia and other aspects of stroke prognosis and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20041?source=see_link\">",
"     \"Approach to the patient with aphasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recovery from aphasia is influenced by lesion location and type of aphasia. As an example, large lesions in the left hemisphere with global aphasia have a much poorer recovery than small, subcortical lesions with anomia.",
"   </p>",
"   <p>",
"    The prognosis for aphasia recovery depends in large part upon the underlying etiology. This has been best studied in cerebrovascular disease. Most patients with post-stroke aphasia improve to some extent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/1-4,14,15\">",
"     1-4,14,15",
"    </a>",
"    ]. Most improvement occurs within the first few months and plateaus after one year. The severity of the initial aphasia strongly correlates with the long-term deficit; those with milder degrees of aphasia at onset are the most likely to recover completely [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Nonetheless, patients with significant aphasia may benefit from intensive treatment regimens even after the period of spontaneous recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Smaller studies in patients with aphasia resulting from traumatic brain injury indicate that the clinical course is similar to post-stroke aphasia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diffusion and perfusion magnetic resonance imaging (MRI) studies demonstrate that early recovery after stroke (in the first few days and weeks) is related to reperfusion of language areas [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. Functional neuroimaging studies suggest that subsequent improvement is associated with increased activation of contiguous areas in the perisylvian language areas as well as homologous brain regions in the right hemisphere [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/21-28\">",
"     21-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with aphasia resulting from right hemisphere lesions often have less severe permanent language deficits, likely as a consequence of incomplete language lateralization in these individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20041?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to the patient with aphasia\", section on 'Cerebral dominance'",
"    </a>",
"    .) While there is some evidence to suggest that left-handed individuals with left hemisphere stroke and women have less complete lateralization of language dominance than right-handed individuals and men, neither handedness nor gender have consistently been shown to impact recovery from post-stroke aphasia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/4,15,16,29\">",
"     4,15,16,29",
"    </a>",
"    ]. Similarly, increased age has not been shown to influence prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying cause of the aphasia should be treated specifically, whether it is degenerative, vascular, inflammatory, neoplastic, or epileptic (see appropriate topic reviews).",
"   </p>",
"   <p>",
"    Aphasia resulting from an intraparenchymal mass or hematoma, or from an extra-axial mass or fluid collection, may improve dramatically with removal of the offending mass. In the case of central nervous system (CNS) tumors, treatment of edema with steroids may result in rapid improvement, but worsening of the neoplastic disease is likely to be accompanied by recurrence of aphasia.",
"   </p>",
"   <p>",
"    Episodes of aphasia resulting from epileptic seizures should resolve with adequate anticonvulsant therapy. The treatment of acquired epileptic aphasia (Landau-Kleffner syndrome) is problematic, and children with this disease may be left with permanent linguistic dysfunction, particularly auditory comprehension defects [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H10#H10\">",
"     \"Epilepsy syndromes in children\", section on 'Landau-Kleffner syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Speech and language therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aphasia may resolve spontaneously, especially when it is caused by a small ischemic lesion, but in most cases, a speech-language pathologist is consulted to assist the patient in recovering linguistic abilities and to train the patient and family members in alternative strategies for communication. The available data from clinical trials offer weak support for this approach, but no single technique has emerged as more effective than others [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Challenges in studying the use of speech and language therapy include the heterogeneity of aphasia syndromes, the wide variety and lack of standardized techniques employed in speech and language therapy, as well as the fact that many patients improve spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/33\">",
"     33",
"    </a>",
"    ]. The actual speech-language rehabilitation technique may not matter as much as the actual number and intensity of therapy.",
"   </p>",
"   <p>",
"    One review of 10 studies of 864 patients with post-stroke aphasia found that intense (in excess of two hours per week) speech and language therapy over a short period of time was more effective than less intense therapy provided over a longer period of time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. However, a randomized study in 116 patients found that in the subacute setting, patients who received two hours of therapy per week had similar recoveries compared to those who received five hours of therapy a week [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/35\">",
"     35",
"    </a>",
"    ]. Study results have also differed as to whether similar or disparate benefits are expected from professional therapists versus community-based programs or trained family members [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. While some have found that language therapy works best when administered early after stroke, others have found that, after adjusting for the effects of early spontaneous recovery, similar gains can be attained when speech therapy is administered in more chronic stages [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/33,37,38\">",
"     33,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newer language therapy techniques that are being studied include the use of computer-assisted techniques, as well as so-called constraint-induced aphasia therapy (CIAT) (high intensity therapy that restricts the use of nonverbal communication) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. In one study of 27 patients with chronic post-stroke aphasia, CIAT produced benefits both when used alone and when combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Pharmacologic approaches'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/42\">",
"     42",
"    </a>",
"    ]. Developments are also being made in the application of augmentive and alternative communication devices. The recent development of smarter phones, computer pads, and similar devices has led to the availability of downloadable applications for therapy and communication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pharmacologic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale behind pharmacologic treatment of aphasia involves replacing depleted neurotransmitters, enhancing neuroplasticity, and improving cerebral blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/21\">",
"     21",
"    </a>",
"    ]. No pharmacological intervention has been proven to result unequivocally in long-term benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/43\">",
"     43",
"    </a>",
"    ]. Examples of clinical trials of medications in patients with post-stroke aphasia include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"       Bromocriptine",
"      </a>",
"      was studied in a randomized, double-blind trial in 38 patients with a post-stroke nonfluent aphasia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/14\">",
"       14",
"      </a>",
"      ]. After 16 weeks of treatment, there was no difference in the recovery of language function between active and placebo-treated groups. This negative result was concurrent with the results of a previous randomized study [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Amphetamine in conjunction with",
"      <span class=\"nowrap\">",
"       speech/language",
"      </span>",
"      therapy (10 sessions over five weeks) appeared to improve language more than therapy alone in a randomized, double-blind study in 21 post-stroke aphasia patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/45\">",
"       45",
"      </a>",
"      ]. The between-group differences appeared to be maintained at the six-week and six-month assessments but were no longer significant after six-months. A 2003 systematic review of the use of amphetamines in post-stroke rehabilitation concluded that the aggregated results of small studies supported future research of this treatment approach, but not their use in routine clinical practice [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Piracetam was studied in 24 stroke patients with aphasia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/47\">",
"       47",
"      </a>",
"      ]. After six weeks of treatment, the piracetam-treated group appeared to make greater gains in language function on certain subtest areas compared with the placebo-treated group. A meta-analysis of prior studies of piracetam in acute stroke concluded that there was weak evidence of piracetam's efficacy in the treatment of post-stroke aphasia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The acetylcholinesterase inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"       donepezil",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/27/6582?source=see_link\">",
"       galantamine",
"      </a>",
"      have shown promise in open-label studies in patients with post-stroke aphasia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/2,48,49\">",
"       2,48,49",
"      </a>",
"      ]. There is some evidence that donepezil and other acetylcholinesterase inhibitors may be efficacious in vascular dementia and also in aphasia resulting from neurodegenerative dementia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10104?source=see_link\">",
"       \"Treatment and prevention of vascular dementia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1913?source=see_link\">",
"       \"Cholinesterase inhibitors in the treatment of dementia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"       Memantine",
"      </a>",
"      (10 mg twice daily) was studied along with constraint-induced aphasia therapy (CIAT) in 27 patients with chronic post-stroke aphasia in a randomized, controlled, parallel-group study [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/42\">",
"       42",
"      </a>",
"      ]. Memantine treatment was associated with a sustained benefit at 48 weeks on measures of aphasia and communication. The benefit of drug treatment appeared to be augmented by CIAT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depression often develops in patients with chronic or progressive aphasias and may impair aphasia recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Psychotherapy or pharmacological management may improve the outcome in these patients. However, a six-month clinical trial of the monoamine oxidase inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/5/18518?source=see_link\">",
"     moclobemide",
"    </a>",
"    , in 90 unselected patients with post-stroke aphasia did not find that treatment was associated with greater improvement of the aphasia compared to placebo treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/53\">",
"     53",
"    </a>",
"    ]. The use of prophylactic antidepressant medications is not supported in patients with post-stroke aphasia or aphasia of other etiologies. It seems reasonable, however, to monitor such patients for the development of depression and institute treatment if depression does emerge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=see_link\">",
"     \"Diagnosis and management of late-life depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transcranial magnetic or electrical stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Applied to the contralateral, unaffected cerebral hemisphere, transcranial magnetic stimulation (TMS) is believed to suppress its activity, and as a result, the tonic inhibition of the affected hemisphere [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/21\">",
"     21",
"    </a>",
"    ]. While uncontrolled reports in a small number of patients with post-stroke aphasia report evidence of efficacy, further study of this modality is required [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. A small, placebo-controlled study of TMS in 10 patients with Alzheimer disease suggested a benefit from treatment in auditory sentence comprehension but not other test measures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative approach applies a weak polarizing electric current to the cortex using electrodes applied to the skull. In one study this modality was applied to 10 patients with chronic stroke-induced aphasia and appeared to induce enhanced naming accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/58\">",
"     58",
"    </a>",
"    ]. In another nonrandomized study in eight patients with chronic post-stroke aphasia, cortical stimulation applied via surgically implanted electrodes appeared to augment the effect of speech and language therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3111/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/61/30674?source=see_link\">",
"       \"Patient information: Aphasia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/45/3795?source=see_link\">",
"       \"Patient information: Recovery after stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aphasia is a common complication of cerebrovascular disease and is associated with significant disability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with post-stroke aphasia are likely to experience some improvement after the initial event. The prognosis for full recovery is greatest when patients have milder degrees of aphasia at the onset.",
"     </li>",
"     <li>",
"      We suggest speech and language therapy for patients with post-stroke aphasia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The available data from clinical trials offer weak support for this approach, but no single technique has emerged as more effective than others. The use of speech and language therapy has become the standard of care and has value in helping patients and families compensate for the devastating loss in the patient's communication skills. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Speech and language therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with aphasia are at risk of developing depression, which is likely to interfere with recovery and rehabilitation efforts. Patients should be monitored for the development of depression. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pharmacologic approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is insufficient evidence to recommend other pharmacologic interventions to improve patients' recovery from aphasia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/1\">",
"      Inatomi Y, Yonehara T, Omiya S, et al. Aphasia during the acute phase in ischemic stroke. Cerebrovasc Dis 2008; 25:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/2\">",
"      Berthier ML. Poststroke aphasia : epidemiology, pathophysiology and treatment. Drugs Aging 2005; 22:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/3\">",
"      Wade DT, Hewer RL, David RM, Enderby PM. Aphasia after stroke: natural history and associated deficits. J Neurol Neurosurg Psychiatry 1986; 49:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/4\">",
"      Pedersen PM, J&oslash;rgensen HS, Nakayama H, et al. Aphasia in acute stroke: incidence, determinants, and recovery. Ann Neurol 1995; 38:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/5\">",
"      Solomon NA, Glick HA, Russo CJ, et al. Patient preferences for stroke outcomes. Stroke 1994; 25:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/6\">",
"      Davidson B, Howe T, Worrall L, et al. Social participation for older people with aphasia: the impact of communication disability on friendships. Top Stroke Rehabil 2008; 15:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/7\">",
"      Isaki E, Turkstra L. Communication abilities and work re-entry following traumatic brain injury. Brain Inj 2000; 14:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/8\">",
"      Hilari K, Byng S. Health-related quality of life in people with severe aphasia. Int J Lang Commun Disord 2009; 44:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/9\">",
"      Bakas T, Kroenke K, Plue LD, et al. Outcomes among family caregivers of aphasic versus nonaphasic stroke survivors. Rehabil Nurs 2006; 31:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/10\">",
"      Choi-Kwon S, Kim HS, Kwon SU, Kim JS. Factors affecting the burden on caregivers of stroke survivors in South Korea. Arch Phys Med Rehabil 2005; 86:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/11\">",
"      Demir SO, Altinok N, Aydin G, K&ouml;seolu F. Functional and cognitive progress in aphasic patients with traumatic brain injury during post-acute phase. Brain Inj 2006; 20:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/12\">",
"      Paolucci S, Matano A, Bragoni M, et al. Rehabilitation of left brain-damaged ischemic stroke patients: the role of comprehension language deficits. A matched comparison. Cerebrovasc Dis 2005; 20:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/13\">",
"      Ellis C, Simpson AN, Bonilha H, et al. The one-year attributable cost of poststroke aphasia. Stroke 2012; 43:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/14\">",
"      Ashtary F, Janghorbani M, Chitsaz A, et al. A randomized, double-blind trial of bromocriptine efficacy in nonfluent aphasia after stroke. Neurology 2006; 66:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/15\">",
"      Laska AC, Hellblom A, Murray V, et al. Aphasia in acute stroke and relation to outcome. J Intern Med 2001; 249:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/16\">",
"      Pedersen PM, Vinter K, Olsen TS. Aphasia after stroke: type, severity and prognosis. The Copenhagen aphasia study. Cerebrovasc Dis 2004; 17:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/17\">",
"      Bakheit AM, Shaw S, Carrington S, Griffiths S. The rate and extent of improvement with therapy from the different types of aphasia in the first year after stroke. Clin Rehabil 2007; 21:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/18\">",
"      Lazar RM, Minzer B, Antoniello D, et al. Improvement in aphasia scores after stroke is well predicted by initial severity. Stroke 2010; 41:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/19\">",
"      Poeck K, Huber W, Willmes K. Outcome of intensive language treatment in aphasia. J Speech Hear Disord 1989; 54:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/20\">",
"      Moss A, Nicholas M. Language rehabilitation in chronic aphasia and time postonset: a review of single-subject data. Stroke 2006; 37:3043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/21\">",
"      Jordan LC, Hillis AE. Disorders of speech and language: aphasia, apraxia and dysarthria. Curr Opin Neurol 2006; 19:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/22\">",
"      Richter M, Miltner WH, Straube T. Association between therapy outcome and right-hemispheric activation in chronic aphasia. Brain 2008; 131:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/23\">",
"      Saur D, Lange R, Baumgaertner A, et al. Dynamics of language reorganization after stroke. Brain 2006; 129:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/24\">",
"      de Boissezon X, D&eacute;monet JF, Puel M, et al. Subcortical aphasia: a longitudinal PET study. Stroke 2005; 36:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/25\">",
"      Price CJ, Crinion J. The latest on functional imaging studies of aphasic stroke. Curr Opin Neurol 2005; 18:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/26\">",
"      Warren JE, Crinion JT, Lambon Ralph MA, Wise RJ. Anterior temporal lobe connectivity correlates with functional outcome after aphasic stroke. Brain 2009; 132:3428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/27\">",
"      Turkeltaub PE, Messing S, Norise C, Hamilton RH. Are networks for residual language function and recovery consistent across aphasic patients? Neurology 2011; 76:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/28\">",
"      Lidzba K, Staudt M, Zieske F, et al. Prestroke/poststroke fMRI in aphasia: perilesional hemodynamic activation and language recovery. Neurology 2012; 78:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/29\">",
"      Hagmann P, Cammoun L, Martuzzi R, et al. Hand preference and sex shape the architecture of language networks. Hum Brain Mapp 2006; 27:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/30\">",
"      Nieuwenhuis L, Nicolai J. The pathophysiological mechanisms of cognitive and behavioral disturbances in children with Landau-Kleffner syndrome or epilepsy with continuous spike-and-waves during slow-wave sleep. Seizure 2006; 15:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/31\">",
"      Kelly H, Brady MC, Enderby P. Speech and language therapy for aphasia following stroke. Cochrane Database Syst Rev 2010; :CD000425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/32\">",
"      de Jong-Hagelstein M, van de Sandt-Koenderman WM, Prins ND, et al. Efficacy of early cognitive-linguistic treatment and communicative treatment in aphasia after stroke: a randomised controlled trial (RATS-2). J Neurol Neurosurg Psychiatry 2011; 82:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/33\">",
"      Robey RR. A meta-analysis of clinical outcomes in the treatment of aphasia. J Speech Lang Hear Res 1998; 41:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/34\">",
"      Bhogal SK, Teasell R, Speechley M. Intensity of aphasia therapy, impact on recovery. Stroke 2003; 34:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/35\">",
"      Bakheit AM, Shaw S, Barrett L, et al. A prospective, randomized, parallel group, controlled study of the effect of intensity of speech and language therapy on early recovery from poststroke aphasia. Clin Rehabil 2007; 21:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/36\">",
"      Meinzer M, Streiftau S, Rockstroh B. Intensive language training in the rehabilitation of chronic aphasia: efficient training by laypersons. J Int Neuropsychol Soc 2007; 13:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/37\">",
"      Aftonomos LB, Appelbaum JS, Steele RD. Improving outcomes for persons with aphasia in advanced community-based treatment programs. Stroke 1999; 30:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/38\">",
"      Cherney LR, Erickson RK, Small SL. Epidural cortical stimulation as adjunctive treatment for non-fluent aphasia: preliminary findings. J Neurol Neurosurg Psychiatry 2010; 81:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/39\">",
"      Szaflarski JP, Ball A, Grether S, et al. Constraint-induced aphasia therapy stimulates language recovery in patients with chronic aphasia after ischemic stroke. Med Sci Monit 2008; 14:CR243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/40\">",
"      Cherney LR, Patterson JP, Raymer A, et al. Evidence-based systematic review: effects of intensity of treatment and constraint-induced language therapy for individuals with stroke-induced aphasia. J Speech Lang Hear Res 2008; 51:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/41\">",
"      Meinzer M, Djundja D, Barthel G, et al. Long-term stability of improved language functions in chronic aphasia after constraint-induced aphasia therapy. Stroke 2005; 36:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/42\">",
"      Berthier ML, Green C, Lara JP, et al. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Ann Neurol 2009; 65:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/43\">",
"      Greener J, Enderby P, Whurr R. Pharmacological treatment for aphasia following stroke. Cochrane Database Syst Rev 2001; :CD000424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/44\">",
"      Sabe L, Salvarezza F, Garc&iacute;a Cuerva A, et al. A randomized, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia. Neurology 1995; 45:2272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/45\">",
"      Walker-Batson D, Curtis S, Natarajan R, et al. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke 2001; 32:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/46\">",
"      Martinsson L, H&aring;rdemark HG, Wahlgren NG. Amphetamines for improving stroke recovery: a systematic cochrane review. Stroke 2003; 34:2766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/47\">",
"      Kessler J, Thiel A, Karbe H, Heiss WD. Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke 2000; 31:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/48\">",
"      Berthier ML, Hinojosa J, Mart&iacute;n Mdel C, Fern&aacute;ndez I. Open-label study of donepezil in chronic poststroke aphasia. Neurology 2003; 60:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/49\">",
"      Hong JM, Shin DH, Lim TS, et al. Galantamine administration in chronic post-stroke aphasia. J Neurol Neurosurg Psychiatry 2012; 83:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/50\">",
"      Code C, Hemsley G, Herrmann M. The emotional impact of aphasia. Semin Speech Lang 1999; 20:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/51\">",
"      Kauhanen ML, Korpelainen JT, Hiltunen P, et al. Aphasia, depression, and non-verbal cognitive impairment in ischaemic stroke. Cerebrovasc Dis 2000; 10:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/52\">",
"      Thomas SA, Lincoln NB. Factors relating to depression after stroke. Br J Clin Psychol 2006; 45:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/53\">",
"      Laska AC, von Arbin M, Kahan T, et al. Long-term antidepressant treatment with moclobemide for aphasia in acute stroke patients: a randomised, double-blind, placebo-controlled study. Cerebrovasc Dis 2005; 19:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/54\">",
"      Martin PI, Naeser MA, Theoret H, et al. Transcranial magnetic stimulation as a complementary treatment for aphasia. Semin Speech Lang 2004; 25:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/55\">",
"      Naeser MA, Martin PI, Nicholas M, et al. Improved picture naming in chronic aphasia after TMS to part of right Broca's area: an open-protocol study. Brain Lang 2005; 93:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/56\">",
"      Mottaghy FM, Sparing R, T&ouml;pper R. Enhancing picture naming with transcranial magnetic stimulation. Behav Neurol 2006; 17:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/57\">",
"      Cotelli M, Calabria M, Manenti R, et al. Improved language performance in Alzheimer disease following brain stimulation. J Neurol Neurosurg Psychiatry 2011; 82:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3111/abstract/58\">",
"      Baker JM, Rorden C, Fridriksson J. Using transcranial direct-current stimulation to treat stroke patients with aphasia. Stroke 2010; 41:1229.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5107 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3111=[""].join("\n");
var outline_f3_2_3111=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Speech and language therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pharmacologic approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transcranial magnetic or electrical stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20041?source=related_link\">",
"      Approach to the patient with aphasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1913?source=related_link\">",
"      Cholinesterase inhibitors in the treatment of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=related_link\">",
"      Frontotemporal dementia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/61/30674?source=related_link\">",
"      Patient information: Aphasia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/45/3795?source=related_link\">",
"      Patient information: Recovery after stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10104?source=related_link\">",
"      Treatment and prevention of vascular dementia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_2_3112="Lymphedema stageIII ABC";
var content_f3_2_3112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Lymphedema stage III",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stage III lymphedema. A) Left lower extremity. B) Right upper extremity. C) Right upper extremity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tammy Mondry, DPT, MSRS, CLT-LANA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3112=[""].join("\n");
var outline_f3_2_3112=null;
var title_f3_2_3113="Confocal laser endomicroscopy and endocytoscopy";
var content_f3_2_3113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Confocal laser endomicroscopy and endocytoscopy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/2/3113/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/2/3113/contributors\">",
"     Alexander Meining, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/2/3113/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/2/3113/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/2/3113/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/2/3113/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/2/3113/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H455771632\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confocal laser endomicroscopy and endocytoscopy are emerging endoscopic technologies that permit high-resolution assessment of gastrointestinal mucosal histology at a cellular and sub-cellular level. Endomicroscopy and endocytoscopy dramatically expand the imaging capabilities of flexible endoscopy by their ability to obtain \"optical biopsies\" of nearly any accessible endoluminal surface.",
"   </p>",
"   <p>",
"    The examinations are carried out in vivo with real-time image display. The techniques have primarily been applied to the differentiation of colon polyps and for the detection of dysplasia and neoplasia in conditions such as Barrett's esophagus and ulcerative colitis. Since the first visible neoplastic changes in epithelial cancers occur at a cellular level, these imaging techniques may allow for earlier diagnosis and treatment. In addition, confocal laser endomicroscopy and endocytoscopy may allow for targeted biopsies of abnormal mucosa, thereby decreasing the number of biopsies required to diagnose dysplasia or neoplasia while increasing diagnostic yield.",
"   </p>",
"   <p>",
"    This topic will review confocal laser endomicroscopy and endocytoscopy, including the technical aspects of the procedures, their indications, and efficacies. Chromoendoscopy, magnification endoscopy, optical coherence tomography, narrow band imaging, and autofluorescence endoscopy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=see_link\">",
"     \"Magnification endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/41/7831?source=see_link\">",
"     \"Optical coherence tomography in the gastrointestinal tract\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=see_link\">",
"     \"Narrow band imaging in Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13750?source=see_link\">",
"     \"Autofluorescence endoscopy for Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455771639\">",
"    <span class=\"h1\">",
"     TECHNICAL OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455771646\">",
"    <span class=\"h2\">",
"     Confocal laser endomicroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confocal laser endomicroscopy (CLE) is based upon the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. The laser is focused at a specific depth and only light reflected back from that plane is refocused and able to pass through the pinhole confocal aperture. As a result, scattered light from above and below the plane of interest is not detected, increasing spacial resolution. The area being examined is scanned in the horizontal and vertical planes and an image is reconstructed. In this manner, microscopic imaging of biological tissue in vivo is possible due to the high lateral resolution of confocal imaging.",
"   </p>",
"   <p>",
"    Since CLE relies upon tissue fluorescence, intravenous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    topically applied contrast agents are required. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    is used to highlight the vasculature, lamina propria, and intracellular spaces of this tissue being examined. However, it does not stain cell nuclei. Nuclear staining can be achieved using topical contrast agents such as acriflavine and cresyl violet, but there is concern over mutagenic potential with the topical agents. (See",
"    <a class=\"local\" href=\"#H4168208\">",
"     'Adverse events'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The greatest challenge for CLE has been miniaturization and integration of the technology into endoscopic equipment. Two systems have been approved by the Food and Drug Administration and are commercially available: a tip-integrated confocal laser endomicroscope and a flexible fiber-based confocal miniprobe. Both systems contain a laser scanning unit and a PC-based image viewer for image acquisition and storage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455771653\">",
"    <span class=\"h3\">",
"     Confocal laser endomicroscope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscope-based confocal laser endomicroscopy (eCLE) uses a miniaturized confocal laser endomicroscope (Optiscan, Australia) that is integrated into the distal tip of a conventional endoscope (Pentax, Japan). An eCLE scope can be used in the upper and lower gastrointestinal tract, but is too large to be used for biliary examinations. A single optical fiber acts as both the illumination point source and the detection pinhole. White-light endoscopy and eCLE are performed simultaneously with white-light and confocal images displayed side-by-side on separate monitors.",
"   </p>",
"   <p>",
"    The diameter of the eCLE scope is 12.8 mm. The length of the tip is increased relative to a standard endoscope due to the integrated laser microscope (5 cm rigid portion). The endoscope has a working (biopsy) channel and a water cleansing channel.",
"   </p>",
"   <p>",
"    Confocal image data are collected at a scan rate of 0.8",
"    <span class=\"nowrap\">",
"     frames/second",
"    </span>",
"    (1024 x 1024 pixels) or 1.6",
"    <span class=\"nowrap\">",
"     frames/second",
"    </span>",
"    (1024 x 512 pixels). The optical slice thickness is 7 microns and the depth of scanning can vary from 0 to 250 microns. The field of view is 475 x 475 microns and the lateral resolution (ie, the minimum detectable separation between two interfaces) is 0.7 microns. The depth of imaging relative to the surface of the tissue is controlled using two additional buttons on the endoscope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455771660\">",
"    <span class=\"h3\">",
"     Confocal miniprobe",
"    </span>",
"    &nbsp;&mdash;&nbsp;A flexible probe-based system (Cellvizio, Mauna Kea Technologies, Paris, France) is an alternative to using a confocal laser endomicroscope. In probe-based confocal laser endomicroscopy (pCLE), both the laser scanning unit and light source are outside the body of the patient, making the confocal miniprobe a \"passive\" conduit. Multiple probes are available that vary with regard to field of view, depth of confocal plane, and lateral resolution (",
"    <a class=\"graphic graphic_table graphicRef63228 \" href=\"UTD.htm?34/47/35579\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The miniprobes are very flexible and can be passed through the working channel of a standard endoscope. Their diameters range from 0.9 to 2.5 mm. The probes can be disinfected and reused, but the number of uses is limited (approximately 20). Other accessories, such as a hood on the tip of an endoscope or endoscopic retrograde cholangiopancreatography accessories, may be helpful, but are not mandatory. (See",
"    <a class=\"local\" href=\"#H17143174\">",
"     'Maximizing image quality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The 488 nm laser beam is transmitted via several thousand optical fibers within the probe. These same fibers return the reflected fluorescent light to a distal micro-objective. Confocal image data are collected at a frame rate of 12 frames per second that, unlike eCLE at 0.8 to 1.6 frames per second, enables video quality. Depending upon which probe is used, the field of view ranges from 240 x 240 microns to 600 x 500 microns, the lateral resolution ranges from 1 to 3.5 microns, and the depth of imaging ranges from 0 to 100 microns. While in eCLE the depth of imaging can be adjusted, in pCLE the depth of imaging depends upon the probe being used and is fixed (",
"    <a class=\"graphic graphic_table graphicRef63228 \" href=\"UTD.htm?34/47/35579\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An advantage of pCLE is that probes have been developed for biliary and pancreatic examinations. The Cholangioflex-probe has a diameter of 0.9 mm and can be passed through the instrumentation channel of a cholangioscope [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/1\">",
"     1",
"    </a>",
"    ]. During cholangioscopy, the probe can be placed against the lesion or area of interest under direct visual control and guidance. There are also reports of the probe being passed under fluoroscopic guidance using endoscopic retrograde cholangiopancreatography catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The tip of the probe has a metallic ring and can be easily seen on fluoroscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=see_link\">",
"     \"Cholangioscopy and pancreatoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18166?source=see_link\">",
"     \"Percutaneous transhepatic cholangioscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455771667\">",
"    <span class=\"h2\">",
"     Endocytoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to confocal laser endomicroscopy (CLE), endocytoscopy aims to enable real-time microscopic imaging of the mucosa in vivo. The main difference between CLE and endocytoscopy is that endocytoscopy is based solely on high-level magnification using optical lenses. Therefore, because there is no confocal plane, only the very superficial layer of the mucosa can be imaged. In addition, the lens must come into direct contact with the tissue being examined.",
"   </p>",
"   <p>",
"    An endocytoscopy system is not yet commercially available, but studies have been performed with prototypes manufactured by Olympus (Tokyo, Japan). The prototypes include a system that is integrated within an endoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/4,5\">",
"     4,5",
"    </a>",
"    ] and one that is probe-based [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The probe-based system consists of two flexible catheters that provide surface magnification of 450- and 1125-fold with a 14-inch monitor or 570- and 1400-fold using a 19-inch monitor.",
"   </p>",
"   <p>",
"    As with confocal endomicroscopy, acquisition of quality images requires application of a contrast agent. Typically, topical application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    or a combination of methylene blue with crystal violet is used [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. In epithelia that produce significant amounts of mucin (eg, gastric epithelium or Barrett's mucosa), imaging may be hampered by the contrast agent failing to penetrate the mucin barrier, resulting in inadequate staining. (See",
"    <a class=\"local\" href=\"#H17143214\">",
"     'Staining'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17143174\">",
"    <span class=\"h2\">",
"     Maximizing image quality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The keys to obtaining high-quality images are optimizing contrast administration, positioning, and stability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17143214\">",
"    <span class=\"h3\">",
"     Staining",
"    </span>",
"    &nbsp;&mdash;&nbsp;Image quality following intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    administration is best within the first 10 minutes following contrast administration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/9\">",
"     9",
"    </a>",
"    ], though imaging may continue for 30 to 45 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. For examinations using topical contrast agents, it is essential to thoroughly remove the mucin layer prior to staining. This can be done by applying N-acetylcysteine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    , flushing with water, and then homogeneously staining the mucosa using a spraying catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17143221\">",
"    <span class=\"h3\">",
"     Device placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;To improve image quality, when possible, the probe or endoscope should be placed perpendicular to the mucosa rather than tangentially. The way the device is placed is also important in patients with friable lesions because blood causes visual interference. In such cases, the probe or endoscope should be carefully apposed to the mucosa to decrease tissue disruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17143314\">",
"    <span class=\"h3\">",
"     Stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Movements caused by the examiner or the patient (breathing or peristalsis) can impair positioning and cause artifacts. For probe-based examinations, attaching a clear plastic cap to the tip of the endoscope and applying gentle suction helps hold the probe in position. Such an approach can be particularly helpful when imaging Barrett's esophagus, since probe placement in the distal esophagus can be challenging. In addition, using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    to sedate the patient helps to avoid retching, belching, and patient movement during the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43049?source=see_link\">",
"     \"Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4168398\">",
"    <span class=\"h2\">",
"     Obtaining biopsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eCLE scope has a regular working channel that is not occupied by a probe, and a biopsy can be taken from the same area. On the other hand, with pCLE systems the miniprobes occupy the working channel of the endoscope, so biopsies can only be obtained after the probe is removed. This limitation can be overcome by creating a suction polyp that contains the area of interest. In the case of cholangioscopy, after the lesion or area of interest has been examined, the probe is removed and a biopsy forceps is passed through the biopsy channel of the cholangioscope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455771674\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for confocal laser endomicroscopy (CLE) and endocytoscopy are still being defined. In general, these procedures are used to target biopsies of abnormal tissue and decrease biopsies of normal tissue. The goal is to increase diagnostic yield, while minimizing procedure-related risks and the costs of tissue acquisition and analysis. A potential indication that has not yet been evaluated is using \"optical biopsies\" with these techniques instead of conventional histology in patients at high risk for procedure-associated bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CLE and endocytoscopy have been used to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Differentiate neoplastic from non-neoplastic colon polyps and lesions (colon and stomach)",
"     </li>",
"     <li>",
"      Detect dysplasia and neoplasia in patients undergoing surveillance for Barrett's esophagus or ulcerative colitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link&amp;anchor=H23#H23\">",
"       \"Management of Barrett's esophagus\", section on 'Guidelines'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link&amp;anchor=H21#H21\">",
"       \"Colorectal cancer surveillance in inflammatory bowel disease\", section on 'Colonoscopy with biopsy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Differentiate benign from malignant biliary strictures",
"     </li>",
"     <li>",
"      Guide endoscopic mucosal resection of dysplastic lesions in Barrett's esophagus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=see_link\">",
"       \"Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Potentially detect celiac disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With further miniaturization of confocal miniprobes, it has become possible to perform CLE via the needles used for endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/12\">",
"     12",
"    </a>",
"    ]. This may permit improved diagnostic accuracy of cystic pancreatic lesions as shown by an early feasibility study that included 16 patients with cystic lesions and 2 patients with pancreatic masses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CLE (and to some extent endocytoscopy) may also have a role in the evaluation of organs outside the gastrointestinal tract. Probe-based CLE has been used for the detection and classification of chronic pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, probe-based CLE and endocytoscopy have been applied for the detection of bladder cancer via a transurethral approach [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17697294\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary contraindication to confocal laser endomicroscopy and endocytoscopy is an allergy to the contrast agent being used. In addition, patients must be deemed fit candidates for endoscopy. (See",
"    <a class=\"local\" href=\"#H4168208\">",
"     'Adverse events'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455771695\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a limited but increasing number of studies evaluating the accuracy of confocal laser endomicroscopy. Fewer studies have been performed with endocytoscopy. In general, the reported results have been excellent, with accuracy rates often greater than 90 percent. However, almost all of these studies were performed in centers with significant experience in endoscopic imaging technologies. The patients were highly selected, and the examiners in many studies were not blinded to other relevant clinical and endoscopic data. Thus, further studies are needed to confirm these initially promising results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1911573\">",
"    <span class=\"h2\">",
"     Efficacy of confocal laser endomicroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confocal laser endomicroscopy (CLE) has been studied for use in the upper and lower gastrointestinal (GI) tract, as well as in the hepatobiliary tree:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper GI applications have included detection of neoplasia in the esophagus and stomach, identification of Helicobacter pylori in the stomach [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/17\">",
"       17",
"      </a>",
"      ], and detection of villous atrophy and increased intraepithelial lymphocytes in the small bowel of patients with celiac disease [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/18-25\">",
"       18-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The primary focus on CLE in the lower GI tract has been for the differentiation of neoplastic from non-neoplastic polyps. CLE has also been used to detect disease activity and dysplasia in patients with chronic ulcerative colitis and to diagnose microscopic colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the hepatobiliary tree, CLE has been used to differentiate benign from malignant strictures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1911984\">",
"    <span class=\"h3\">",
"     Barrett's esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with normal columnar esophageal epithelium, Barrett's epithelium is characterized on CLE by a more tubular shaped mucosa, with a regular and constant width of the epithelial layer (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64674 \" href=\"UTD.htm?19/45/20177\">",
"     image 1",
"    </a>",
"    ). In addition, goblet cells, which are not seen in normal columnar esophagus, can be identified. Findings suggestive of neoplasia include a loss of the normal epithelial architecture, a variable epithelial layer width, a dark epithelial appearance, and the presence of irregular vasculature with leakage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Studies of the sensitivity and specificity of CLE in Barrett's esophagus have had variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/28-35\">",
"     28-35",
"    </a>",
"    ]. However, most studies suggest the sensitivity is at least 70 percent, and the specificity is at least 90 percent. Due to its deeper confocal imaging plane, CLE appears to be superior to endocytoscopy for the evaluation Barrett's esophagus and gastric neoplasia. (See",
"    <a class=\"local\" href=\"#H1911398\">",
"     'Stomach and columnar esophagus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    CLE has also been used to guide endoscopic mucosal resection (EMR) in patients with Barrett's esophagus. In a study of 62 such patients, 22 had flat high-grade dysplasia by CLE and underwent EMR [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/33\">",
"     33",
"    </a>",
"    ]. Histopathology revealed low-grade dysplasia in six, high-grade dysplasia in 12, and no dysplasia in four. The sensitivity of CLE for dysplasia was 94 percent, with a specificity of 50 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1912081\">",
"    <span class=\"h3\">",
"     Gastric cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest a possible role for CLE in the evaluation of gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. A classification scheme based upon pit patterns has been proposed to aid with the evaluation of gastric neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 27 patients, images were successfully obtained in 16 (59 percent). The CLE images from 52 examined sites were evaluated by two pathologists [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/36\">",
"       36",
"      </a>",
"      ]. The sensitivity of CLE for gastric neoplasia was 82 to 91 percent, and the specificity was 98 percent. However, CLE failed to obtain adequate images in approximately 40 percent of the patients. Lesions at the fornix, antral lesser curvature, and the posterior wall of the gastric body were often difficult to image. This high failure rate for image acquisition may limit the value of CLE for detecting gastric neoplasia.",
"     </li>",
"     <li>",
"      In a second study, 521 sites from 137 patients were evaluated by CLE using a pit pattern classification that was developed based upon the examination of seven healthy controls and 10 resected gastric cancers [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/38\">",
"       38",
"      </a>",
"      ]. Gastric cancer was present at 20 of the examined sites (4 percent) and was associated with a pit pattern characterized by the disappearance of the normal round pits and the appearance of diffusely atypical cells or glands. When that pattern was present, CLE had a sensitivity for detecting gastric cancer of 90 percent and a specificity of 99 percent. Interobserver and intraobserver variability were not reported.",
"     </li>",
"     <li>",
"      A third study included 1572 patients undergoing upper endoscopy with CLE [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/39\">",
"       39",
"      </a>",
"      ]. The indications for the procedures included dyspeptic symptoms (the vast majority), gastric cancer, gastric polyps, gastritis, and suspicious lesions. Early gastric cancer was diagnosed in 40 patients on clinicopathologic grounds. An additional 15 patients had high-grade dysplasia. The sensitivity of CLE for detecting superficial neoplastic lesions (early gastric cancer or high-grade dysplasia) was 89 percent, and the specificity was 99 percent. The corresponding values for white-light endoscopy were 72 and 95 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1912232\">",
"    <span class=\"h3\">",
"     Colon polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic architecture and microvascular changes are used to differentiate neoplastic polyps (eg, adenomas and carcinomas) from non-neoplastic polyps (eg, hyperplastic polyps). The following findings are seen with neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/10,40\">",
"     10,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of goblet cells.",
"     </li>",
"     <li>",
"      Variable width of the epithelial layer with tubular shaped (elongated) crypts.",
"     </li>",
"     <li>",
"      The lamina propria is thin and irregular.",
"     </li>",
"     <li>",
"      Due to the volume loss in the lamina propria, fewer blood vessels are present, which results in decreased diffusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      and darkening of the image. In addition, the vessels may become irregular (tortuous with variable diameter) with leakage of fluorescein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical utility of CLE for colon polyps has been evaluated in several studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study looked at the ability of CLE to differentiate hyperplastic from adenomatous polyps [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/41\">",
"       41",
"      </a>",
"      ]. A total of 37 polyps were evaluated in 25 patients. CLE discriminated between neoplastic and non-neoplastic polyps with a sensitivity of 83 percent and a specificity of 100 percent.",
"     </li>",
"     <li>",
"      A second report examined 162 colonic lesions as well as normal mucosal controls [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/42\">",
"       42",
"      </a>",
"      ]. Chromoendoscopy was used to guide CLE (ie, lesions detected by chromoendoscopy were then further evaluated using CLE). Chromoendoscopy-guided CLE had a sensitivity of 97 percent and a specificity of 99 percent for predicting intraepithelial neoplasia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=see_link\">",
"       \"Chromoendoscopy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another study with 102 lesions used a new classification for probe-based CLE. Presence of neoplasia was assessed by blinded scoring of video sequences. The overall accuracy (81 percent) for predicting neoplasia was acceptable but became excellent (94 percent) in cases where all blinded observers agreed [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1912275\">",
"    <span class=\"h3\">",
"     Ulcerative colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that CLE may be able to assess the degree of inflammation in patients with ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In addition, CLE is superior to routine surveillance colonoscopy for the detection of dysplasia and may be able to differentiate dysplasia-associated lesions or masses from sporadic adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link&amp;anchor=H13#H13\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\", section on 'Dysplasia associated lesion or mass'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CLE was compared with routine surveillance colonoscopy in a report of 161 patients with chronic ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/45\">",
"     45",
"    </a>",
"    ]. CLE detected significantly more areas of intraepithelial neoplasia (19 versus 4 with routine surveillance) and required fewer biopsies per patient (average 21 versus 42).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455771716\">",
"    <span class=\"h3\">",
"     Bile duct strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;CLE probes exist that are small enough to fit through the biopsy channel of a cholangioscope, making imaging of the hepatobiliary system possible. The goal is to differentiate benign from malignant strictures, which can be difficult. Brush cytology, for example, has a reported sensitivity of 35 to 70 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19816?source=see_link&amp;anchor=H5#H5\">",
"     \"Endoscopic methods for the diagnosis of pancreatobiliary neoplasms\", section on 'Brush cytology'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H455771660\">",
"     'Confocal miniprobe'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The available data on hepatobiliary CLE are promising [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/1,2,47\">",
"     1,2,47",
"    </a>",
"    ]. The hallmarks of neoplasia in the bile duct include epithelial structures characterized by glands or villi and increased vascularity. The reported sensitivity of CLE for diagnosing neoplasia is 83 to 98 percent, and the specificity is 67 to 100 percent. In a study with 102 patients with indeterminate pancreaticobiliary strictures, 89 were able to be evaluated with CLE [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/47\">",
"     47",
"    </a>",
"    ]. Forty patients were proven to have cancer. CLE had a sensitivity of 98 percent and a specificity of 67 percent for diagnosing malignancy.",
"   </p>",
"   <p>",
"    In a second study with 14 patients, CLE was compared with standard histopathology [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/1\">",
"     1",
"    </a>",
"    ]. CLE had a higher sensitivity than standard histopathology (83 versus 50 percent), but a lower specificity (88 versus 100 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2154988\">",
"    <span class=\"h3\">",
"     Interobserver reliability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies of CLE have demonstrated good interobserver agreement for the interpretation of the CLE images, with kappa values of 0.6 to 0.8 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/28-30,32,48,49\">",
"     28-30,32,48,49",
"    </a>",
"    ]. The kappa statistic is a measure of the agreement between two observers and can range from -1.0 to +1.0. If there is perfect agreement, the value is 1.0, whereas if the observed agreement is what would be expected by chance alone, the value is zero. If the degree of agreement is worse than what would be expected by chance, the kappa value will be negative, with complete disagreement resulting in a value of -1.0. Kappa statistics are often interpreted as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excellent agreement &mdash; 0.8 to 1.0",
"     </li>",
"     <li>",
"      Good agreement &mdash; 0.6 to 0.8",
"     </li>",
"     <li>",
"      Moderate agreement &mdash; 0.4 to 0.6",
"     </li>",
"     <li>",
"      Fair agreement &mdash; 0.2 to 0.4",
"     </li>",
"     <li>",
"      Poor agreement &mdash; less than 0.2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although CLE is relatively easy to perform, there is a learning curve [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In one study, interobserver agreement was higher among gastroenterologists who had performed more than 30 CLE examinations compared with those who had performed fewer than 30 (kappa 0.72 versus 0.34).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1911384\">",
"    <span class=\"h2\">",
"     Efficacy of endocytoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocytoscopy has been studied for the evaluation of dysplasia and neoplasia in the esophagus, stomach, and colon. Other applications that have been described include visualization of Helicobacter pylori in the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/52\">",
"     52",
"    </a>",
"    ] and real-time monitoring of blood flow in the rectal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1911391\">",
"    <span class=\"h3\">",
"     Squamous esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endocytoscopic findings of cancer include enlarged, irregularly arranged cell nuclei (",
"    <a class=\"graphic graphic_picture graphicRef78034 \" href=\"UTD.htm?40/39/41584\">",
"     picture 1",
"    </a>",
"    ). Endocytoscopy has a reported sensitivity of 80 to 90 percent for detecting neoplasia in the squamous esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Small studies have found the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 25 patients, the overall sensitivity and specificity of endocytoscopy for diagnosing pathologic esophageal lesions were 81 and 100 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/7\">",
"       7",
"      </a>",
"      ]. When the x1100 magnification probe was used, the sensitivity and specificity were 91 and 100 percent, respectively; whereas, when the x450 magnification probe was used, they were 77 and 100 percent. However, the authors did not report whether the observed differences in sensitivity were statistically significant.",
"     </li>",
"     <li>",
"      In a second study of 28 patients who underwent endocytoscopy for lesions in the squamous esophagus, the sensitivity and specificity of endocytoscopy for detecting malignancy were 88 and 91 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1911398\">",
"    <span class=\"h3\">",
"     Stomach and columnar esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the detection of neoplasia in the squamous esophagus, the accuracy of endocytoscopy for the detection of neoplasia arising from Barrett's esophagus or in the stomach appears to be only fair [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/7,54\">",
"     7,54",
"    </a>",
"    ]. The reason may be that topically applied contrast agents have difficulty penetrating the cells due to the thick mucin layers covering the epithelium. In addition, in the distal esophagus movement from respiration and esophageal contractions as well as difficult visual coupling may result in poor image resolution.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 23 patients with gastric lesions, the sensitivity and specificity of endocytoscopy for predicting neoplastic change were 56 and 89 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 16 patients undergoing surveillance for Barrett's esophagus, attempts at obtaining adequate imaging were successful 51 percent of the time at x450 magnification and 22 percent of the time at x1125 magnification [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/54\">",
"       54",
"      </a>",
"      ]. Of the images that could be assessed, the respective sensitivity and specificity for diagnosing dysplasia were 50 and 67 percent at x450 magnification and were 43 and 85 percent at x1125 magnification.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1911405\">",
"    <span class=\"h3\">",
"     Colon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocytoscopically, adenomatous and malignant tissues in the colon are characterized by deformed, irregularly branching glands with enlarged cell nuclei and disordered cellular polarity. Preliminary studies of endocytoscopy for the evaluation of colon lesions have been promising:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study with 75 lesions, the overall accuracy of endocytoscopy was 93 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/5\">",
"       5",
"      </a>",
"      ]. When it came to differentiating neoplastic from non-neoplastic lesions, the sensitivity and specificity were both 100 percent. In addition, of the 59 neoplastic lesions, 58 (98 percent) were correctly categorized as being either adenomas (46 lesions) or invasive cancers (12 lesions). One invasive cancer was misdiagnosed as an adenoma.",
"     </li>",
"     <li>",
"      In a second report that included 28 patients with colonic lesions, the sensitivity and specificity of endocytoscopy for diagnosing neoplasia were 79 and 90 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4168208\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse events related to the contrast agents used for confocal laser endomicroscopy and endocytoscopy have been reported. Problems with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    are mainly due to its allergic properties. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     \"Fluorescein: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, no serious adverse events were reported in 2272 gastrointestinal procedures performed with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/55\">",
"     55",
"    </a>",
"    ]. Mild adverse events occurred in 1.4 percent of individuals, including",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    transient hypotension without shock, injection site erythema, diffuse rash, and mild epigastric pain.",
"   </p>",
"   <p>",
"    Data are lacking on potential side effects for topical stains, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    , crystal violet, cresyl violet, or acriflavine. However, some of these stains may cause DNA-damage and are therefore potentially mutagenic [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3113/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In addition, acriflavine and cresyl violet are not approved by the Food and Drug Administration for use in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455771730\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confocal laser endomicroscopy (CLE) and endocytoscopy are emerging endoscopic technologies that permit high-resolution assessment of gastrointestinal mucosal histology at a cellular and sub-cellular level. Endomicroscopy and endocytoscopy dramatically expand the imaging capabilities of flexible endoscopy by their ability to obtain \"optical biopsies\" of nearly any accessible endoluminal surface. (See",
"      <a class=\"local\" href=\"#H455771632\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CLE and endocytoscopy can be performed with probe-based systems that are passed through the working channel of an endoscope or with integrated endoscopic systems. Only CLE systems are currently commercially available. (See",
"      <a class=\"local\" href=\"#H455771639\">",
"       'Technical overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications for confocal laser endomicroscopy (CLE) and endocytoscopy are still being defined. In general, CLE and endocytoscopy are used to target biopsies of abnormal tissue and to avoid taking biopsies of normal tissue. The goal is to increase diagnostic yield while minimizing procedure-related risks and the costs of tissue acquisition and analysis. (See",
"      <a class=\"local\" href=\"#H455771674\">",
"       'Indications'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Some applications of CLE and endocytoscopy include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Differentiation of neoplastic from non-neoplastic polyps and lesions (colon and stomach)",
"     </li>",
"     <li>",
"      Detection of neoplasia in patients with Barrett's esophagus or ulcerative colitis",
"     </li>",
"     <li>",
"      Differentiation of benign from malignant biliary strictures (probe-based CLE)",
"     </li>",
"     <li>",
"      Potentially detecting celiac disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While promising, available data on these new techniques are sparse and further large-scale studies are needed to help define their roles. (See",
"      <a class=\"local\" href=\"#H455771695\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/1\">",
"      Meining A, Frimberger E, Becker V, et al. Detection of cholangiocarcinoma in vivo using miniprobe-based confocal fluorescence microscopy. Clin Gastroenterol Hepatol 2008; 6:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/2\">",
"      Chen Y, Shah R, Douglas K, et al. Miami Classification (MC) of Probe-Based Confocal Laser Endomicroscopy (pCLE) Findings in the Pancreaticobiliary (PB) System for Evaluation of Indeterminate Strictures: Interim Results From an International Multicenter Registry (Abstract). Gastrointestinal Endosc 2010; 71:AB134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/3\">",
"      Wallace MB, Fockens P. Probe-based confocal laser endomicroscopy. Gastroenterology 2009; 136:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/4\">",
"      Inoue H, Yokoyama A, Kudo SE. [Ultrahigh magnifying endoscopy: development of CM double staining for endocytoscopy and its safety]. Nihon Rinsho 2010; 68:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/5\">",
"      Sasajima K, Kudo SE, Inoue H, et al. Real-time in vivo virtual histology of colorectal lesions when using the endocytoscopy system. Gastrointest Endosc 2006; 63:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/6\">",
"      Inoue H, Kazawa T, Sato Y, et al. In vivo observation of living cancer cells in the esophagus, stomach, and colon using catheter-type contact endoscope, \"Endo-Cytoscopy system\". Gastrointest Endosc Clin N Am 2004; 14:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/7\">",
"      Eberl T, Jechart G, Probst A, et al. Can an endocytoscope system (ECS) predict histology in neoplastic lesions? Endoscopy 2007; 39:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/8\">",
"      Inoue H, Sasajima K, Kaga M, et al. Endoscopic in vivo evaluation of tissue atypia in the esophagus using a newly designed integrated endocytoscope: a pilot trial. Endoscopy 2006; 38:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/9\">",
"      Becker V, von Delius S, Bajbouj M, et al. Intravenous application of fluorescein for confocal laser scanning microscopy: evaluation of contrast dynamics and image quality with increasing injection-to-imaging time. Gastrointest Endosc 2008; 68:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/10\">",
"      Kiesslich R, Burg J, Vieth M, et al. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology 2004; 127:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/11\">",
"      Polglase AL, McLaren WJ, Skinner SA, et al. A fluorescence confocal endomicroscope for in vivo microscopy of the upper- and the lower-GI tract. Gastrointest Endosc 2005; 62:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/12\">",
"      Becker V, Wallace MB, Fockens P, et al. Needle-based confocal endomicroscopy for in vivo histology of intra-abdominal organs: first results in a porcine model (with videos). Gastrointest Endosc 2010; 71:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/13\">",
"      Konda VJ, Aslanian HR, Wallace MB, et al. First assessment of needle-based confocal laser endomicroscopy during EUS-FNA procedures of the pancreas (with videos). Gastrointest Endosc 2011; 74:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/14\">",
"      Thiberville L, Sala&uuml;n M, Lachkar S, et al. Human in vivo fluorescence microimaging of the alveolar ducts and sacs during bronchoscopy. Eur Respir J 2009; 33:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/15\">",
"      Ohigashi T, Kozakai N, Mizuno R, et al. Endocytoscopy: novel endoscopic imaging technology for in-situ observation of bladder cancer cells. J Endourol 2006; 20:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/16\">",
"      Sonn GA, Jones SN, Tarin TV, et al. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J Urol 2009; 182:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/17\">",
"      Kiesslich R, Goetz M, Burg J, et al. Diagnosing Helicobacter pylori in vivo by confocal laser endoscopy. Gastroenterology 2005; 128:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/18\">",
"      Matysiak-Budnik T, Coron E, Mosnier JF, et al. In vivo real-time imaging of human duodenal mucosal structures in celiac disease using endocytoscopy. Endoscopy 2010; 42:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/19\">",
"      G&uuml;nther U, Daum S, Heller F, et al. Diagnostic value of confocal endomicroscopy in celiac disease. Endoscopy 2010; 42:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/20\">",
"      Leong RW, Nguyen NQ, Meredith CG, et al. In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease. Gastroenterology 2008; 135:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/21\">",
"      Pohl H, R&ouml;sch T, Tanczos BT, et al. Endocytoscopy for the detection of microstructural features in adult patients with celiac sprue: a prospective, blinded endocytoscopy-conventional histology correlation study. Gastrointest Endosc 2009; 70:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/22\">",
"      Kiesslich R, Goetz M, Neurath MF. Confocal laser endomicroscopy for gastrointestinal diseases. Gastrointest Endosc Clin N Am 2008; 18:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/23\">",
"      Trovato C, Sonzogni A, Ravizza D, et al. Celiac disease: in vivo diagnosis by confocal endomicroscopy. Gastrointest Endosc 2007; 65:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/24\">",
"      Zambelli A, Villanacci V, Buscarini E, et al. Confocal laser endomicroscopy in celiac disease: description of findings in two cases. Endoscopy 2007; 39:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/25\">",
"      Pohl H, Tanczos BT, Rudolph B, et al. Probe-based confocal laser microscopy identifies criteria predictive of active celiac sprue. Dig Dis Sci 2012; 57:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/26\">",
"      Meining A, Schwendy S, Becker V, et al. In vivo histopathology of lymphocytic colitis. Gastrointest Endosc 2007; 66:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/27\">",
"      Kiesslich R, Hoffman A, Goetz M, et al. In vivo diagnosis of collagenous colitis by confocal endomicroscopy. Gut 2006; 55:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/28\">",
"      Meining A, Saur D, Bajbouj M, et al. In vivo histopathology for detection of gastrointestinal neoplasia with a portable, confocal miniprobe: an examiner blinded analysis. Clin Gastroenterol Hepatol 2007; 5:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/29\">",
"      Pohl H, R&ouml;sch T, Vieth M, et al. Miniprobe confocal laser microscopy for the detection of invisible neoplasia in patients with Barrett's oesophagus. Gut 2008; 57:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/30\">",
"      Wallace MB, Sharma P, Lightdale C, et al. Preliminary accuracy and interobserver agreement for the detection of intraepithelial neoplasia in Barrett's esophagus with probe-based confocal laser endomicroscopy. Gastrointest Endosc 2010; 72:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/31\">",
"      Bajbouj M, Vieth M, R&ouml;sch T, et al. Probe-based confocal laser endomicroscopy compared with standard four-quadrant biopsy for evaluation of neoplasia in Barrett's esophagus. Endoscopy 2010; 42:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/32\">",
"      Kiesslich R, Gossner L, Goetz M, et al. In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol 2006; 4:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/33\">",
"      Badreddine R, Wang K, Ganapathy A, et al. Confocal laser microscopy (CLM) guided endoscopic mucosal resection in Barrett's esophagus with high grade dysplasia. Gastrointest Endosc 2008; 67:AB179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/34\">",
"      Sharma P, Meining AR, Coron E, et al. Real-time increased detection of neoplastic tissue in Barrett's esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial. Gastrointest Endosc 2011; 74:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/35\">",
"      Jayasekera C, Taylor AC, Desmond PV, et al. Added value of narrow band imaging and confocal laser endomicroscopy in detecting Barrett's esophagus neoplasia. Endoscopy 2012; 44:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/36\">",
"      Kitabatake S, Niwa Y, Miyahara R, et al. Confocal endomicroscopy for the diagnosis of gastric cancer in vivo. Endoscopy 2006; 38:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/37\">",
"      Kakeji Y, Yamaguchi S, Yoshida D, et al. Development and assessment of morphologic criteria for diagnosing gastric cancer using confocal endomicroscopy: an ex vivo and in vivo study. Endoscopy 2006; 38:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/38\">",
"      Zhang JN, Li YQ, Zhao YA, et al. Classification of gastric pit patterns by confocal endomicroscopy. Gastrointest Endosc 2008; 67:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/39\">",
"      Li WB, Zuo XL, Li CQ, et al. Diagnostic value of confocal laser endomicroscopy for gastric superficial cancerous lesions. Gut 2011; 60:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/40\">",
"      Buchner AM, Shahid MW, Heckman MG, et al. Comparison of probe-based confocal laser endomicroscopy with virtual chromoendoscopy for classification of colon polyps. Gastroenterology 2010; 138:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/41\">",
"      Buchner AM, Ghabril MS, Krishna M. High-resolution confocal endomicroscopy probe system for in vivo diagnosis of colorectal neoplasia. Gastroenterol 2008; 135:AB295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/42\">",
"      Hurlstone DP, Baraza W, Brown S, et al. In vivo real-time confocal laser scanning endomicroscopic colonoscopy for the detection and characterization of colorectal neoplasia. Br J Surg 2008; 95:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/43\">",
"      Kuiper T, van den Broek FJ, van Eeden S, et al. New classification for probe-based confocal laser endomicroscopy in the colon. Endoscopy 2011; 43:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/44\">",
"      Li CQ, Xie XJ, Yu T, et al. Classification of inflammation activity in ulcerative colitis by confocal laser endomicroscopy. Am J Gastroenterol 2010; 105:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/45\">",
"      Kiesslich R, Goetz M, Lammersdorf K, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 2007; 132:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/46\">",
"      Hurlstone DP, Thomson M, Brown S, et al. Confocal endomicroscopy in ulcerative colitis: differentiating dysplasia-associated lesional mass and adenoma-like mass. Clin Gastroenterol Hepatol 2007; 5:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/47\">",
"      Meining A, Chen YK, Pleskow D, et al. Direct visualization of indeterminate pancreaticobiliary strictures with probe-based confocal laser endomicroscopy: a multicenter experience. Gastrointest Endosc 2011; 74:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/48\">",
"      Dunbar KB, Kiesslich R, Deiner K, et al. Confocal Laser Endomicroscopy Image Interpretation: Interobserver Agreement Among Gastroenterologists and Pathologists. Gastrointest Endosc 2007; 65:AB348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/49\">",
"      Kuiper T, Kiesslich R, Ponsioen C, et al. The learning curve, accuracy, and interobserver agreement of endoscope-based confocal laser endomicroscopy for the differentiation of colorectal lesions. Gastrointest Endosc 2012; 75:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/50\">",
"      Dunbar KB, Montgomer EA, Canto MI. The Learning Curve of In Vivo Confocal Laser Endomicroscopy for Prediction. Gastroenterol 2008; 134:A62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/51\">",
"      Kiesslich R, Anagnostopoulos G, Axon A, et al. Interobserver Variation and Standardized Training for Confocal Laser Endomicroscopy Image Interpretation in the Upper and Lower GI Tract. Gastrointest Endosc 2007; 65:AB354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/52\">",
"      Kimura S, Inoue H, Sato Y, et al. Ex vivo visualization of Helicobacter pylori using an endocytoscopic probe. Biomed Res 2006; 27:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/53\">",
"      Yan BM, Van Dam J. In vivo real-time endocytoscopic visualization of blood flow in rectal microvasculature. Endoscopy 2008; 40:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/54\">",
"      Pohl H, Koch M, Khalifa A, et al. Evaluation of endocytoscopy in the surveillance of patients with Barrett's esophagus. Endoscopy 2007; 39:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/55\">",
"      Wallace MB, Meining A, Canto MI, et al. The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract. Aliment Pharmacol Ther 2010; 31:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/56\">",
"      Olliver JR, Wild CP, Sahay P, et al. Chromoendoscopy with methylene blue and associated DNA damage in Barrett's oesophagus. Lancet 2003; 362:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3113/abstract/57\">",
"      Burleson GR, Caulfield MJ, Pollard M. Ozonation of mutagenic and carcinogenic polyaromatic amines and polyaromatic hydrocarbons in water. Cancer Res 1979; 39:2149.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13923 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-FB51BAF4EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3113=[""].join("\n");
var outline_f3_2_3113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H455771730\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455771632\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455771639\">",
"      TECHNICAL OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H455771646\">",
"      Confocal laser endomicroscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H455771653\">",
"      - Confocal laser endomicroscope",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H455771660\">",
"      - Confocal miniprobe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H455771667\">",
"      Endocytoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17143174\">",
"      Maximizing image quality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17143214\">",
"      - Staining",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17143221\">",
"      - Device placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17143314\">",
"      - Stabilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4168398\">",
"      Obtaining biopsies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455771674\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17697294\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455771695\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1911573\">",
"      Efficacy of confocal laser endomicroscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1911984\">",
"      - Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1912081\">",
"      - Gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1912232\">",
"      - Colon polyps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1912275\">",
"      - Ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H455771716\">",
"      - Bile duct strictures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2154988\">",
"      - Interobserver reliability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1911384\">",
"      Efficacy of endocytoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1911391\">",
"      - Squamous esophagus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1911398\">",
"      - Stomach and columnar esophagus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1911405\">",
"      - Colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4168208\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455771730\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/13923\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13923|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/45/20177\" title=\"diagnostic image 1\">",
"      Endomicroscopic image of neoplasia in Barretts esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13923|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/39/41584\" title=\"picture 1\">",
"      Endocytoscopic image of esophageal squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13923|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/47/35579\" title=\"table 1\">",
"      Specifications for confocal miniprobes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43049?source=related_link\">",
"      Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13750?source=related_link\">",
"      Autofluorescence endoscopy for Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=related_link\">",
"      Cholangioscopy and pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=related_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19816?source=related_link\">",
"      Endoscopic methods for the diagnosis of pancreatobiliary neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=related_link\">",
"      Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=related_link\">",
"      Fluorescein: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=related_link\">",
"      Magnification endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=related_link\">",
"      Narrow band imaging in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/41/7831?source=related_link\">",
"      Optical coherence tomography in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18166?source=related_link\">",
"      Percutaneous transhepatic cholangioscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_2_3114="Virology of Epstein-Barr virus";
var content_f3_2_3114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Virology of Epstein-Barr virus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/2/3114/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/2/3114/contributors\">",
"     John L Sullivan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/2/3114/contributors\">",
"     Katherine Luzuriaga, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/2/3114/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/2/3114/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/2/3114/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/2/3114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/2/3114/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/2/3114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epstein-Barr virus (EBV) is a widely disseminated herpesvirus, which is spread by intimate contact between susceptible persons and asymptomatic EBV shedders. The majority of primary EBV infections throughout the world are subclinical and unapparent. Antibodies to EBV have been demonstrated in all population groups with a worldwide distribution; approximately 90 to 95 percent of adults are EBV-seropositive.",
"   </p>",
"   <p>",
"    Like other members of the herpesvirus family, EBV has a latency phase. The host cells for the organism in humans are B lymphocytes, T lymphocytes, epithelial cells and myocytes. Unlike herpes simplex (HSV) or cytomegalovirus (CMV), EBV is capable of transforming B cells and does not routinely display a cytopathic effect in cell culture.",
"   </p>",
"   <p>",
"    EBV is the primary agent of infectious mononucleosis, persists asymptomatically for life in most adults, and is associated with the development of B cell lymphomas, T cell lymphomas, Hodgkin lymphoma and nasopharyngeal carcinomas in certain patients. Reactivation disease is not a prominent issue with EBV, in contrast to other prominent herpesviruses, but it has been associated with an aggressive lymphoproliferative disorder in transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The virology and biology of EBV will be reviewed here. The epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of EBV infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBV is a member of the gamma herpesvirus family and is the prototype for the lymphocryptovirus genus. In vitro, all gamma herpesviruses replicate in lymphoid cells and some are capable of lytic replication in epithelial cells and fibroblasts. Infection of primate B lymphocytes typically results in latent infection. This is characterized by persistence of the viral genome along with expression of a restricted set of latent gene products, which contribute to the transformation process and help drive cell proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Composition of virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membership in the Herpesviridae family is based upon virion architecture. EBV consists of a toroid-shaped protein core wrapped with linear double-stranded DNA, an icosahedral nucleocapsid containing 162 capsomeres, an amorphous protein tegument surrounding the capsid, and an outer envelope containing glycoprotein spikes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to HSV-1, the major EBV capsid proteins range in size from 28 to 160 KDa [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/3\">",
"     3",
"    </a>",
"    ]. However, unlike most other herpesviruses, the outer viral envelope of EBV contains only a single predominant glycoprotein known as",
"    <span class=\"nowrap\">",
"     gp350/220",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type and strain variations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of EBV, referred to as EBV-1 and EBV-2 (formerly EBV-A and EBV-B), have been identified in most human populations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. This nomenclature parallels the terminology for HSV-1 and HSV-2. However, in contrast to the latter viruses, there is extensive homology and restriction endonuclease site conservation throughout most of the EBV-1 and EBV-2 genomes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/9\">",
"     9",
"    </a>",
"    ]. The major identified differences between the EBV-1 and EBV-2 genomes exist in the latent infection cycle nuclear antigen genes EBNA-2, EBNA-LP [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/9\">",
"     9",
"    </a>",
"    ], EBNA-3A, -3B, and -3C [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/10\">",
"     10",
"    </a>",
"    ] and in the small, nonpolyadenylated RNAs EBERs 1 and 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differences between EBV-1 and EBV-2 EBNA genes are reflected in type-specific and type-common EBNA epitopes. Similarly, the immune recognition of EBV transformed B lymphoblastoid cells by EBV-specific cytotoxic lymphocytes is dependent upon the infecting EBV strain [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seroepidemiologic studies of reactivity to EBNA-2 have been used to determine the prevalence and geographic distribution of the two EBV strains. In the United States and Europe, the EBV genomes are 10 times more likely to be EBV-1 than EBV-2; in contrast the two genomes are equally distributed in Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/14\">",
"     14",
"    </a>",
"    ]. Similar serologic findings extend to the EBNA-3A, -3B, and -3C genes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/10\">",
"     10",
"    </a>",
"    ]. Sera from patients infected with EBV-1 preferentially react with type 1 EBNA-3A, -3B, and -3C, whereas sera from individuals infected with EBV-2 preferentially react with type-2 EBNA-3 gene products.",
"   </p>",
"   <p>",
"    With respect to homology, the various EBNA gene products share between 50 to 85 percent primary amino acid sequence identity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/15\">",
"     15",
"    </a>",
"    ]. Limited genomic divergence between various EBV-1 isolates has also been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genome structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EBV genome consists of a linear, 172-kilobase-pair, double-stranded DNA molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/17\">",
"     17",
"    </a>",
"    ], and was completely sequenced in the early 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/18\">",
"     18",
"    </a>",
"    ]. Genetic studies have been particularly important in determining the biology of this virus (see below). The characteristic features of the EBV genome include a single overall format and gene arrangement and variable tandem repeats. These DNA repeat elements are important landmarks on the EBV genome, which allow the EBV strains to be distinguished [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although EBV DNA is linear in the virus particle, the terminal repeats mediate circularization in infected cells; each infected cell contains 1 to 20 copies of the EBV episomes in the nucleus. The characteristic DNA repeat elements serve as important landmarks on the EBV genome, which allow one to distinguish between EBV strains. While various EBV isolates differ in their tandem repeat frequency, individual EBV isolates tend to contain a constant number of repeats even through serial passage. This is exemplified each time EBV establishes latent infection where the virus persists as an episome containing a set number of tandem terminal repeats. This principle is extremely useful in determining whether or not latently infected cells, such as Burkitt's lymphoma, arise from a single progenitor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is general conservation of the genetic organization between herpesvirus saimiri, a primate gamma herpesvirus, and Epstein-Barr virus; however, there are unique EBV DNA segments which function in latent B cell infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/14\">",
"     14",
"    </a>",
"    ]. Antigenic cross-reactivity between EBV and other herpesviruses is rare, even among the proteins encoded by the more conserved genes. The EBV genes expressed in latent infection, as well as certain lytic cycle genes, have no detectable homology to other herpesvirus genes and may have arisen in part from cellular DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of EBV lytic cycle genes with significant homology to the human genome, but little homology to other herpesviruses, including BHRF1 and BCRF1 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. BHRF1 is an EBV early gene with significant homology to the human B cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    2 (bcl-2) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/21\">",
"     21",
"    </a>",
"    ], thought to be involved in preventing B cells and other cells from undergoing apoptosis. BCRF1 is an EBV late gene with nearly identical primary amino acid sequence homology and biological activity to human IL-10 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the function of EBV has been determined from genetic studies of the virus. Various components of EBV and the cells that the virus infects contribute to the pathogenesis of infection including the virus receptor, penetration and uncoating, virus expression in latent infection, and cell transformation with the production of latent proteins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Virus receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The host range of Epstein-Barr virus is restricted to humans and certain sub-human primates including squirrel monkeys and cotton top marmosets [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/23\">",
"     23",
"    </a>",
"    ]. &nbsp;Related oncogenic herpesviruses have been detected in Old-World primate species and more recently in New-World primates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/24\">",
"     24",
"    </a>",
"    ]. The EBV receptor on human cells is the B cell surface molecule CD21, which is the receptor for the C3d component of complement (also called CR2, complement receptor type 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/25\">",
"     25",
"    </a>",
"    ]. The following observations have confirmed this association:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Purified CD21 binds to EBV [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Virus infection is blocked by anti-CD21 antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Expression of CD21 on heterologous cells also allows these cells to bind EBV [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/28\">",
"       28",
"      </a>",
"      ]. Currently, gp350 is believed to bind exclusively to the CD21 molecule.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infection is initiated by the interaction of the major EBV outer envelope glycoprotein",
"    <span class=\"nowrap\">",
"     gp350/220",
"    </span>",
"    with CD21 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/29\">",
"     29",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     gp350/220",
"    </span>",
"    is believed to bind exclusively to the CD21 molecule. Comparison of the primary amino acid sequences of",
"    <span class=\"nowrap\">",
"     gp350/220",
"    </span>",
"    and C3d has revealed a shared nonapeptide, which probably explains their common binding properties with CD21 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of primary EBV infections in humans are thought to originate in the oropharynx. Oropharyngeal epithelial cells, unlike B lymphocytes, are permissive for viral replication [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. EBV binds much less efficiently to epithelial cells than B cells. Although most anti-CD21 antibodies do not bind to epithelial cells, small amounts of CD21 mRNA indistinguishable in size from that expressed in B cells have been identified by northern blot hybridization in these cells. Cloning and sequencing of epithelial cell derived RNA has shown it to be identical to B cell derived CD21 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CD21 or related structures are also present on cells of the T lineage [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/34\">",
"     34",
"    </a>",
"    ]. As an example, both thymocytes and peripheral T cells express CD21 or CD21-like molecules; however, their reactivity with anti-CD21 antibodies differs from that of B cells, suggesting there may be structural differences between T cell and B cell CD21 molecules.",
"   </p>",
"   <p>",
"    EBV has also been demonstrated to enter and replicate within monocytes in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/35\">",
"     35",
"    </a>",
"    ]. Once infected, these monocytes displayed decreased phagocytic activity. These cells may serve as another potential early site for viral replication and for a blunted immune response to the virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adsorption, penetration, and uncoating",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, virus binding to CD21 and the initial phase of penetration are mediated through the major viral coat glycoprotein",
"    <span class=\"nowrap\">",
"     gp350/220",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/29,36\">",
"     29,36",
"    </a>",
"    ]. Virus adsorption on the surface of B cell results in capping of CD21, followed by endocytosis of EBV into smooth membrane vesicles [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/37\">",
"     37",
"    </a>",
"    ]. A second EBV envelope glycoprotein (gp85) then mediates fusion of the virus with the vesicle membrane, causing release of the nucleocapsid into the B cell cytoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/38\">",
"     38",
"    </a>",
"    ]. Depletion of this protein abolishes fusion with EBV receptor-bearing cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/39\">",
"     39",
"    </a>",
"    ]. A third membrane glycoprotein, gp42, also appears to be essential for penetration of B cells by binding to HLA class II on the cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dissolution of the viral nucleocapsid and transport of the genome to the B cell nucleus are less well understood. Once inside the nucleus, the linear EBV genome circularizes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. This event precedes or at least coincides with the earliest gene expression [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/43\">",
"     43",
"    </a>",
"    ], directed by Wp, an important viral promoter. Wp has been shown to be 11- to 190-fold more active in B cells than other cells and to contain three regions which act as transcriptional binding sites; one of these regions appears to be most active in B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While EBV can also infect epithelial cells in vitro and in vivo, the precise role of the epithelium in EBV replication and persistence has been somewhat controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/45\">",
"     45",
"    </a>",
"    ]. Current evidence suggests that the epithelium surrounding Waldeyer&rsquo;s ring provides a source of infectious virus in the saliva following lytic infection with EBV [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/46\">",
"     46",
"    </a>",
"    ]. B cell-epithelial cell interactions may facilitate the infection of epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/47\">",
"     47",
"    </a>",
"    ], but the receptor used by EBV to initiate attachment to epithelial cells remains unknown. &nbsp;Currently available data suggest that EBV may use different CD21-independent mechanisms to enter epithelial cells, depending on the membrane domain [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/48\">",
"     48",
"    </a>",
"    ]. Fusion of the EBV envelope with the cell membrane appears to be mediated by an interaction between gH-gL and an unidentified cell surface receptor on epithelial cells.",
"   </p>",
"   <p>",
"    The EBV genome is replicated by cellular DNA polymerases during the cell cycle S phase [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/49\">",
"     49",
"    </a>",
"    ]. It persists as multiple, extrachromosomal double-stranded EBV episomes, which are organized into nucleosomes similar to chromosomal DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Virus expression in latent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of B lymphocyte infection with EBV is the establishment of latency. The viral genes and products have been studied in detail, but the triggers for the shift from latency to lytic replication are not clearly defined.",
"   </p>",
"   <p>",
"    Latency is characterized by three distinct processes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Viral persistence",
"     </li>",
"     <li>",
"      Restricted virus expression which alters cell growth and proliferation",
"     </li>",
"     <li>",
"      Retained potential for reactivation to lytic replication",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persistent EBV infection likely results from a dynamic interplay between viral evasion strategies and host immune responses. Potent T-cell activation occurs and high levels of EBV-specific CD4+ and CD8+ responses are generated during acute EBV infection. How and why EBV persists despite these broad and vigorous immune responses is unclear, but recent studies have provided insight into potential EBV immune evasion strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EBV exploits normal pathways of B cell differentiation to allow it to persist in a transcriptionally quiescent state in memory B cells and thus minimize immune recognition [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. Two genes (LMP-1 and LMP-2) encoded by the virus allow an EBV-infected B blast to become a resting memory cell, where EBV persists in a transcriptionally quiescent state (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Transformation and latent proteins'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      EBV can infect resting naive B cells that traffic to germinal centers within lymphoid follicles; these cells escape immune surveillance by turning off production of certain viral proteins (EBNA 2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intracellular persistence of the entire viral genome is achieved through circularization of the linear EBV genome, and maintenance of multiple copies of this covalently closed episomal DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/49\">",
"     49",
"    </a>",
"    ]. The episomes are replicated semiconservatively during cell cycle S-phase by cellular DNA polymerases, and equal partitioning of episomes to daughter cells is mediated by interactions between the latent origin of plasmid replication (OriP) and EBV nuclear protein-1 (EBNA-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 172 Kbp EBV genome encodes approximately 100 genes, ten of which are expressed during latency and are thought to be involved in establishing and maintaining the \"immortalized\" state. Included in this group are six nuclear proteins (EBNAs 1, 2, 3A, 3B, 3C, and LP), two latent membrane proteins (LMP-1 and 2), and two EBERS = EBV encoded RNA's (EBERs 1, 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Latency can be disrupted by a variety of cellular activators, resulting in the expression of BZLF1 (Z), which induces the switch from viral latency to lytic replication [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. During lytic replication, the virus reproduces with associated destruction of the host cell. A mutation in Z results in inhibition of the ability to induce lytic replication, but addition of a second factor BRLF1 (R) partially restores this activity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although only about 10 percent of the genes encoded by EBV are expressed in latently infected B cells, the transcribed regions encompass a major portion of the viral genome. The most abundantly transcribed EBV genes in latently infected cells are the EBERs (107",
"    <span class=\"nowrap\">",
"     copies/cell),",
"    </span>",
"    distantly followed by LMP-1, which is significantly more abundant than the EBNAs and LMP-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EBNA-LP and EBNA-2 are the first EBV proteins expressed during latent infection of B cells, reaching their steady state levels within 24 to 32 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/43\">",
"     43",
"    </a>",
"    ]. EBNA-2 is essential to the immortalization process since viruses with deletions encompassing EBNA 2 are immortalization incompetent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Infection of primary B cells with such EBNA-2 mutants results in failure of expression of EBNA-2 and of genes that have not been deleted such as EBNA-1 and EBNA-3 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/64\">",
"     64",
"    </a>",
"    ]; there is also less or no transactivation of LMP-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/65\">",
"     65",
"    </a>",
"    ]. Restoration of the deleted DNA in defective EBV produces progeny virus with the ability to transform primary human B lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EBNA-2 is also required for expression of other EBV latent genes, for the transactivation of both EBV genes and cellular genes (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Transformation and latent proteins'",
"    </a>",
"    below), and probably for promoter switching during the initial stages of latent B cell infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/68\">",
"     68",
"    </a>",
"    ]. By 32 hours after infection, all of the EBNA proteins and LMP-1 can be detected using appropriate antisera [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/43\">",
"     43",
"    </a>",
"    ]. Concomitant with LMP-1 expression is a further increase in the level of CD23 and the onset of cell DNA synthesis. Expression of the EBNA proteins reaches a steady state level within 48 hours of primary B cell infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike the other EBV genes expressed during latent infection, the EBERs (the most abundantly expressed EBV RNAs in latently infected cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/59\">",
"     59",
"    </a>",
"    ]) are also transcribed during lytic infection. The majority of EBERs are localized within the cell nucleus but their functions remain unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/71\">",
"     71",
"    </a>",
"    ]. EBV recombinants carrying EBER mutations do not affect in vitro replication and transformation of B-lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Transformation and latent proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the proteins described above are involved in cellular transformation including the EBNAs (1, 2, and 3) and the LMPs (1 and 2).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     EBNA-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBNA-1 is required for episome replication and maintenance of the viral genome once the cell has been immortalized [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/73\">",
"     73",
"    </a>",
"    ]. It is diffusely associated with all chromosomes in latently infected cell nuclei, and the combined interaction of EBNA-1 with both OriP and chromosomal proteins assures equal partitioning of EBV episomes to progeny cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/74\">",
"     74",
"    </a>",
"    ]. EBV-infected",
"    <strong>",
"     resting",
"    </strong>",
"    (ie, nondividing) B cells growing in vivo express only EBNA-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/75\">",
"     75",
"    </a>",
"    ], which is required for episome maintenance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     EBNA-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, EBNA-2 mutants have demonstrated that EBNA-2 is essential to the process of B lymphocyte immortalization [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/61-63\">",
"     61-63",
"    </a>",
"    ] and for the expression of EBNA-1 and EBNA-3 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/64\">",
"     64",
"    </a>",
"    ]. Variations in the EBNA-2 protein impart the most significant biologic difference between the two major EBV types, EBV-1 and EBV-2. In general, EBV-1 transforms normal human B lymphocytes much more efficiently than EBV-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/76\">",
"     76",
"    </a>",
"    ]. Confirmation of the critical role played by the type of EBNA-2 in the transformation process was made by inserting cloned type 1 EBNA-2 DNA into EBV-2; the recombinant EBV-2 displayed a highly efficient transformation phenotype identical to that of EBV-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first biochemical evidence for a role of EBNA-2 in B cell growth-transformation came from the demonstration that EBNA-2 specifically transactivates expression of the B lymphocyte activation marker CD23 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/77\">",
"     77",
"    </a>",
"    ], which is abundantly expressed on EBV-transformed and antigen-primed B lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/78\">",
"     78",
"    </a>",
"    ]. EBNA-2 also upregulates expression of the cellular genes CD21 (the EBV receptor) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/79\">",
"     79",
"    </a>",
"    ] and c-fgr [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/80\">",
"     80",
"    </a>",
"    ], and the EBV latent genes LMP-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/81,82\">",
"     81,82",
"    </a>",
"    ] and LMP-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/83\">",
"     83",
"    </a>",
"    ]. Thus, most of the effect of EBNA-2 in B lymphocyte transformation comes from its ability to transactivate cellular and EBV genes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     EBNA-3",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBNA-3 consists of a family of three high molecular weight gene products (EBNA-3A, 3B, 3C) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/7,84-87\">",
"     7,84-87",
"    </a>",
"    ]. The EBNA 3 genes are located in tandem on the EBV genome. Much like EBNA-2, the EBNA-3 genes are polymorphic and differ according to EBV type. Unlike the difference in transformation phenotype imparted by the EBNA-2 type, the type specificity of the EBNA-3 genes (types 1 or 2) does not affect the ability of the virus to initiate growth transformation, episome maintenance, or lytic replication. Systematic analysis of the transformation capability of EBV recombinants having specific mutations in each of the EBNA 3 genes demonstrated that while EBNA-3B is dispensable for B-lymphocyte growth transformation, mutations in either EBNA-3A or -3C renders the virus transformation incompetent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     EBNA-LP",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBNA-LP, or leader protein, is a set of highly polymorphic protein. Although the function of EBNA-LP remains unclear, it may play a role in RNA processing, associate with some nuclear regulatory protein [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/88\">",
"     88",
"    </a>",
"    ], or upregulate expression of autocrine factors critical to B-cell growth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     LMP-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second most abundant EBV mRNA species (the EBERs are first, see below) in latently infected B cells (60",
"    <span class=\"nowrap\">",
"     copies/cell)",
"    </span>",
"    is highly stable and encodes an integral membrane protein LMP-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. The LMP-1 promoter contains an EBNA-2 response element which upregulates LMP-1 expression [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/81\">",
"     81",
"    </a>",
"    ]. However, LMP-1 can be expressed in the absence of EBNA-2 during lytic cycle activation in BL cells, and in nasopharyngeal carcinoma (NPC) tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of LMP-1 is associated into discrete patches within the plasma membrane, which are often further assembled into a single cap-like structure, a behavior characteristic of many activated receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/94\">",
"     94",
"    </a>",
"    ]. This characteristic plasma membrane patching of LMP-1 prompted an exploration of its role in B-lymphocyte growth transformation. The following observations illustrate its role in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In vitro, LMP-1 is essential for EBV-induced transformation of B cells into immortalized lymphoblastoid cells [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/95,96\">",
"       95,96",
"      </a>",
"      ], and induces many of the activation markers associated with EBV infection of B lymphocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transfer of the LMP-1 gene into continuous rodent fibroblast lines produces multiple transforming effects [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/98\">",
"       98",
"      </a>",
"      ]. Importantly, some of these cells, which are not normally tumorigenic in nude mice, become uniformly tumorigenic when expressing LMP-1; mice expressing the transgene develop B cell lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/98,99\">",
"       98,99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Expression of LMP-1 in EBV-negative Burkitt's lymphoma lines induces many of the changes typically associated with EBV infection or antigen activation of primary B lymphocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/79,100,101\">",
"       79,100,101",
"      </a>",
"      ]. LMP-expressing cells grow in tight clumps due to increased expression of the cellular adhesion molecules LFA-1 and ICAM-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/100\">",
"       100",
"      </a>",
"      ]. LMP-1 induction of the adhesion molecules LFA-1, LFA-3 and ICAM-1 promotes an interaction between B and T lymphocytes via the",
"      <span class=\"nowrap\">",
"       LFA-3/CD2",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       LFA-1/ICAM-1",
"      </span>",
"      pathways. These heterotypic adhesions are important since the in vivo elimination of EBV-transformed B lymphocytes is dependent upon conjugate formation with cytotoxic T cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"       \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      LMP-1 protects EBV-infected B cells from programmed cell death (apoptosis), in part via induction of the cellular oncogene bcl-2 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/102,103\">",
"       102,103",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The transforming action of LMP-1 appears to involve the engagement of signaling proteins from the tumor necrosis factor receptor-associated factors (TRAF) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/104-106\">",
"     104-106",
"    </a>",
"    ]. LMP-1 mutations that eliminate the association with TRAF prevent B cell growth transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/105\">",
"     105",
"    </a>",
"    ]. A second LMP-1 site required for lymphoblastoid cell outgrowth also has been identified which interacts with the tumor necrosis factor receptor-associated death domain protein [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     LMP-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;LMP-2 is an integral membrane protein that co-localizes with LMP-1 in the plasma membrane of EBV-infected lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/108\">",
"     108",
"    </a>",
"    ]. Among the transformation-associated EBV proteins, EBNA-1, LMP-1, and LMP-2 are present most consistently in nasopharyngeal carcinomas and EBV-related malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/93,109,110\">",
"     93,109,110",
"    </a>",
"    ]. Since both LMP-1 and LMP-2 contain T cell epitopes, their persistent expression in vivo suggests an important role in the persistence of EBV in the human host [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Functionally, LMP-2 is a substrate for the B lymphocyte src family tyrosine kinases, and associates with a 70 kDa tyrosine phosphorylated cellular protein [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. In view of the prominent role of tyrosine kinases in growth factor receptor-mediated transmembrane signaling, the association of LMP-2 with a tyrosine kinase had been thought to reflect an important role in the effect of LMP-2 on cell growth.",
"   </p>",
"   <p>",
"    However, more recent studies are in conflict with this hypothesis. EBV recombinants carrying LMP-2A mutations, which do not express LMP-2A protein, are capable of initiating and maintaining B lymphocyte growth transformation in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/114\">",
"     114",
"    </a>",
"    ]. Furthermore, lymphoblastoid cell lines derived from the LMP-2A mutants are identical to wild type EBV-transformed cells with regard to growth characteristics and virus replication. Surprisingly, expression of EBNA-1, EBNA-2 and LMP-1 is unaffected by these mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     EBER-1 and EBER-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most abundant EBV RNAs in latently infected B-cells are the EBV-encoded, small, nonpolyadenylated RNAs named EBER-1 and EBER-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/59\">",
"     59",
"    </a>",
"    ]. The construction of EBV recombinants carrying EBER mutations has demonstrated that neither EBER is required for the in vitro growth transformation of B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/72\">",
"     72",
"    </a>",
"    ]. These EBER deletion mutants transform B cells into lymphoblastoid cell lines which are phenotypically identical to those induced by wild-type virus in terms of growth characteristics and ability to undergo lytic virus replication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     EBV DNA persistence in latency",
"    </span>",
"    &nbsp;&mdash;&nbsp;During convalescence, low levels of virus are thought to be maintained by sporadic replication in the epithelial cells lining the oropharynx and in 1 in 10(5) to 10(6) infected memory B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/115\">",
"     115",
"    </a>",
"    ]. Viral replication occurs in response to normal physiologic signals that drive B cell differentiation to a plasma cell [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/116\">",
"     116",
"    </a>",
"    ]. Latently infected B cells typically contain between one and ten complete EBV episomes per cell [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/41,117\">",
"     41,117",
"    </a>",
"    ] and all latently-infected cells express a minimum of the EBNA-1 protein, which is required for episome maintenance and probably for episome amplification.",
"   </p>",
"   <p>",
"    Although most EBV DNA persists in latently infected cells in an episomal form, the EBV genome also integrates into chromosomal DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. This integration is neither site specific nor a regular feature of EBV-mediated growth transformation. Furthermore, since LMP-2 is the only EBV latent gene disrupted by linearization of the genome, the integrated form of EBV still retains the potential to transform B cells into permanently growing lymphoblastoid cells. However, the integrated form of EBV DNA is limited in its ability to infect new cells, since episomal DNA is probably necessary for lytic cycle EBV replication, which has not been reported in cells containing only the integrated form of EBV.",
"   </p>",
"   <p>",
"    While lymphoblastoid B cell lines grown in vitro express a restricted set of EBV latent genes (EBNAs 1, 2, 3A, 3B, 3C and LP, LMP-1 and 2, and EBER-1 and 2). Following acute infection, EBV resides in small resting B cells, which express a minimal number of B-cell activation markers or adhesion molecules and, primarily for this reason, escape immune surveillance in the normal host. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3703?source=see_link\">",
"     \"The role of Epstein-Barr virus in Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, EBV-infected latent B cells should be considered oncogenically transformed since they will proliferate indefinitely when cultured in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/120-122\">",
"     120-122",
"    </a>",
"    ]. These cells can also give rise to lymphoproliferative disorders including lymphoma in individuals with congenital (severe combined immunodeficiency; ataxia telangiectasia) or acquired (allograft recipients and AIDS) immunodeficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/106,123,124\">",
"     106,123,124",
"    </a>",
"    ]. LMP-1-mediated signaling through the TRAF system may have a role in the pathogenesis of EBV-positive lymphomas in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated EBV loads constitute a risk factor for the development of EBV-related malignancies in patients with AIDS. Higher levels of viremia may be related to loss of immune control or as a result of aberrant cellular tropism. In a study of 54 HIV-infected children and adolescents and 88 controls, EBV DNA levels were comparable to those seen in acutely EBV-infected HIV-seronegative children [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/125\">",
"     125",
"    </a>",
"    ]. Levels of EBV DNA did not correlate with HIV RNA or CD4 cell counts. However, in the HIV-infected patients, EBV DNA was found not only in B cells, but also in CD4+ and CD8+ T-cell populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lytic infection/virus replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of latently infected B cells do not undergo lytic cycle replication, but can be induced to do so in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/126-128\">",
"     126-128",
"    </a>",
"    ]. Following induction, cells undergo cytopathic changes characteristic of lytic herpesvirus infection, including chromatin margination, viral DNA synthesis, nucleocapsid assembly at the nucleus periphery, virus budding through nuclear membrane, and inhibition of host cell protein synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/129\">",
"     129",
"    </a>",
"    ]. Spontaneous reactivation from latency into a lytic cycle within EBV infected B lymphocytes is a frequent occurrence in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/130,131\">",
"     130,131",
"    </a>",
"    ]. Viral replication in plasma cells occurs within Waldeyer&rsquo;s ring and leads to secondary lytic infection of the surrounding epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In lytic EBV infection, immediate-early genes are defined as genes that are transcribed in newly infected cells in the absence of new viral protein synthesis. The key immediate-early transactivators of EBV lytic cycle genes are the 1 kb ZLF1 mRNA and the 2.8 kb RLF1 mRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/57,132\">",
"     57,132",
"    </a>",
"    ]. Transient expression of the ZLF1 ORF transactivates two major EBV early gene promoters, HLF1 and DR [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/133\">",
"     133",
"    </a>",
"    ]. One study suggests that polymorphisms in the BZLF1 promoter may distinguish subtypes of EBV that are not associated with malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The induction of EBV lytic cycle replication results in increased episome copy number, which suggests that circular episomal DNA replication is a precursor to subsequent DNA replication [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/135\">",
"     135",
"    </a>",
"    ]. Surprisingly, EBV DNA polymerase is not required for viral DNA replication associated with episome establishment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The EBV genes expressed during the late stages of lytic infection are mostly structural viral proteins that permit virion maintenance and egress. These proteins are all late genes, which are of potential importance in antibody-mediated immunity to EBV [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two EBV glycoproteins forming important parts of the virus coat are",
"    <span class=\"nowrap\">",
"     gp350/220",
"    </span>",
"    and gp85 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/4,138,139\">",
"     4,138,139",
"    </a>",
"    ]. As noted above,",
"    <span class=\"nowrap\">",
"     gp350/220",
"    </span>",
"    is the major virus coat glycoprotein and mediates virus binding to the B lymphocyte receptor CD21 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. Gp85 is a relatively minor virus component that is functionally involved in the fusion between virus and cell membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/2/3114/abstract/39,139\">",
"     39,139",
"    </a>",
"    ]. The finding that",
"    <span class=\"nowrap\">",
"     gp350/220",
"    </span>",
"    is the most abundant viral protein in lytically infected cell membranes has led to the hypothesis that high levels of",
"    <span class=\"nowrap\">",
"     gp350/220",
"    </span>",
"    may saturate CD21 so that newly released virus can infect uninfected cells rather than being reabsorbed to lytically infected cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9046953\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epstein-Barr virus (EBV) is the etiologic agent of infectious mononucleosis. EBV persists as an asymptomatic latent infection for life in most adults, and is associated with the development of B cell lymphoma, T cell lymphoma, Hodgkin lymphoma and nasopharyngeal carcinoma. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection of primate B lymphocytes typically results in latent infection. This is characterized by persistence of the viral genome along with expression of a restricted set of latent gene products, which contribute to the transformation process and drive cellular proliferation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Virology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of primary EBV infections in humans are thought to originate in the oropharynx. Oropharyngeal epithelial cells are permissive for viral replication, unlike B lymphocytes. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Virus receptor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Viral latency is characterized by three distinct processes including viral persistence, restricted viral gene expression, and potential to reactivate to lytic replication.",
"     </li>",
"     <li>",
"      Persistent EBV infection may be the result of viral evasion strategies to host immune responses. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Virus expression in latent infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EBV-infected latent B cells are considered oncogenically transformed since they proliferate indefinitely when cultured in vitro. These cells can also give rise to lymphoproliferative disorders including lymphoma in individuals with congenital or acquired immunodeficiency. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'EBV DNA persistence in latency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kieff, E, Rickinson, AB. Epstein-Barr Virus and Its Replication. In: Fields Virology, 5th ed, Knipe, DM, Howley, PM (Ed), Lippincott Williams and Wilkins, Philadelphia 2007. pp. 2603-2654.",
"    </li>",
"    <li>",
"     Liebowitz, D, Kieff, E. Epstein-Barr virus. In: The Human Herpesviruses, Roizman, B, Whitley, R, Lopez, C (Eds), Raven Press New York 1993. p.107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/3\">",
"      Dolyniuk M, Wolff E, Kieff E. Proteins of Epstein-Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus. J Virol 1976; 18:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/4\">",
"      Dolyniuk M, Pritchett R, Kieff E. Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus. J Virol 1976; 17:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/5\">",
"      Thorley-Lawson DA, Edson CM. Polypeptides of the Epstein-Barr virus membrane antigen complex. J Virol 1979; 32:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/6\">",
"      Bornkamm GW, Delius H, Zimber U, et al. Comparison of Epstein-Barr virus strains of different origin by analysis of the viral DNAs. J Virol 1980; 35:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/7\">",
"      Sample J, Young L, Martin B, et al. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 1990; 64:4084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/8\">",
"      Zimber U, Adldinger HK, Lenoir GM, et al. Geographical prevalence of two types of Epstein-Barr virus. Virology 1986; 154:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/9\">",
"      Dambaugh T, Hennessy K, Chamnankit L, Kieff E. U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A 1984; 81:7632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/10\">",
"      Rowe M, Young LS, Cadwallader K, et al. Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol 1989; 63:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/11\">",
"      Arrand JR, Young LS, Tugwood JD. Two families of sequences in the small RNA-encoding region of Epstein-Barr virus (EBV) correlate with EBV types A and B. J Virol 1989; 63:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/12\">",
"      Moss DJ, Misko IS, Burrows SR, et al. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature 1988; 331:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/13\">",
"      Misko IS, Schmidt C, Moss DJ, et al. Cytotoxic T lymphocyte discrimination between type A Epstein-Barr virus transformants is mapped to an immunodominant epitope in EBNA 3. J Gen Virol 1991; 72 ( Pt 2):405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/14\">",
"      Nicholas J, Cameron KR, Coleman H, et al. Analysis of nucleotide sequence of the rightmost 43 kbp of herpesvirus saimiri (HVS) L-DNA: general conservation of genetic organization between HVS and Epstein-Barr virus. Virology 1992; 188:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/15\">",
"      Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986; 47:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/16\">",
"      Hatfull G, Bankier AT, Barrell BG, Farrell PJ. Sequence analysis of Raji Epstein-Barr virus DNA. Virology 1988; 164:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/17\">",
"      Pritchett RF, Hayward SD, Kieff ED. DNA of Epstein-Barr virus. I. Comparative studies of the DNA of Epstein-Barr virus from HR-1 and B95-8 cells: size, structure, and relatedness. J Virol 1975; 15:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/18\">",
"      Baer R, Bankier AT, Biggin MD, et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 1984; 310:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/19\">",
"      Heller M, Henderson A, Kieff E. Repeat array in Epstein-Barr virus DNA is related to cell DNA sequences interspersed on human chromosomes. Proc Natl Acad Sci U S A 1982; 79:5916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/20\">",
"      Heller M, Flemington E, Kieff E, Deininger P. Repeat arrays in cellular DNA related to the Epstein-Barr virus IR3 repeat. Mol Cell Biol 1985; 5:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/21\">",
"      Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986; 47:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/22\">",
"      Hsu DH, de Waal Malefyt R, Fiorentino DF, et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 1990; 250:830.",
"     </a>",
"    </li>",
"    <li>",
"     Miller, G., T. Shope, H. Lisco, D. Stitt, and M. Lipman. 1972. Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc. Natl. Acad. Sci. U S A. 69:383-387.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/24\">",
"      Cho Y, Ramer J, Rivailler P, et al. An Epstein-Barr-related herpesvirus from marmoset lymphomas. Proc Natl Acad Sci U S A 2001; 98:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/25\">",
"      Cooper NR, Moore MD, Nemerow GR. Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment. Annu Rev Immunol 1988; 6:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/26\">",
"      Nemerow GR, Siaw MF, Cooper NR. Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein. J Virol 1986; 58:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/27\">",
"      Nemerow GR, Mold C, Schwend VK, et al. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol 1987; 61:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/28\">",
"      Ahearn JM, Hayward SD, Hickey JC, Fearon DT. Epstein-Barr virus (EBV) infection of murine L cells expressing recombinant human EBV/C3d receptor. Proc Natl Acad Sci U S A 1988; 85:9307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/29\">",
"      Tanner J, Weis J, Fearon D, et al. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 1987; 50:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/30\">",
"      Lambris JD, Ganu VS, Hirani S, M&uuml;ller-Eberhard HJ. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci U S A 1985; 82:4235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/31\">",
"      Sixbey JW, Vesterinen EH, Nedrud JG, et al. Replication of Epstein-Barr virus in human epithelial cells infected in vitro. Nature 1983; 306:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/32\">",
"      Li QX, Young LS, Niedobitek G, et al. Epstein-Barr virus infection and replication in a human epithelial cell system. Nature 1992; 356:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/33\">",
"      Birkenbach M, Tong X, Bradbury LE, et al. Characterization of an Epstein-Barr virus receptor on human epithelial cells. J Exp Med 1992; 176:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/34\">",
"      Tsoukas CD, Lambris JD. Expression of EBV/C3d receptors on T cells: biological significance. Immunol Today 1993; 14:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/35\">",
"      Savard M, B&eacute;langer C, Tardif M, et al. Infection of primary human monocytes by Epstein-Barr virus. J Virol 2000; 74:2612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/36\">",
"      Wells A, Koide N, Klein G. Two large virion envelope glycoproteins mediate Epstein-Barr virus binding to receptor-positive cells. J Virol 1982; 41:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/37\">",
"      Nemerow GR, Cooper NR. Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology 1984; 132:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/38\">",
"      Miller N, Hutt-Fletcher LM. A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus. J Virol 1988; 62:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/39\">",
"      Haddad RS, Hutt-Fletcher LM. Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells. J Virol 1989; 63:4998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/40\">",
"      Wang X, Hutt-Fletcher LM. Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect. J Virol 1998; 72:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/41\">",
"      Adams A, Lindahl T. Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells. Proc Natl Acad Sci U S A 1975; 72:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/42\">",
"      Lindahl T, Adams A, Bjursell G, et al. Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line. J Mol Biol 1976; 102:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/43\">",
"      Alfieri C, Birkenbach M, Kieff E. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 1991; 181:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/44\">",
"      Bell A, Skinner J, Kirby H, Rickinson A. Characterisation of regulatory sequences at the Epstein-Barr virus BamHI W promoter. Virology 1998; 252:149.",
"     </a>",
"    </li>",
"    <li>",
"     Hutt-Fletcher, L. EBV Entry and Epithelial Infection. In: Epstein-Barr Virus, Robertson, ES (Ed), Caister Academic Press, Norfolk, England 2005. pp. 359-378.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/46\">",
"      Thorley-Lawson DA, Duca KA, Shapiro M. Epstein-Barr virus: a paradigm for persistent infection - for real and in virtual reality. Trends Immunol 2008; 29:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/47\">",
"      Shannon-Lowe CD, Neuhierl B, Baldwin G, et al. Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. Proc Natl Acad Sci U S A 2006; 103:7065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/48\">",
"      Tugizov SM, Berline JW, Palefsky JM. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med 2003; 9:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/49\">",
"      Adams A. Replication of latent Epstein-Barr virus genomes in Raji cells. J Virol 1987; 61:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/50\">",
"      Dyson PJ, Farrell PJ. Chromatin structure of Epstein-Barr virus. J Gen Virol 1985; 66 ( Pt 9):1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/51\">",
"      Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001; 1:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/52\">",
"      Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/53\">",
"      Yates J, Warren N, Reisman D, Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A 1984; 81:3806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/54\">",
"      Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/55\">",
"      Kirchmaier AL, Sugden B. Rep*: a viral element that can partially replace the origin of plasmid DNA synthesis of Epstein-Barr virus. J Virol 1998; 72:4657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/56\">",
"      Packham G, Economou A, Rooney CM, et al. Structure and function of the Epstein-Barr virus BZLF1 protein. J Virol 1990; 64:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/57\">",
"      Flemington E, Speck SH. Epstein-Barr virus BZLF1 trans activator induces the promoter of a cellular cognate gene, c-fos. J Virol 1990; 64:4549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/58\">",
"      Adamson AL, Kenney SC. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product. Virology 1998; 251:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/59\">",
"      Howe JG, Shu MD. Epstein-Barr virus small RNA (EBER) genes: unique transcription units that combine RNA polymerase II and III promoter elements. Cell 1989; 57:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/60\">",
"      Arrand JR, Rymo L. Characterization of the major Epstein-Barr virus-specific RNA in Burkitt lymphoma-derived cells. J Virol 1982; 41:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/61\">",
"      Bornkamm GW, Hudewentz J, Freese UK, Zimber U. Deletion of the nontransforming Epstein-Barr virus strain P3HR-1 causes fusion of the large internal repeat to the DSL region. J Virol 1982; 43:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/62\">",
"      Jones MD, Foster L, Sheedy T, Griffin BE. The EB virus genome in Daudi Burkitt's lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR-1) of the virus. EMBO J 1984; 3:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/63\">",
"      Miller G, Robinson J, Heston L, Lipman M. Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference. Proc Natl Acad Sci U S A 1974; 71:4006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/64\">",
"      Rooney C, Howe JG, Speck SH, Miller G. Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. J Virol 1989; 63:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/65\">",
"      Cohen JI, Wang F, Kieff E. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol 1991; 65:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/66\">",
"      Skare J, Farley J, Strominger JL, et al. Transformation by Epstein-Barr virus requires DNA sequences in the region of BamHI fragments Y and H. J Virol 1985; 55:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/67\">",
"      Cohen JI, Wang F, Mannick J, Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A 1989; 86:9558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/68\">",
"      Woisetschlaeger M, Jin XW, Yandava CN, et al. Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc Natl Acad Sci U S A 1991; 88:3942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/69\">",
"      Allday MJ, Crawford DH, Griffin BE. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J Gen Virol 1989; 70 ( Pt 7):1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/70\">",
"      Moss DJ, Rickinson AB, Wallace LE, Epstein MA. Sequential appearance of Epstein-Barr virus nuclear and lymphocyte-detected membrane antigens in B cell transformation. Nature 1981; 291:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/71\">",
"      Howe JG, Steitz JA. Localization of Epstein-Barr virus-encoded small RNAs by in situ hybridization. Proc Natl Acad Sci U S A 1986; 83:9006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/72\">",
"      Swaminathan S, Tomkinson B, Kieff E. Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proc Natl Acad Sci U S A 1991; 88:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/73\">",
"      Gahn TA, Schildkraut CL. The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication. Cell 1989; 58:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/74\">",
"      Harris A, Young BD, Griffin BE. Random association of Epstein-Barr virus genomes with host cell metaphase chromosomes in Burkitt's lymphoma-derived cell lines. J Virol 1985; 56:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/75\">",
"      Miyashita EM, Yang B, Lam KM, et al. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 1995; 80:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/76\">",
"      Rickinson AB, Young LS, Rowe M. Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol 1987; 61:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/77\">",
"      Wang F, Gregory CD, Rowe M, et al. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A 1987; 84:3452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/78\">",
"      Hurley EA, Thorley-Lawson DA. B cell activation and the establishment of Epstein-Barr virus latency. J Exp Med 1988; 168:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/79\">",
"      Wang F, Gregory C, Sample C, et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 1990; 64:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/80\">",
"      Knutson JC. The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. J Virol 1990; 64:2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/81\">",
"      Abbot SD, Rowe M, Cadwallader K, et al. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol 1990; 64:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/82\">",
"      Sj&ouml;blom A, Yang W, Palmqvist L, et al. An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter. J Virol 1998; 72:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/83\">",
"      Zimber-Strobl U, Suentzenich KO, Laux G, et al. Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J Virol 1991; 65:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/84\">",
"      Hennessy K, Fennewald S, Kieff E. A third viral nuclear protein in lymphoblasts immortalized by Epstein-Barr virus. Proc Natl Acad Sci U S A 1985; 82:5944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/85\">",
"      Hennessy K, Wang F, Bushman EW, Kieff E. Definitive identification of a member of the Epstein-Barr virus nuclear protein 3 family. Proc Natl Acad Sci U S A 1986; 83:5693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/86\">",
"      Petti L, Kieff E. A sixth Epstein-Barr virus nuclear protein (EBNA3B) is expressed in latently infected growth-transformed lymphocytes. J Virol 1988; 62:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/87\">",
"      Petti L, Sample J, Wang F, Kieff E. A fifth Epstein-Barr virus nuclear protein (EBNA3C) is expressed in latently infected growth-transformed lymphocytes. J Virol 1988; 62:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/88\">",
"      Jiang WQ, Szekely L, Wendel-Hansen V, et al. Co-localization of the retinoblastoma protein and the Epstein-Barr virus-encoded nuclear antigen EBNA-5. Exp Cell Res 1991; 197:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/89\">",
"      Mannick JB, Cohen JI, Birkenbach M, et al. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol 1991; 65:6826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/90\">",
"      Fennewald S, van Santen V, Kieff E. Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol 1984; 51:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/91\">",
"      Hennessy K, Fennewald S, Hummel M, et al. A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proc Natl Acad Sci U S A 1984; 81:7207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/92\">",
"      Contreras-Salazar B, Ehlin-Henriksson B, Klein G, Masucci MG. Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection. J Virol 1990; 64:5441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/93\">",
"      Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992; 66:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/94\">",
"      Schechter Y, Hernaez L, Schlessinger J, Cuatrecasas P. Local aggregation of hormone-receptor complexes is required for activation by epidermal growth factor. Nature 1979; 278:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/95\">",
"      Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A 1993; 90:9150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/96\">",
"      Kaye KM, Izumi KM, Mosialos G, Kieff E. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol 1995; 69:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/97\">",
"      Rowe M, Peng-Pilon M, Huen DS, et al. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers. J Virol 1994; 68:5602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/98\">",
"      Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985; 43:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/99\">",
"      Kulwichit W, Edwards RH, Davenport EM, et al. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci U S A 1998; 95:11963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/100\">",
"      Wang D, Liebowitz D, Wang F, et al. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 1988; 62:4173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/101\">",
"      Liebowitz D, Mannick J, Takada K, Kieff E. Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells. J Virol 1992; 66:4612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/102\">",
"      Gregory CD, Dive C, Henderson S, et al. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 1991; 349:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/103\">",
"      Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991; 65:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/104\">",
"      Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/105\">",
"      Izumi KM, Kaye KM, Kieff ED. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci U S A 1997; 94:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/106\">",
"      Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998; 338:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/107\">",
"      Izumi KM, Kieff ED. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci U S A 1997; 94:12592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/108\">",
"      Longnecker R, Kieff E. A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol 1990; 64:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/109\">",
"      Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989; 321:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/110\">",
"      Busson P, McCoy R, Sadler R, et al. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol 1992; 66:3257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/111\">",
"      Murray RJ, Kurilla MG, Brooks JM, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992; 176:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/112\">",
"      Longnecker R, Druker B, Roberts TM, Kieff E. An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J Virol 1991; 65:3681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/113\">",
"      Burkhardt AL, Bolen JB, Kieff E, Longnecker R. An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases. J Virol 1992; 66:5161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/114\">",
"      Longnecker R, Miller CL, Miao XQ, et al. The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential. J Virol 1992; 66:6461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/115\">",
"      Tosato G, Blaese RM. Epstein-Barr virus infection and immunoregulation in man. Adv Immunol 1985; 37:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/116\">",
"      Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 2005; 79:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/117\">",
"      Heller M, Dambaugh T, Kieff E. Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells. J Virol 1981; 38:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/118\">",
"      Matsuo T, Heller M, Petti L, et al. Persistence of the entire Epstein-Barr virus genome integrated into human lymphocyte DNA. Science 1984; 226:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/119\">",
"      Hurley EA, Agger S, McNeil JA, et al. When Epstein-Barr virus persistently infects B-cell lines, it frequently integrates. J Virol 1991; 65:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/120\">",
"      Henle W, Diehl V, Kohn G, et al. Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 1967; 157:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/121\">",
"      Pope JH, Horne MK, Scott W. Identification of the filtrable leukocyte-transforming factor of QIMR-WIL cells as herpes-like virus. Int J Cancer 1969; 4:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/122\">",
"      Miller G, Enders JF, Lisco H, Kohn HI. Establishment of lines from normal human blood leukocytes by co-cultivation with a leukocyte line derived from a leukemic child. Proc Soc Exp Biol Med 1969; 132:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/123\">",
"      Randhawa PS, Jaffe R, Demetris AJ, et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med 1992; 327:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/124\">",
"      Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 1991; 70:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/125\">",
"      Bekker V, Scherpbier H, Beld M, et al. Epstein-Barr virus infects B and non-B lymphocytes in HIV-1-infected children and adolescents. J Infect Dis 2006; 194:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/126\">",
"      Luka J, Kallin B, Klein G. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 1979; 94:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/127\">",
"      Takada K, Ono Y. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol 1989; 63:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/128\">",
"      Sinclair AJ, Brimmell M, Shanahan F, Farrell PJ. Pathways of activation of the Epstein-Barr virus productive cycle. J Virol 1991; 65:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/129\">",
"      Takagi S, Takada K, Sairenji T. Formation of intranuclear replication compartments of Epstein-Barr virus with redistribution of BZLF1 and BMRF1 gene products. Virology 1991; 185:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/130\">",
"      Tan LC, Gudgeon N, Annels NE, et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 1999; 162:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/131\">",
"      Prang NS, Hornef MW, J&auml;ger M, et al. Lytic replication of Epstein-Barr virus in the peripheral blood: analysis of viral gene expression in B lymphocytes during infectious mononucleosis and in the normal carrier state. Blood 1997; 89:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/132\">",
"      Jenson HB, Miller G. Polymorphisms of the region of the Epstein-Barr virus genome which disrupts latency. Virology 1988; 165:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/133\">",
"      Takada K, Shimizu N, Sakuma S, Ono Y. trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol 1986; 57:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/134\">",
"      Guti&eacute;rrez MI, Ibrahim MM, Dale JK, et al. Discrete alterations in the BZLF1 promoter in tumor and non-tumor-associated Epstein-Barr virus. J Natl Cancer Inst 2002; 94:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/135\">",
"      Shaw JE. The circular intracellular form of Epstein-Barr virus DNA is amplified by the virus-associated DNA polymerase. J Virol 1985; 53:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/136\">",
"      Sixbey JW, Pagano JS. Epstein-Barr virus transformation of human B lymphocytes despite inhibition of viral polymerase. J Virol 1985; 53:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/137\">",
"      Gong M, Kieff E. Intracellular trafficking of two major Epstein-Barr virus glycoproteins, gp350/220 and gp110. J Virol 1990; 64:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/138\">",
"      Beisel C, Tanner J, Matsuo T, et al. Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene. J Virol 1985; 54:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/2/3114/abstract/139\">",
"      Heineman T, Gong M, Sample J, Kieff E. Identification of the Epstein-Barr virus gp85 gene. J Virol 1988; 62:1101.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8276 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-5DB5CB92DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3114=[""].join("\n");
var outline_f3_2_3114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9046953\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Composition of virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type and strain variations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genome structure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Virus receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adsorption, penetration, and uncoating",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Virus expression in latent infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Transformation and latent proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - EBNA-1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - EBNA-2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - EBNA-3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - EBNA-LP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - LMP-1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - LMP-2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - EBER-1 and EBER-2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EBV DNA persistence in latency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lytic infection/virus replication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9046953\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3703?source=related_link\">",
"      The role of Epstein-Barr virus in Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_2_3115="Classification proximal fifth metatarsal fracture";
var content_f3_2_3115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of proximal fifth metatarsal fractures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Tuberosity avulsion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute diaphyseal fracture (\"Jones fracture\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Stress fracture of the diaphysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Torg type 1 (early)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Torg type 2 (delayed union)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Torg type 3 (nonunion)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Quill GE Jr. Fractures of the proximal fifth metatarsal. Orthop Clin North Am 1995; 26:353.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3115=[""].join("\n");
var outline_f3_2_3115=null;
var title_f3_2_3116="Graded prognostic assessment brain metastases from lung cancer";
var content_f3_2_3116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Graded prognostic assessment for brain metastases from lung cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Prognostic factor",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Scoring criteria",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Patient score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        0",
"       </td>",
"       <td class=\"subtitle3\">",
"        0.5",
"       </td>",
"       <td class=\"subtitle3\">",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age in years",
"       </td>",
"       <td>",
"        &gt;60",
"       </td>",
"       <td>",
"        50-60",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Karnofsky performance score",
"       </td>",
"       <td>",
"        &lt;70",
"       </td>",
"       <td>",
"        70-80",
"       </td>",
"       <td>",
"        90-100",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extracranial metastases",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        &mdash;",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Number of brain metastases",
"       </td>",
"       <td>",
"        &gt;3",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td align=\"right\" colspan=\"4\">",
"        <strong>",
"         Total:",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Median survival (months) by score: 0-1.0 = 3.0; 1.5-2.0 = 5.5; 2.5-3.0 = 9.4; 3.5-4.0 = 14.8.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30:419. Reprinted with permission. Copyright &copy; 2012 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3116=[""].join("\n");
var outline_f3_2_3116=null;
var title_f3_2_3117="Methods to assess cardiovascular disability";
var content_f3_2_3117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of three methods of assessing cardiovascular disability",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        New York Heart Association functional classification",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Canadian Cardiovascular Society functional classification",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific activity scale",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"centered\">",
"        I",
"       </td>",
"       <td>",
"        Patients with cardiac disease but without resulting limitations of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.",
"       </td>",
"       <td>",
"        Ordinary physical activity, such as walking and climbing stairs, does not cause angina. Angina with strenuous or rapid prolonged exertion at work or recreation.",
"       </td>",
"       <td>",
"        Patients can perform to completion any activity requiring &ge;7 metabolic equivalents, eg, can carry 24 lb up eight steps; do outdoor work (shovel snow, spade soil); do recreational activities (skiing, basketball, squash, handball, jog/walk 5 mph).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"centered\">",
"        II",
"       </td>",
"       <td>",
"        Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.",
"       </td>",
"       <td>",
"        Slight limitation of ordinary activity. Walking or climbing stairs rapidly, walking uphill, walking or stair climbing after meals, in cold, in wind, or when under emotional stress, or only during the few hours after awakening. Walking more than two blocks on the level and climbing more than one flight of ordinary stairs at a normal pace and in normal conditions.",
"       </td>",
"       <td>",
"        Patients can perform to completion any activity requiring &le;5 metabolic equivalents, eg, have sexual intercourse without stopping, garden, rake, weed, roller skate, dance fox trot, walk at 4 mph on level ground, but cannot and do not perform to completion activities requiring &ge;7 metabolic equivalents.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"centered\">",
"        III",
"       </td>",
"       <td>",
"        Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain.",
"       </td>",
"       <td>",
"        Marked limitation of ordinary physical activity. Walking one to two blocks on the level and climbing one flight in normal conditions.",
"       </td>",
"       <td>",
"        Patients can perform to completion any activity requiring &le;2 metabolic equivalents, eg, shower without stopping, strip and make bed, clean windows, walk 2.5 mph, bowl, play golf, dress without stopping, but cannot and do not perform to completion any activities requiring &gt;5 metabolic equivalents.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        IV",
"       </td>",
"       <td>",
"        Patient with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.",
"       </td>",
"       <td>",
"        Inability to carry on any physical activity without discomfort - anginal syndrome may be present at rest.",
"       </td>",
"       <td>",
"        Patients cannot or do not perform to completion activities requiring &gt;2 metabolic equivalents. Cannot carry out activities listed above (Specific activity scale III).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed, Little, Brown &amp; Co, Boston, 1994. p.253.",
"       </li>",
"       <li>",
"        Lucien C. Grading of angina pectoris. Circulation 1976 54:5223.",
"       </li>",
"       <li>",
"        Goldman L, Hashimoto B, et al. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: Advantages of a new specific activity scale. Circulation 1981; 64:1227.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3117=[""].join("\n");
var outline_f3_2_3117=null;
var title_f3_2_3118="Newborn procedure analgesia";
var content_f3_2_3118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Analgesia for specific neonatal procedures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Procedures",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stepwise interventions*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tracheal aspiration&bull;",
"       </td>",
"       <td>",
"        Step 1, consider Step 4 or lidocaine via the endotracheal tube",
"       </td>",
"       <td>",
"        Perform rapidly, limit catheter insertion to the endotracheal tube only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heelstick&bull;",
"       </td>",
"       <td>",
"        Step 1 &amp; use mechanical lance",
"       </td>",
"       <td>",
"        Venipuncture is more efficient, less painful; Steps 2, 3, &amp; heel warming are ineffective",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adhesive removal",
"       </td>",
"       <td>",
"        Use solvent swab, consider Step 1 or 4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric tube insertion&bull;",
"       </td>",
"       <td>",
"        Step 1, consider Step 2",
"       </td>",
"       <td>",
"        Perform rapidly, use lubricant, avoid injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Venipuncture&bull;",
"       </td>",
"       <td>",
"        Steps 1 &amp; 2",
"       </td>",
"       <td>",
"        Requires less time &amp; less resampling than heelstick",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arterial puncture&bull;",
"       </td>",
"       <td>",
"        Steps 1 &amp; 2, consider Step 5",
"       </td>",
"       <td>",
"        More painful than venipuncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravenous cannulation&bull;",
"       </td>",
"       <td>",
"        Steps 1 &amp; 2",
"       </td>",
"       <td>",
"        Data only available for topical tetracaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest physiotherapy",
"       </td>",
"       <td>",
"        Gentle positioning, consider Step 4",
"       </td>",
"       <td>",
"        Avoid areas of injured or inflamed skin, drains or catheters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Removal of intravenous catheter",
"       </td>",
"       <td>",
"        Solvent swab, consider Step 1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wound treatment&bull;",
"       </td>",
"       <td>",
"        Step 1, consider Steps 2,4 5, or 6 depending upon the extent of the wound",
"       </td>",
"       <td>",
"        See also \"dressing change\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tracheal intubation",
"       </td>",
"       <td>",
"        Step 4 or 6, use muscle relaxant only if experienced clinician, consider atropine",
"       </td>",
"       <td>",
"        Superiority of a specific drug regimen over the others has not been investigated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central line placement",
"       </td>",
"       <td>",
"        Steps 1, 2, 5, consider Step 4 or 6",
"       </td>",
"       <td>",
"        Some centers prefer using general anesthesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Finger stick&bull;",
"       </td>",
"       <td>",
"        Step 1 &amp; use mechanical lance",
"       </td>",
"       <td>",
"        Venipuncture is more efficient, less painful; Steps 2 &amp; 3 are ineffective",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Umbilical catheterization",
"       </td>",
"       <td>",
"        Step 1, avoid sutures on skin",
"       </td>",
"       <td>",
"        Cord tissue is not innervated, avoid injury to skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bladder compression&bull;",
"       </td>",
"       <td>",
"        Consider Steps 1, 4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tracheal extubation",
"       </td>",
"       <td>",
"        Use solvent swab, consider Step 1",
"       </td>",
"       <td>",
"        Step 1 may be used after the procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subcutaneous injection&bull;",
"       </td>",
"       <td>",
"        Avoid if possible, Steps 1 &amp; 2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intramuscular injection&bull;",
"       </td>",
"       <td>",
"        Avoid if possible, Steps 1 &amp; 2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dressing change",
"       </td>",
"       <td>",
"        Step 1, consider Steps 4 or 6 (if extensive)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lumbar puncture",
"       </td>",
"       <td>",
"        Steps 1, 2, 5, careful positioning",
"       </td>",
"       <td>",
"        Consider Step 4 if patient is intubated/ventilated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral arterial line&bull;",
"       </td>",
"       <td>",
"        Steps 1 &amp; 2, consider Steps 5, 4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Circumcision",
"       </td>",
"       <td>",
"        Steps 1, 2, 5, consider Step 3 post-procedure",
"       </td>",
"       <td>",
"        Step 5: Distal, ring, or dorsal penile nerve blocks; liposomal lidocaine is more effective than DPNB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suprapubic bladder aspiration",
"       </td>",
"       <td>",
"        Steps 1 &amp; 2, consider Steps 4 or 5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Areterial or venous cutdown",
"       </td>",
"       <td>",
"        Steps 1, 2, 4, 5, consider Step 6",
"       </td>",
"       <td>",
"        Avoid if possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral insertion of central catheter (PICC line placement)",
"       </td>",
"       <td>",
"        Steps 1 &amp; 2, consider Steps 4 &amp; 5",
"       </td>",
"       <td>",
"        Some centers prefer using general anesthesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        * Stepwise interventions with increasing analgesia as the degree of anticipated procedural pain increases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        <strong>",
"         Step 1:",
"        </strong>",
"        Nonpharmacologic measures: pacifier, oral sucrose, swaddling, kangaroo care (skin-to-skin contact with the mother), sensorial saturation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        <strong>",
"         Step 2:",
"        </strong>",
"        Topical anesthetics (topical lidocaine, lidocaine-prilocaine cream, amethocaine gel, tetracaine gel)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        <strong>",
"         Step 3:",
"        </strong>",
"        Acetaminophen: orally (10-15 mg/kg per dose every 6 to 8 hours) or rectally (20-25 mg/kg per dose every 6 to 8 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        <strong>",
"         Step 4:",
"        </strong>",
"        Opioids: slow intravenous infusion of fentanyl (1-2 mcg/kg per hour) or morphine (10-30 mcg/kg per hour)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        <strong>",
"         Step 5:",
"        </strong>",
"        Lidocaine: subcutaneous infilitration (0.5 mL/kg of 1 percent lidocaine solution OR 0.25 mL/kg of 2 percent lidocaine solution) or as nerve block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        <strong>",
"         Step 6:",
"        </strong>",
"        Deep sedation/analgesia using fentanyl (2-4 mcg/kg) or morphine (50-100 mcg/kg), with midazolam (50-100 mg/kg), ketamine (1-2 mg/kg), or thiopental sodium (2 mg/kg)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     &bull; The frequency of these procedures can be reduced without sacrificing the quality of neonatal care.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: KJS Anand, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3118=[""].join("\n");
var outline_f3_2_3118=null;
var title_f3_2_3119="RA hand 2";
var content_f3_2_3119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Swelling of the metacarpophalangeal joints of the right hand in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Swelling of the MCP joints, moderate MCP flexion, and swan neck deformities are evident in this patient with rheumatoid arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick J Venables, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_2_3119=[""].join("\n");
var outline_f3_2_3119=null;
